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Abstract 
 
Results from this study indicate that non-adherence in hemodialysis sessions 
marginally affects health care costs and does not significantly increase the likelihood of 
kidney transplantation failure. 
 This dissertation explores the short-term and long-term impacts of non-adherence 
in hemodialysis (HD) sessions on health care costs and on kidney transplantation failure.  
This dissertation uses a conventional non-adherence measure, a broader data set which 
includes HD patients nationwide, and rigorous statistical models to tackle these research 
questions.  Informed policy recommendations are especially important because of the 
difficulty for dialysis patients to adhere to treatments. 
 There are five principal findings from my first dissertation paper, which 
investigates the impact of non-adherence on separately billable (SB) Medicare Allowable 
Payments (MAP), one of the two components that constitute the dialysis costs for HD 
patients.  There is a negative association between non-adherence and SB MAP, consistent 
across three different regression estimations, namely, ordinary-least square (OLS), two-
stage least square (2SLS), and log-linear regression models.  Since SB MAP have a 
skewed distribution, the estimation from the OLS model could be biased and inefficient.  
The instrumental variables, the distance from patient residence to dialysis facilities and 
its square term, are weak instruments because the partial R-square is very small.  The 
standard error from the 2SLS is quite large, suggesting the instability of the estimation.  
xi 
 
A log-linear model was applied to reduce skewness, but the estimates need to be 
retransformed back on the unlogged scale, which could lead to biases if 
heteroscedasticity is present on the log scale.  Finally, results from three lagged effect 
models do not support the hypothesis that dialysis patients who are non-adherent in the 
concurrent period would use more SB drug injectables in the following periods.  
 My second dissertation paper explores the association between non-adherence and 
composite rate (CR) costs, the second component of dialysis costs, for dialysis facilities.  
There are four principle findings. CR costs, similar to SB MAP, represent a skewed 
distribution.  Hence, a log transformation of CR costs might be a better measure for the 
dependent variable.  The explanatory power increases significantly for log-linear models 
comparing to that for OLS models.  There is no association between non-adherence and 
CR costs except for the log-linear model without facility control variables.  Finally, 
adding facility control variables significantly increases the explanatory power for log-
linear models. This effect is not as pronounced for OLS models.  
 My third dissertation paper explores whether non-adherence is a contributing 
factor to kidney transplantation failure.  The results from the Cox proportional hazards 
models consistently show that non-adherence in hemodialysis sessions does not have a 
significant influence on kidney transplantation failure after controlling for none, some, or 
a full list of patient characteristics.  The coefficient estimates from a binary non-
adherence measure also confirm this finding.  
 Findings from this dissertation may provide valuable information for dialysis 
patients, dialysis facilities, and policy makers when faced with concerns related to non-
adherence.
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Chapter I 
 
Chapter I. Introduction 
 
Medical expenditures associated with treating dialysis patients have rapidly increased, 
accounting for 6.4% of the Medicare budget with 506,256 prevalent patients, according 
to the U.S. Renal Data System in 2007.  There is little literature pertaining to the 
economic consequences of non-adherence for ESRD patients.  
To fill this void, I examined the short-run economic consequences and long-run 
health deterioration outcome of non-adherence.  Informed policy recommendations are 
especially important because of the difficulty for dialysis patients to adhere to three 
treatments per week and take medication 6 to 10 times per day (Loghman-Adham, 2003). 
For my first paper, I investigate the causality between non-adherence and health 
care costs, and explore whether the fluctuation in health care costs due to non-adherence 
would continue or stabilize in subsequent periods.  Most previous studies use a relatively 
small number of study observations, representing only a subset of Medicare HD patients.  
This study uses the population of 416,164 Medicare HD patients, substantially increasing 
the statistical power.  Earlier studies used cross-sectional data to conduct statistical 
analyses, failing to control for plausible time trends.  This study uses longitudinal data 
from 2004 to 2006 and controls for time fixed effects.  Finally, previous studies do not 
handle the potential endogeneity, when the independent variable of interest is correlated 
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with the error term due to either simultaneity or omitted variable bias.  This study tackles 
this concern by applying a two-stage least square (2SLS) estimation.  
I define non-adherence as the number of dialysis sessions skipped by a dialysis 
patient in a month.  The measure of health care costs is separately billable (SB) Medicare 
Allowable Payments (MAP).  I hypothesize that non-adherence would lead to a 
significant drop in SB MAP, and am interested in investigating the magnitude of this 
short-run impact.  In addition, I would like to test the hypothesis that non-adherent 
patients would adjust for missed treatments by using more drug injectables to reach their 
clinical target level in the subsequent period immediately following the non-adherent 
month, and that this lagged impact would vanish over a longer period of time.   
 I shift the focus of study population from dialysis patients to dialysis facilities in 
my second paper.  This paper investigates whether there is an association between non-
adherence, as measured by the average HD sessions missed per patient per month, and 
composite rate (CR) costs for dialysis facilities, using a nationally representative sample.    
Results from this study might be useful for both dialysis facilities and the CMS.  From 
the dialysis facilities’ perspective, they could implement strategies to increase the 
adherence rate if the results show that they are faced with revenue loss with no 
meaningful cost-savings due to non-adherence.  From the CMS’s perspective, it is 
important to know what the magnitude of non-adherence on CR costs is, in order to better 
monitor reimbursement and regulate budgetary issues.  
Policy mandates often target facilities directly, not patients.  Since a fully-bundled 
ESRD payment system was implemented in January 1, 2011, relevancy for issues 
explored by this paper increases.  CMS may want to explore the importance of non-
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adherence and determine whether a pay-for-performance scheme to reward facilities with 
higher adherence rates should be implemented.   
Previous literature does demonstrate the relation between non-adherence and 
kidney transplantation failure, showing that non-adherence with use of 
immunosuppressive drugs is a major cause of graft loss. (Garcia et al., 1997; Michelon et 
al., 1999; Morrissey et al., 2005).  However, many of these studies were limited by 
focusing on only one medical institution, failing to control for other exogenous variables, 
and neglecting the impact of non-adherence before a transplantation occurs.  My third 
paper uses Medicare data that include hemodialysis patients who receive kidney 
transplantation nationwide.  I use Cox Proportional Hazards models to predict kidney 
transplantation failure controlling for a full list of patient case-mix characteristics, and 
conduct sensitivity analysis using a nonlinear non-adherence measure.  
My study results provide a different perspective in addressing the effect of non-
adherence on kidney transplantation failure.  Previous studies established the association 
between non-adherence in medication, which occurs after the kidney transplantation is 
operated, and kidney transplantation failure.  The non-adherence measure the researchers 
used was immunosuppressive drugs, not dialysis sessions.  I examine the impact of non-
adherence even before the kidney transplantation takes place.  If non-adherence in 
hemodialysis sessions is associated with a higher kidney transplantation failure rate, If 
there is an association between non-adherence in hemodialysis sessions and kidney 
transplantation failure, then this finding could possibly affect the kidney allocation score 
system, or be used to target patients for counseling about adherence prior to transplant 
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and for more aggressive monitoring after transplant.  I use a subset of Medicare HD 
patients, the kidney transplantation recipients, to evaluate this impact.   
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Chapter II 
 
Chapter II. The Intertemporal Impact of Non-adherence on Separately Billable 
Medicare Allowable Payments in Medicare Hemodialysis Patients 
 
Abstract  
 
Objective. To understand whether a causal relationship exists between non-adherence 
and health care costs in the concurrent period and to explore whether this impact extends 
to the following periods for Medicare hemodialysis (HD) patients. 
Data Sources.  CMS Form 2728 and Medicare claims from 2004-2006. 
Study Design. I use a two-stage least square (2SLS) model to investigate the impact of 
non-adherence on health care costs.  Non-adherence is measured by the number of 
dialysis sessions an HD patient skipped in each month.  Health care costs are measured 
by Medicare Allowable Payments (MAP) for separately billable (SB) services, including 
Erythropoietin (EPO), iron, vitamin D, other injectables, and certain laboratory services.  
The estimates from this model are compared with the estimates from the ordinary least 
squares (OLS) and log-linear models.  Additionally, three lagged effect models are fitted 
to see whether the fluctuation in SB MAP due to non-adherence stabilized after one, two, 
or three months. 
Principal Findings. The OLS model provides more reliable results with a tighter 
standard error distribution in examining the association of non-adherence on SB MAP, 
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after comparing coefficient estimates derived from OLS, 2SLS, and log-linear models.  
The findings obtained through the OLS model suggested that dialysis facilities would 
lose $67.65 in payment if a patient skipped one treatment, which was lower than the 
average SB MAP per treatment of $86.52.  Since the impact of non-adherence on SB 
MAP is significant, though small, the finding could potentially provide a financial 
incentive for dialysis facilities to monitor and improve patient adherence.  Results from 
the lagged effect models supported the hypothesis that non-adherent patients would make 
up for missed treatments by using slightly more drug injectables to reach their clinical 
target level in subsequent periods.   
Conclusions. Medical costs and patient outcomes are two components used to evaluate 
the effect of non-adherence on treatment efficiency.  As long as the saved cost of missed 
treatments offsets the cost of increased morbidity, non-adherence could potentially have 
cost saving effects for the CMS.  Future research should focus on measuring the cost of 
increased morbidity due to non-adherence in order to fully examine the net cost effect. 
 
Key Words. Hemodialysis, non-adherence, health care costs, instrumental variables,           
ESRD  
 
Introduction 
 
The causal relationship between non-adherence and the use of injectable medications and 
laboratory tests associated with dialysis treatments has not been well established.  
Elevating costs in treating dialysis patients has drawn much attention in the end-stage 
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renal disease (ESRD) community from policy makers, health care researchers, dialysis 
providers, and dialysis patients.  Using an OLS approach, I found that there is a negative 
association between non-adherence and SB MAP, controlling for a comprehensive list of 
patient and facility characteristics.  The coefficient estimates on non-adherence differ 
substantially amongst the OLS, 2SLS, and log-linear regression models.  There is a 
modest statistically significant association between lagged months non-adherence 
measures and the current month SB MAP.  
 On average, dialysis patients need to take medication six to ten times per day 
(Loghman-Adham, 2003).  In-center hemodialysis patients need to undergo dialysis 
sessions three times a week, each session taking about three to four hours.  They often 
watch television or take a nap during their sessions.  It takes an enormous amount of 
discipline for dialysis patients to adhere to routine sessions and properly take the 
prescribed medications.  Based on different definitions of non-adherence, prevalence has 
been reported to vary from as little as 2 percent to as much as 100 percent (Leggat, 2005).  
To date, few studies have investigated the association between non-adherence and ESRD 
health care costs.  Of these, most use a relatively small number of study observations, 
which makes generalizability questionable.  Most studies use cross-sectional data to 
conduct analysis, failing to control for plausible time trends that may be associated with 
health care costs.  None of these studies deal with the concern of endogeneity, when the 
independent variable of interest − non-adherence − is correlated with the error term due 
to either simultaneity or omitted variable bias.  Causality between non-adherence and 
health care costs cannot be drawn.  All these issues have prompted the need to conduct a 
more rigorous study in examining the economic consequences of non-adherence.  
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 The total ESRD expenditures for Medicare dialysis patients increased from 5.5 
billion dollars in 1991 to 20.4 billion dollars in 2006, which represents a 73% increase.  
The prevalent ESRD patients increased from roughly 60,000 in 1980 to 500,000 in 2006, 
representing an 84% increase.  The results of this study suggest that non-adherence in 
hemodialysis sessions should not be encouraged, even when considering cost-savings for 
the CMS.  Rather point to how significant, in terms of dollars, non-adherence can be.  
   
Literature Review 
 
Previous literature already demonstrates that non-adherence would lead to worsening 
health outcomes, e.g., higher mortality, and worsening quality of life.  This chapter fills 
the void in the literature by providing more concrete information to explore the impact of 
non-adherence on health care costs, as measured by SB MAP. 
Within the ESRD-related literature, issues concerning patient non-adherence with 
hemodialysis (HD) prescriptions have been discussed extensively.  A large body of 
research regarding predictors and clinical outcomes of non-adherence has been published 
in the clinical literature (Denhaerynck et al., 2005; Jarzembowski et al., 2004; Leggat et 
al., 1998; Leggat et al., 2005; Saran et al., 2003).  Most researchers define non-adherence 
in dialysis patients when there is an interdialytic weight gain >1.5 kg, a serum 
phosphorus level >6 mg/dL, and/or a predialysis serum potassium level >5.5 mEq/L, or 
when dialysis sessions are shortened or skipped by the patient.  Many studies found a 
positive correlation between non-adherence in dialysis sessions and worsening health 
outcomes, and a negative association between non-adherence and quality of life 
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(Denhaerynck et al., 2005; Leggat et al., 1998; Saran et al., 2003).  Nevertheless, it is 
surprising to find that the economic consequences of non-adherence have rarely been 
investigated in the ESRD community.  Only a few studies have applied cost-effectiveness 
or cost-utility analyses to estimate the economic impact of non-adherence in renal 
transplant patients.  For example, Swanson and colleagues (1992) estimated that the non-
adherence related additional hospital cost, after transplantation, amounts to $900 per non-
adherent patient per year.  Cleemput and colleagues (2004) conducted cost-utility 
analyses to assess non-adherence and its economic consequences in a renal transplant 
population and found that non-adherent recipients’ lifetime treatment costs are actually 
lower due to lower life expectancies.      
It is important to understand whether non-adherence has a significant impact on 
dialysis costs facing the current cost-consciousness U.S. healthcare environment.  In 
1973, the Medicare ESRD Program was established as a national health insurance 
program for people diagnosed with end-stage renal disease.  Over the past few decades, 
the total number of prevalent dialysis patients and the total expenditure of the ESRD 
program have continuously increased.  In 2007, there were 506,256 prevalent patients in 
the U.S.  The medical expenditures associated with treating these patients have reached 
$20 billion, accounting for 6.4% of the Medicare budget (U.S. Renal Data System 
[USRDS] 2007).  The improved mortality rates of prevalent ESRD patients and the 
continuing growth of incident ESRD patients both contribute to the rising cost pressures 
encountered by the Centers for Medicare and Medicaid Services.     
 Non-adherence is commonly observed in dialysis patients (Curtin et al., 1999; 
Leggat et al., 1998).  Although dialysis is lifesaving, it only replaces 10% of normal renal 
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function.  Patients may continue to encounter many medical problems such as salt and 
water retention, hyperparathyroidism, hypertension, and heart disease, among others 
(Loghman-Adham, 2003).  On average, dialysis patients need to take medication 6 to 10 
times per day (Loghman-Adham, 2003).  It takes a tremendous amount of discipline and 
determination for patients to adhere to routine sessions and properly take the prescribed 
medications.  The non-adherence issue is particularly important for those living in the 
United States.  Bleyer and colleagues’ (1999) studies on international comparisons of 
patient adherence on hemodialysis found that roughly 2.3% of dialysis sessions were 
skipped by patients in the United States, whereas missed dialysis treatments were 
virtually nonexistent in Japan and Sweden.  
There are wide variations in terms of what constitutes non-adherence.  How 
researchers define their non-adherence measures would affect the estimated prevalence of 
non-adherence and associated mortality risks (Kimmel et al., 1998; Kimmel et al., 1995; 
Leggat et al., 1998; Saran et al., 2003).  Based on these definitions, the prevalence of 
non-adherence has been reported to vary from as little as 2% to as much as 100% 
(Leggat, 2005).  Because different definitions have been used, it is difficult to make 
direct comparisons across studies.  Results of predictors of non-adherence are mixed.  
Most studies show that predictors of non-adherence in adult HD patients include age, 
race, sex, marital status, socioeconomic status, and educational level (Bame et al., 1993; 
Brownbridge et al., 1994; Gordon et al., 2003; Hoover, 1989; Morduchowicz et al., 
1993).  However, Leggat and colleagues (1998) did not find sex or education level 
statistically significant.  
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Most studies examining the issues regarding skipped and shortened HD sessions 
focus on patient characteristics and individual reasons leading to non-adherence (Gordon 
et al., 2003; Loghman-Adham, 2003).  In general, younger patients, incident patients, 
low-income patients, African-Americans, and males are more likely to be associated with 
non-adherent behaviors.  Reasons may include medical problems, life tasks, and 
difficulty in transportation.  Conclusions drawn from these studies often emphasize the 
development of interventions to target patient-specific characteristics in order to improve 
the adherence of HD sessions.  In terms of outcomes research, studies by Leggat and 
colleagues (1998), Loghman-Adham (2003), and Saran and colleagues (2003) have 
shown that non-adherence with HD treatment is associated with increased mortality risk.  
Missed or shortened dialysis sessions can reduce dialysis adequacy, a potential factor for 
increased mortality.  A majority of dialysis patients suffer from anemia problems related 
to erythropoietin (EPO) deficiency and require renal anemia management.  It has been 
shown that untreated or under-treated anemia in the dialysis population is associated with 
increased morbidity and mortality (Tong et al., 2001).   
 Summarizing non-adherence studies within the ESRD transplantation literature, 
Denhaerynck and colleagues (2005) concluded that non-adherence in adult renal 
transplant patients is associated with poor clinical outcomes.  However, non-adherence 
results in lower life-time costs because of shorter survival as well as lower quality 
adjusted life years.  Consistent determinants were age, social isolation, health beliefs, and 
health cognitions.  Jarzembowski and colleagues (2004) examined pediatric patients who 
received renal transplantation and found that African-American recipients had a 
significantly higher rate of graft loss when compared to Caucasian and Hispanic 
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recipients.  They drew the conclusion that non-adherence is a problem of great 
importance in the African-American pediatric transplant population.  In contrast to the 
excellent long-term survival rate in pediatric receipts of renal transplantation, Ettenger 
and colleagues (2005) found that the long-term transplant outcomes in adolescents were 
disappointing because of non-adherence with immunosuppressive medications.  With 
early identification and appropriate interventions, significant improvement in adolescent 
graft survival is highly possible.  
 There are several studies that investigated the impact of non-adherence with 
medication regimens on health care costs (Coambs et al., 1995; Sullivan et al., 1990).  
Cleemput and colleagues (2002) provided a literature review on the economics of non-
adherence of therapeutic treatments and concluded that non-adherence is often associated 
with increased morbidity and mortality for chronic patients.  Studies from Iskedjian and 
colleagues (1998), Sullivan and colleagues (1990), and Coambs and colleagues (1995) 
have all suggested positive correlations between non-adherence in medication and 
hospitalization admissions.  Though it is very difficult to compare study results because 
of the lack of a gold standard in the assessment of methodology, the literature seems to 
support the premise that it is more costly to treat non-adherent patients than adherent 
ones.  Clearly, the underlying core concept of these studies is based on the idea that 
higher adherence is desirable.     
Non-adherence in medication utilization and refill behavior associated with cost 
pressure within Medicare, Medicaid, and VA population has also received considerable 
attention.  Hirth and colleagues (2008) examined the relationship between out-of-pocket 
spending and cost-related medication underuse of hemodialysis patients across twelve 
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countries, and concluded that drug costs were associated with national drug financing 
policies as well as the non-adherence rate.  Using data on diabetic management, Piette 
and colleagues (2004) found that VA enrollees, who generally have more generous drug 
coverage, reported less cost-related medication underuse than patients with no health 
insurance, patients with Medicare or Medicaid coverage, and even patients with private 
health insurance.  Their study results also suggest that many diabetic patients use less 
than the required medication and have poorer health, due to cost-related non-adherence.  
Mojtabai and colleagues (2003) tested the association of prescription drug coverage with 
adherence to chronic disease medications and the association of cost-related poor 
adherence with health outcomes among Medicare beneficiaries at various income and 
out-of-pocket spending levels.  Results showed a positive correlation between lack of 
drug coverage and cost-related poor adherence.  Cost-related poor adherence is related to 
adverse health outcomes, lower income level, and higher out-of-pocket spending.  
 
Hypotheses  
 
I am interested in investigating the causal and intertemporal effects of non-adherence on 
SB MAP per month, using OLS, 2SLS, and log-linear models. 
 I would like to test the following two hypotheses: (1) An HD patient who is non-
adherent in the current month will cause a lower SB MAP in that month due to a drop in 
the use of drug injectables and related services.  (2) An HD patient who is non-adherent 
in the current month will increase the use in drug injectables in the following months, in 
order to make up for his missed treatments.  
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Conceptual Framework 
 
My conceptual framework considers the non-adherence choice of a utility-maximizing 
HD patient.  The patient faces the decision of how to spend his time in order to maximize 
his utility.  In this case, the utility is a measure of the satisfaction derived from the 
allocation of time used to receive dialysis treatments or do other activities.  To maximize 
his utility function, the patient must choose whether to adhere to routine dialysis 
treatments for the value of health benefits or to be non-adherent so that he can spend the 
time on other activities, which provide more utility.  From the health perspective, 
receiving dialysis treatments affects the patient’s utility directly because he should feel 
better after each treatment.  The tradeoff is the opportunity costs for the three to four hour 
session which he could use to do other activities that might provide more utility for that 
patient.  A rational patient should be less likely to skip routine sessions for long-term 
health benefits.  A myopic patient may care more about short-term benefits (e.g., 
watching a movie, spending time with friends) rather than the long-term benefits (e.g., 
prolonged life expectancy). 
 Some patients who need to travel for a long time to get to the facility may be 
more likely to skip more sessions than patients who live nearby the facility.  Since 
previous literature did not find the association between medication utilization and travel 
distance, I claim that resource utilization of SB services has no correlation with the 
distance that a patient needs to travel to get to the facility.  These factors motivate the 
rationale for using travel distance as an instrumental variable to tackle the endogeneity 
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concern, for that distance is correlated with missed treatments but uncorrelated with SB 
MAP.  
 I consider two conceptual models.  In the first model, the hypothesis is that 
healthier patients tend to skip more sessions based on their own perception of health 
status.  These healthier patients in general have lower resource utilization in SB services.  
Assuming the presence of omitted variable bias (unobservable patient health status), the 
OLS estimate on non-adherence would tend to be biased away from the null.  The 
rationale is that for patients who skip routine sessions, they would use fewer SB services, 
and thus the coefficient estimate on non-adherence would be negative.  If I was able to 
observe the coefficient on this omitted variable of health status in which a healthier 
patient is characterized with more skipped sessions and uses fewer SB services, then the 
coefficient on this variable should be negative as well.  Therefore, I expect to see a 
negative coefficient estimate on non-adherence, with a coefficient estimate from the 
2SLS to be smaller than that from the OLS estimate, in absolute value. 
 In the second model, the hypothesis is that seriously ill patients tend to skip more 
because they are too fragile to go to the facility and receive treatments thrice a week.  
Since these patients demand more resource utilization on SB services, the coefficient 
estimate on the omitted health status measure should be positive.  As stated before, the 
coefficient estimate of non-adherence on SB MAP should be negative.  If the omitted 
variable bias exists, then the OLS estimate on non-adherence would be biased towards 
the null.  Under this scenario, I expect to see the 2SLS coefficient estimate to be larger 
than that from the OLS estimate in absolute value. 
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Methods and Data 
 
Methods 
 
The OLS and log-linear models were first used to estimate the association between non-
adherence and SB MAP, controlling for patient case-mix and certain facility 
characteristics.  This was followed by the application of a 2SLS model using the distance 
from patient residence to dialysis facility, the square of distance, and the square root of 
distance as three instruments to tackle the potential endogeneity that lies between skipped 
sessions and SB MAP.  Additionally, three lagged effect models were fitted to see 
whether the fluctuation in SB MAP due to non-adherence stabilizes after one, two, or 
three months.  All regression analyses were weighted by the number of HD-equivalent 
sessions. 
 
2.1 OLS estimation 
 
Models of resource use for separately billable services could be estimated as either linear 
models or logarithmic models.  Typically, health care cost data feature a skewed 
distribution in which a relatively small fraction of individuals account for a 
disproportionate fraction of costs.  Logarithmic models are useful with skewed data.  I 
examined both linear and logarithmic forms of the non-adherence case-mix models.  For 
these analyses, the dependent variable was SB MAP per month ( itSBMAP  ) in the linear 
models and the log transformation of SB MAP per month ( )log( itSBMAP ) in the 
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logarithmic models.  The independent variable of interest, non-adherence ( itNA ), and 
other exogenous variables were the same in both models.   
Equation 2-1 specifies the OLS model, and Equation 2-2 specifies the log-linear 
model.  The notations on i and t refer to patient i admitted month t for dialysis treatments. 
 
Equation 2-1  ittiitititit XFACNASBMAP   3210  
Equation 2-2  ittiitititit XFACNASBMAP   3210)log(  
 
itNA  is the non-adherence measure that represents the number of dialysis sessions 
a HD patient skipped in each month.  itFAC  is a vector of facility characteristics, 
including a dummy variable indicating a dialysis facility’s status (hospital-based or 
freestanding (reference group)), facility size (< 5,000 treatments, 5,000-9,999 treatments, 
> 10,000 treatments (reference group)), chain status (large dialysis organization, regional 
chain, unknown chain status, and independent chain as the reference group), and 
metropolitan status.  itX  is a set of patient demographics including age, sex, race, time 
since renal replacement therapy, body surface area, BMI<18.5 kg/m
2
, clinical hematocrit 
value, and 37 comorbid conditions.  The census region ( i ) and year ( t ) dummies are 
also included to control for regional fixed effects and time trends.  Finally, I used robust 
standard errors to account for the heteroscedasticity in error terms.   
 
2.2 2SLS estimation 
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If unmeasured variables (e.g. patient's health status) affecting SB MAP are also 
correlated with non-adherence, results of the OLS estimation are likely to be biased.  To 
ensure consistent estimates of the non-adherence measure, I re-estimated this association 
by using instrumental variables.  The instrumental variables I used were the distance from 
a patient’s residence to the dialysis facility, the square of distance, and the square root of 
distance.  This set of distance instruments have been used extensively in various 
publications (McClellan et. al, 1994; Hirth et. al, 2003).  A good set of instruments 
should fulfill the criterion in which they are strongly correlated with the endogenous 
variable but uncorrelated with the dependent variable.  
For the first stage estimation (Equation 2-3), I regressed non-adherence on 
distance, distance
2
, distance
0.5
, patient characteristics, facility characteristics, and census 
region and year dummies to obtain the predicted probabilities of non-adherence.  Then, I 
regressed SB MAP on predicted probabilities of non-adherence as well as all other 
exogenous variables as the second stage estimation (Equation 2-4).  I performed a 
Durbin-Wu-Hausman test to check for the existence of endogeneity.  
 
Equation 2-3  
ittiitititit eXFACDISTDISTDISTNA   54
5.0
3
2
210  
Equation 2-4  ittiititit XFACANSBMAP   3210
ˆ  
 
2.3 Lagged effect models  
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I fitted three lagged effect models to see whether non-adherence in the prior month 
(Equation 2-5), prior two months (Equation 2-6), and prior three months (Equation 2-7) 
has an influence on the current month SB MAP.  Similar to previous estimations, I 
controlled for the same set of exogenous variables, census regions and time fixed effects.  
 
Equation 2-5  ittiitittiit XFACNASBMAP    321,10  
Equation 2-6  ittiitittiit XFACNASBMAP    322,10  
Equation 2-7  ittiitittiit XFACNASBMAP    323,10  
 
Data 
 
Data for the measures of SB MAP, patient characteristics, and factors associated with the 
interrupted dialysis month were obtained from the ESRD Medical Evidence Report 
(CMS Form 2728) and/or Medicare claims.  The sources of facility characteristics were 
obtained from the Medicare Independent Renal Dialysis Facility Cost Reports (Form 
CMS 265-94) and the Medicare Hospital Cost Reports (Form CMS 2552-96). 
Originally, there were 8.9 million patient-month-facility records for 2004-2006 in 
the crude data set.  Since I am merely interested in Medicare in-center HD patients, I 
excluded dialysis patients whose primary modality is either peritoneal dialysis or home 
hemodialysis.  The reason that I only investigated in-center HD patients is because 90 
percent of dialysis patients use this modality, and the payment schemes for three modality 
types are different.  This procedure excluded 568,316 records (6.4 percent).  I used the 
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standard outer fence method
1
 to exclude influential SB MAP observations, so that the 
resulting models would characterize the pattern that represented most HD patients, rather 
than being disproportionately affected by a few exceptional, non-representative, and 
perhaps erroneous cases.  This eliminated 102,104 records (1.2 percent).  I then excluded 
observations with dialysis sessions greater than 20 sessions per month, because it is 
unlikely for an HD patient to receive more than 20 dialysis treatments in a month.  This 
eliminated 6,326 records (0.1 percent).  I excluded any distance measure that was greater 
than 150 miles.  This cutoff threshold is based on a consultation with a clinical 
nephrologist.  This eliminated another 261,824 records (3.2 percent).  Subsequently, I 
excluded any missing values from any covariates used in this study, which eliminated 
538,680 records (6.8 percent).  Finally, I incorporated the information about rural and 
urban status from another data source.  After excluding the missing values generated 
from this procedure, I obtained 7,188,698 patient-month-facility records, which accounts 
for 80.8 percent of the original 8.9 million data file (Table 2-1).  
  
Measures 
 
Dependent variables 
 
Since the data set does not include actual costs of SB services, MAP were used as a proxy 
to measure resource use, calculated from payment data on the claims.  In this analysis, 
                                                 
1
 Upper outer fence: 75
th
 percentile + 3interquartile range (IQR, the 75th percentile – the 25th percentile) 
   Lower outer fence: 25
th
 percentile - 3interquartile range (IQR, the 75th percentile – the 25th percentile) 
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MAP for the top injectables were adjusted according to the reimbursement levels during 
the first quarter of 2006, since the CMS recently changed its reimbursement levels to 
reflect the typical facility acquisition costs.   
SB services included EPO, iron, vitamin D, other injectables, laboratory services 
that were either (1) billed by dialysis facilities or (2) billed by freestanding laboratory 
suppliers and ordered by physicians who received Medicare capitation payments for 
treating ESRD patients, and other services that were billed by dialysis facilities (i.e., 
syringes and other supplies) provided by dialysis facilities and their affiliates to 
individuals receiving chronic dialysis under Medicare’s ESRD payment system.  MAP 
for SB services were obtained from 2004-2006 Medicare claims files for all HD patients 
with Medicare as the primary payer.  A log transformation of SB MAP is used as a 
second dependent variable.  
 
Independent variable of interest 
 
The non-adherence measure − the number of HD sessions skipped − was derived using 
the following strategy.  Medicare claims from 2004 to 2006 were selected for analysis 
only if the number of dialysis sessions was between 0 and 20 for each claim.  The 
average number of HD equivalent dialysis sessions was 12 sessions.  Several events may 
explain low sessions in HD sessions, including starting month for dialysis with or without 
hospitalization, withdrawal from the dialysis services, transplant with or without 
hospitalization, death with or without hospitalization, hospitalization only, switching 
dialysis modality, transfer between facilities, and training sessions.  Multiple events 
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based on these aforementioned categories were identified using the patient-month-facility 
level data set.   
 The measure of skipped sessions was then defined as fewer than 12 HD 
equivalent sessions billed, with none of the above events identified on each record.  If the 
record is identified as a skipped month, I then calculated the total number of skipped 
sessions for that month, using 12 minus dialysis sessions received for that month.  For 
example, suppose a dialysis patient was identified as a skipped patient in December 2004.  
If that patient-month-facility record shows that he received eight HD sessions in that 
month, then the total number of HD sessions skipped in December is four sessions.   
 Other studies have used different measures for non-adherence.  The most common 
four measures for non-adherence are skipped HD sessions, shortened HD sessions by 10 
or more minutes, an interdialytic weight gain of more than 5.7 percent or dry weight, or a 
serum phosphate of greater than 7.5 mg/Dl (Leggat et. al, 1998).  Since my data set did 
not include information besides the number of HD sessions skipped, it is important to 
understand whether this measure is a sensitive proxy to capture the non-adherence 
measure in general.  Based on a study from Leggat and colleagues (1998), researchers 
showed that there was a high degree of correlation among various definitions of non-
adherence.  For example, if a patient is classified as non-adherent using one definition, 
e.g., an interdialytic weight gain of more than 5.7 percent, then the odds of this patient 
being identified as a non-adherent patient using other definitions (e.g., skipped sessions) 
are significantly higher.  The strongest correlation was between skipping and shortening 
HD sessions.   
 
25 
 
Instrumental variables 
 
There are three instrumental variables used in this study.  I used the Great Circle Distance 
formula (Distance = 3959  arcos(sin(latitude of facility zipcode/57.3)  sin(latitude of 
patient zipcode/57.3) + cos(latitude of facility zipcode/57.3)  cos(latitude of patient 
zipcode /57.3) cos((longitude of facility zipcode – longitude of patient zipcode)/57.3) ) 
to calculate the distance between patient residence zip code centroid and dialysis 
facility’s zip code.  In addition, the square and square root terms of the distance measure 
are used as two other instruments to test for nonlinearity.   
 
Patient characteristics 
 
Several patient characteristics including demographics (age, sex, race), time since start of 
renal replacement therapy (RRT), body surface area, an indicator of low body mass index 
(BMI<18.5 kg/m
2
), functional statuses, and clinical comorbidities that have significant 
impacts on explaining the variation of SB MAP based on prior research (Hirth et al., 
2003; Hirth et al., 2007), were included in the regression models as control variables.  
Data for the measures of patient characteristics were obtained from the ESRD Medical 
Evidence Report (CMS Form 2728) and/or Medicare claims.  Clinical comorbidities were 
obtained from CMS Form 2728 and/or Medicare claims, since there were issues 
concerning underreporting of comorbidities using only CMS Form 2728.  Additionally, 
this Medical Evidence Report does not capture changes in patients’ comorbidities after 
the initiation of RRT.  Comorbid conditions based purely on this form were not perfectly 
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measured.  Clinical comorbidity conditions were based on diagnosis codes reported on 
Medicare inpatient, outpatient, skilled nursing facility, home health, hospice, and 
physician claims covering a specified period of time.  
These claims-based comorbidity measures were limited to recent diagnoses (i.e., 
during the previous six months only) for acute conditions such as gastrointestinal 
bleeding.  Longer periods were used for chronic conditions.  Several ―look back‖ periods 
(i.e., diagnoses in last year vs. last two years) were tested to determine their ability to 
predict costs.  The most predictive look back period was chosen as the measure of the 
comorbidity to be entered into the regression models.   
 
Facility characteristics 
 
The relationship between non-adherence and the SB MAP may be affected by the 
inclusion or exclusion of facility characteristics.  Therefore, several facility 
characteristics including hospital-based vs. freestanding, facility size, membership in 
major chains, and urban vs. rural location, metropolitan status, and census region were 
also used in the regression models. 
 
Results 
 
Descriptive analysis 
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To test the normality assumption for statistical models, I compared the shape for the 
distribution of SB MAP and log (SB MAP).  Figure 2-1 shows that SB MAP has a right 
skewed distribution.  After a log transformation on SB MAP, the new distribution looked 
more like a bell-shape, although there seems to be a tail that was marginally skewed to 
the left (Figure 2-2). 
 There are a total of 439,181 patient-month-facility records with at least one 
skipped HD session (Figure 2-3).  The average number of skipped sessions amongst these 
patients is 2.34.  Out of these records, 35.6 percent contains one skipped session and 19.9 
percent shows three skipped sessions in the month. 
 The summary statistics of all variables are listed in Table 2-2.  The mean SB 
MAP per patient per month is $1,049.6 (SD = $759.24).  The average log (SB MAP) is 
6.68 (SD = 0.85).  On average, the number of HD sessions skipped for a HD patient in a 
month is 0.05 (SD = 0.21).  The average travel distance from patient residence to the 
dialysis facility is 7.31 miles (SD = 11.74 miles). 
 For patient demographics, the majority of HD patients in this study are between 
45 and 79 years old, male, and White.  In terms of other patient characteristics and 
comorbid measures, the mean body surface area using the Dubois Formula 
( 425.0725.02 )()(20247.0)( kgWeightmHeightmBSA  ) per 0.1 m2 is 1.87 (SD = 0.25).  
Four percent of these patients were underweight (body mass index < 18.5 kg/m
2
).  About 
49 percent of these patients have been on renal replacement therapy for more than 3 
years.  The most commonly observed comorbidities are diabetes (60 percent), ischemic 
heart disease (51 percent), peripheral vascular disease (45 percent), and cardiac 
dysrhythmia (34 percent).  The least observed comorbidity is esophageal varices (0.04 
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percent).  With respect to facility characteristics, 93 percent of these patients are from 
free-standing facilities, 66 percent are from dialysis facilities which provide more than 
10,000 dialysis treatments, 70 percent are from large dialysis organization (Fresenius, 
Gambro, Davita, Renal Care Group, Dialysis Centers Inc, and National Nephrology 
Associates), 18 percent are from rural locations, and 83 percent are from metropolitan 
areas.  
 Using a simple strategy to test the validity of the instrumental variable, the 
distance measure, I assigned distance into five groups: 02 miles, 25 miles, 510 miles, 
1015 miles, and >15 miles (Table 2-2).  A good instrument should be correlated with 
the independent variable of interest and uncorrelated with the dependent variable.  From 
this table, I observed that as distance gets larger, the number of skipped sessions 
increases accordingly, though the magnitude of this increase is moderate.  This finding 
suggests that there is a modest correlation between the instrumental variable (distance) 
and the independent variable of interest (non-adherence).  Furthermore, it shows that SB 
MAP remain consistently stable across the five distance groups.  More encouragingly, the 
mean values for the four most commonly observed comorbidities do not change at the 
five distance group measures.  These two phenomena suggest that there is no correlation 
between the instrumental variable (distance) and the dependent variable (SB MAP), and 
between the instrumental variable (distance) and the exogenous variables (four 
comorbidities).  
  
Regression analysis 
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To formally test for the strength of the instrumental variable, I conducted several 
specification tests.  The F-statistic from the first-stage least square regression is 179.59, 
which is higher than 10, the cutoff threshold suggested by Staiger and Stock (1995).  
However, the partial R-square is 0.01%, which is very small.  Combining these two 
results, I conclude that the distance measure is a weak instrument for non-adherence.  
 I use distance (per 10 miles), its square, and its square root as three instrumental 
variables in my first-stage estimation.  The logic for including the square and square root 
terms of distance is to check for the effect of nonlinearity.  The result shows that if 
distance increases by 10 miles, the number of skipped sessions would decrease by 
0.0026, statistically significant at the 99 percent confidence interval.  The sign of this 
direction is not as expected, and the magnitude is again small.  The coefficient estimates 
on distance
2
 and distance
0.5
 suggest that as distance gets larger, the speed of the increase 
in the number of skipped sessions slightly goes up.  The results are statistically 
significant at the 99 percent significant level.   
 The comparison of the OLS and 2SLS regression results can be found in Table 2-
5.  Model 1 and Model 2 provide a comparison between OLS and 2SLS results using SB 
MAP per month as the dependent variable.  Model 3 and Model 4 use a different 
dependent variable, log (SB MAP).  All models controlled for census region and time 
fixed effects.    
In Model 1, the OLS estimate on non-adherence shows that if an HD patient 
skipped one HD session in the month, his SB MAP for the month would drop by $67.65 
(SE = $1.29).  This result is statistically significant at the 99 percent confidence level.  
The 2SLS estimate of non-adherence (Model 2) shows that if one HD patient skipped a 
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session in the month, his SB MAP for that month would decrease by $2343.29 (SE = 
$179.19), statistically significant at the 95 percent confidence level.  
 For models with the log transformed SB MAP, the OLS estimate of non-
adherence (Model 3) is -0.095 (SE = 0.001), statistically significant at the 99 percent 
confidence level.  After taking the exponentiation of the coefficient estimate, i.e., exp (-
0.095), I derived the multiplier of non-adherence on SBMAP, which is 0.91.  The 
interpretation is that if an HD patient skipped one HD session, his SB MAP for that 
month would drop by 9 percent, which on the dollar scale is equal to $94.46 
($1049.60.09=$94.46). 
 Model 4 shows the 2SLS estimate of non-adherence on log (SB MAP).  The 
coefficient estimate is -7.60 (SE = 0.37), statistically significant at the 99 percent 
confidence level.  The multiplier for non-adherence is 0.0005, suggesting that if one HD 
patient skipped one session in the month, his SB MAP for that month would decrease by 
99.95%, or in dollar scale, $1049.08.   
 When comparing the explanatory power between the OLS and 2SLS estimations 
using SB MAP as the dependent variable, I found the R-square is higher in the OLS 
estimation (Model 1: R
2
 = 7.47%; Model 2: R
2
 = 5.30%).  This finding holds when using 
the log (SB MAP) as the dependent variable (Model 3: R
2
 = 6.18%; Model 4: R
2
 = 
1.37%).  In general, the explanatory power of log-linear models was slightly lower than 
that of linear models.  
 Finally, the OLS results for the three lagged effect models are presented in Table 
2-6.  The coefficient estimate of one-month lagged non-adherence on the current month 
SB MAP is $18.01 (SE = $1.32), suggesting that if an HD patient skipped a session in the 
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prior month, the current month SB MAP would increase by $18.01.  Similarly, the two 
month lagged model shows that if an HD patient skipped one session two months ago, the 
current month SB MAP would increase by $18.91 (SE = $1.36).  The three-month lagged 
model shows that the current month SB MAP would increase by $19.41 (SD=1.40) if an 
HD patient skipped one treatment three months ago.  All results are statistically 
significant at the 99 percent confidence level.  
 
Sensitivity analysis 
 
It is highly likely to observe more voluntary withdrawal cases for dialysis patients who 
are close to the end of life.  Based on my identification strategy for non-adherence, I was 
not able to distinguish whether individual missed treatments were due to permanent 
withdrawal or temporary withdrawal.  To address this possible misclassification concern, 
I conducted a sensitivity analysis in which I dropped observations on the month of death 
and the month prior to death, to ensure the results are not biased.  
 After excluding the observations of "month of death" and "month prior to death," 
the sample size was reduced from 7,188,698 to 6,969,739 records (Table 2-7).  For the 
OLS model using SB MAP as the dependent variable, the coefficient estimate on non-
adherence changed modestly from -67.65 to -68.58, and remained statistically significant.  
For the 2SLS model, the coefficient estimate changed from -2343.29 to -2254.71.  The 
coefficient estimates on other covariates changed on a moderate scale, as compared with 
the original model.  The coefficient estimate on non-adherence for the OLS model using 
log SB MAP/month as the dependent variable is -0.096 (multiplier=0.91), which remains 
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the same as the original model.  That for the 2SLS model is -7.41 (multiplier=0.0006), 
which is pretty similar to the one derived from the original 2SLS model.  For the three 
lagged effect models, Table 2-8 shows that the coefficient estimates on non-adherence 
remain small and do not differ much from the original models.  
 Since low income patients may have a higher tendency of skipping dialysis 
sessions, I added county-level income information from the Area Resource File, and re-
examined the impact of non-adherence on the SB MAP to understand the importance of 
adding income information in the estimation.  The results showed that the effect of 
adding income information is so trivial that there is basically no change in coefficient 
estimates on non-adherence and no improvement in explanatory power.  The downside 
from adding the income information is a loss in statistical power because 556,341 records 
were excluded due to missing values.  I did not report the coefficient estimates here.  The 
full set of estimated coefficients is available from the author upon request.   
 
Discussion 
 
With the use of Medicare data, which includes all Medicare HD patients, I was able to 
obtain a representative study population, and increase the statistical power and 
generalizability from this study.  This study uses three modeling approaches, OLS, 2SLS, 
and log-linear regression models, to estimate the impact of non-adherence on SB MAP 
and compares the strength and weakness of each model.  After comparing coefficient 
estimates derived from OLS, 2SLS, and log-linear models, I conclude that the OLS 
model provides more reliable results with a tighter standard error distribution in 
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examining the association of non-adherence on SB MAP.  Based on the specification test 
results, distance is a weak instrument.  This property could likely explain the extremely 
large and implausible 2SLS estimates.  Future work could be conducted to find a better 
instrument in order to tackle the endogeneity concern.  A log-linear model may better 
satisfy the normality assumption of statistical models, but the explanatory power is lower 
than that from the OLS.  
 The findings obtained through the OLS model suggested that dialysis facilities 
would lose $67.65 in payment if a patient skipped one treatment, which was lower than 
the average SB MAP per treatment of $86.52.  Since the impact of non-adherence on SB 
MAP is significant, though small, the finding could potentially provide a financial 
incentive for dialysis facilities to monitor and improve patient adherence.  Results from 
the lagged effect models supported the hypothesis that non-adherent patients would make 
up for missed treatments by using slightly more drug injectables to reach their clinical 
target level in subsequent periods.  Overall, the study results suggest that non-adherence 
in HD sessions causes a decrease in SB MAP for facilities, and generates SB cost-savings 
for the CMS.  The size of savings is moderate. 
 Because the 2SLS estimate on non-adherence is greater than the OLS estimate, 
the findings support the second conceptual model − sicker patients tend to skip more.  If 
the CMS and dialysis facilities would like to improve the patient adherence rate, it would 
be more efficient to target this sicker population and provide incentives to address its 
concerns.   
 Since the CMS implemented a full bundling system on January 1, 2011, which 
pays a fixed amount per patient per treatment in order to reimburse both composite rate 
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costs and separately billable items, it is important to understand how this new bundling 
system will change implications of skipped treatments for dialysis facilities and the CMS.  
Based on study results which show that skipping sessions is associated with lower SB 
utilization, with some evidence of slightly more SB utilization in the following months to 
make up for the missed treatments, it is expected that dialysis facilities would respond to 
non-adherence because they earn more profit margins when patients maintain scheduled 
sessions and need not use more SB resources for following months.  Facilities can design 
appointment follow-up programs to target those patients who commonly skip HD 
treatments.  From the CMS perspective, since the bundled payment is made per patient 
per treatment, there is enough financial incentive for facilities to improve patient 
adherence because they will not receive reimbursement from a missed session.  The CMS 
probably needs not design policy intervention in improving patient adherence at this 
point.   
Medical costs and patient outcomes are two components used to evaluate the 
effect of non-adherence on treatment efficiency.  Non-adherence could potentially be cost 
saving for the CMS as long as the saved cost of missed treatments offsets the cost of 
increased morbidity.  Future research should focus on measuring the cost of increased 
morbidity due to non-adherence in order to fully examine the net cost effect. 
It is important to note one limitation.  Non-adherence, as defined in this study, is 
measured conservatively.  For instance, if a patient is identified to have an event (e.g., 
hospitalization) in a month, then he will not be defined as a ―skipped‖ patient for that 
month based on my identification strategy.  In reality, he might be both ―hospitalized‖ 
and ―non-adherent‖ for that month.  For months with 31 days, patients may receive 13 
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treatments instead of 12 treatments.  Suppose a record shows that a patient received 11 
treatments in a 31-day month, without any other event being identified.  Using my 
identification strategy, this patient would be reported as skipping one treatment, although 
in reality he skipped two treatments.  To the extent that this non-adherence measure was 
underestimated, the prevalence of non-adherence should be greater than 0.05 sessions per 
month, and the coefficient estimates on non-adherence as well as other covariates could 
also be affected. 
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Figure 2-1. Distribution of SB MAP/month 
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Figure 2-2. Distribution of log (SB MAP/month) 
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Figure 2-3. Distribution of skipped sessions for the 439,181 pat-mon-fac records with at 
least one skipped HD session 
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Table 2-1. The derivation of final sample size, 2004-2006 
Steps Procedures N Unit 
1 Original 2004-2006 records 8,899,748 pat-mon-fac 
2 Limit to Medicare HD patients only  8,331,432 pat-mon-fac 
3 
Exclude influential SB MAP/month observations using outer 
fence definition* 8,229,328 pat-mon-fac 
4 
Exclude observations with dialysis sessions > 20 sessions 
per month 8,223,002 pat-mon-fac 
5 
Exclude distance to facility > 150 miles (suggested by a 
nephrologist) 7,961,178 pat-mon-fac 
6 Exclude missing values from any covariates 7,422,498 pat-mon-fac 
7 Add rural/urban variable from another data source 7,188,698 pat-mon-fac 
*Outer fence definition:  
  
-Upper outer fence: 75th percentile + 3*interquartile range (IQR, the 75th percentile-the 25th    
percentile)=1344.95+3*(1344.95-457.89)=4006.12 
-Lower outer fence: 25th percentile - 3*interquartile range (IQR, the 75th percentile-the 25th   
percentile)=457.89-3*(1344.95-457.89)=-2203.29 
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Table 2-2. Summary statistics of all variables, 2004-2006 
Variables Mean  S.D. 
Dependent variables 
       SB MAP per month 1049.60 759.24 
     log (SB MAP per month) 6.68 0.85 
Other variable   
     SB MAP per session 86.52 63.98 
Variable of interest 
       Number of HD sessions skipped in the month 0.05 0.21 
Instrumental variable 
       Distance from patient residence to facility (in miles) 7.31 11.74 
Demographic variables   
     Ages <18 yrs 0.0009 - 
     Ages 18-44 yrs 0.13 - 
     Ages 45-59 yrs 0.26 - 
     Ages 60-69 yrs 0.23 - 
     Ages 70-79 yrs 0.24 - 
     Ages 80+ yrs 0.13 - 
     Female 0.47 - 
     Race: Native American 0.02 - 
     Race: Asian 0.03 - 
     Race: Black 0.40 - 
     Race: White 0.54 - 
     Race: Other 0.01 - 
     Race: Unknown/missing 0.0002 - 
Patient characteristics and comorbidities   
     Body surface area (Dubois formula), per 0.1 m
2
 1.87 0.25 
     Underweight (BMI <18.5 kg/m
2
) 0.04 - 
     Started RRT during month 0.01 - 
     1 previous month of RRT 0.01 - 
     2 previous months of RRT 0.01 - 
     3 previous months of RRT 0.02 - 
     4 previous months of RRT 0.02 - 
     5 previous months of RRT 0.02 - 
     6 previous months of RRT 0.02 - 
     7 previous months of RRT 0.02 - 
     8 previous months of RRT 0.02 - 
     9 previous months of RRT 0.02 - 
     10-12 previous months of RRT 0.05 - 
     2nd year of RRT 0.16 - 
     3rd year of RRT 0.14 - 
     3 years or more of RRT 0.49 - 
     Inability to ambulate (2728) 0.03 - 
     Inability to transfer (2728) 0.01 - 
     Smoking 0.03 - 
     Alcohol Dependence between 1999-2004 0.05 - 
     Drug Dependence between 1999-2004 0.04 - 
     Cardiac Arrest within one year 0.01 - 
     Cardiac dysrhythmia within one year 0.34 - 
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     Ischemic heart disease within one year 0.51 - 
     Pericarditis within one year 0.01 - 
     Cerebrovascular disease within one year 0.26 - 
     Diabetes within one year 0.60 - 
     Peripheral vascular disease within one year 0.45 - 
     Chronic obstructive pulmonary disease within one year 0.28 - 
     Acquired immunodeficiency disease within one year 0.02 - 
     Human immnodeficiency virus within one year 0.01 - 
     Bacterial Pneumonia six months ago 0.005 - 
     Hepatitis B within one year 0.01 - 
     Other Hepatitis between 1999-2004 0.07 - 
     Opportunistic Infection six months ago 0.001 - 
     Pneumococcal pneumonia, emphysema, lung abcess within six months 0.002 - 
     Septicemia within six months 0.04 - 
     Gastro-Intestinal (GI) Tract Bleeding six months ago 0.004 - 
     GI Ulcer - no hemorrhage within six months 0.01 - 
     Esophogeal Varices within six months 0.0004 - 
     Acquired Hemolytic Anemias within one year 0.01 - 
     Hereditary Hemolytic Anemias between 1999-2004 0.02 - 
     Sickle-Cell Anemia between 1999-2004 0.004 - 
      Leukemia within one year 0.004 - 
      Lung, Upper Digestive Tract, and Other Severe Cancers within one year 0.01 - 
      Lymphoma within two years 0.01 - 
     Metastatic Cancers within one year 0.01 - 
     Multiple Myeloma within one year 0.01 - 
     Breast, Prostate, Colorectal and Other Cancers within one year 0.08 - 
     Hyperparathyroidism within one year 0.10 - 
     Monoclonal Gammopathy within one year 0.01 - 
     Myelofibrosis within one year 0.005 - 
     Myelodysplastic Syndrome between 1999-2004 0.01 - 
Facility characteristics   
     Hospital-based facility 0.07 - 
     Facility size: < 5,000 treatments 0.08 - 
     Facility size: 5,000 - 9,999 treatments 0.26 - 
     Facility size: 10,000+ treatments 0.66 - 
     Large dialysis organization (chain1-chain6) 0.70 - 
     Regional chain 0.10 - 
     Independent 0.17 - 
     Unknown 0.03 - 
     Rural location 0.18 - 
     Metropolitan area 0.83 - 
     Micropolitan area  0.12 - 
     Not in micro or metro area  0.05 - 
N(pat-mon-fac records) 7,188,698   
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Table 2-3. Descriptive statistics of number of skipped sessions, SB MAP, and four 
comorbidities by five distance groups 
      Means 
Distance 
groups 
(miles) 
N (pat-mon-
fac) 
% Total 
# 
skipped 
sessions 
SB 
MAP 
Diabetes  
Ischemic 
heart 
disease 
Peripheral 
vascular 
disease 
Cardiac 
dysrhythmia 
(1)     0 - 2 2,006,946 27.92% 0.045 1050.62 0.61 0.51 0.45 0.34 
(2)     2 - 5 2,137,152 29.73% 0.048 1053.89 0.60 0.50 0.45 0.34 
(3)     5 - 10 1,506,926 20.96% 0.047 1057.95 0.59 0.50 0.45 0.34 
(4)   10 - 15 600,312 8.35% 0.047 1050.87 0.59 0.51 0.44 0.34 
(5)   15+  937,362 13.04% 0.049 1021.64 0.61 0.50 0.43 0.33 
Total 7,188,698               
 
43 
 
 Table 2-4. First-stage regression results to predict number of skipped sessions  
Variables Number of skipped sessions 
Instrumental variables 
    Distance (per 10 mile) -0.0026** 
 
(0.00033) 
   Distance
2
 (per 10 mile) 0.00015** 
 
(0.000022) 
   Distance square root (per 10 mile) 0.0066** 
 
(0.00047) 
  Census region fixed effects yes 
Time trends  yes 
R
2 0.01% 
Observations 7,188,698 
Note: Standard errors are in parentheses.  
 
The exogenous variables included in all models are age, female, race, duration of 
RRT, body surface area, low BMI, 36 functional and comorbid conditions,  
hospital-based or freestanding facilities, facility size, chain status, exception, 
rural/urban location, and metropolitan status. 
** Significantly different from zero at 99 percent confidence. 
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Table 2-5. OLS and 2SLS regression results 
Variables 
Dependent variable: SB MAP/month 
OLS (1) IV-2SLS (2) 
Coeff.  S.E. Coeff. S.E. 
       
Independent variable of interest 
      Number of skipped sessions -67.65 ** 1.29 -2343.29 ** 179.19 
       
Demographic variables       
Ages <18 yrs 172.49 ** 9.32 176.52 ** 11.17 
Ages 18-44 yrs 128.75 ** 1.00 126.99 ** 1.20 
Ages 45-59 yrs 49.32 ** 0.80 48.60 ** 0.96 
Ages 60-69 yrs (ref.) ref. - - - 
Ages 70-79 yrs -63.79 ** 0.80 -63.67 ** 0.96 
Ages 80+ yrs -111.00 ** 0.98 -110.97 ** 1.18 
Female 101.14 ** 0.61 101.19 ** 0.73 
Race: Native American -38.13 ** 2.29 -38.29 ** 2.75 
Race: Asian 18.59 ** 1.58 18.57 ** 1.89 
Race: Black 98.15 ** 0.63 96.82 ** 0.76 
Race: White or Unknown/missing (ref.) ref. - - - 
Race: Other 8.82 ** 2.68 8.27 ** 3.21 
       
Patient characteristics and Comorbidities       
Started RRT during month -137.50 ** 3.60 -135.37 ** 4.31 
1 previous month of RRT 392.64 ** 2.29 391.45 ** 2.74 
2 previous months of RRT 336.00 ** 2.28 334.66 ** 2.73 
3 previous months of RRT 177.55 ** 2.04 175.65 ** 2.45 
4 previous months of RRT 60.40 ** 2.09 58.49 ** 2.50 
5 previous months of RRT 8.63 ** 2.08 6.69 ** 2.49 
6 previous months of RRT -17.58 ** 2.13 -19.55 ** 2.56 
7 previous months of RRT -40.51 ** 2.12 -42.50 ** 2.54 
8 previous months of RRT -73.23 ** 2.17 -75.24 ** 2.60 
9 previous months of RRT -89.89 ** 2.19 -91.83 ** 2.63 
10-12 previous months of RRT -104.37 ** 1.32 -106.44 ** 1.58 
2nd year of RRT -90.04 ** 0.79 -91.86 ** 0.95 
3rd year of RRT -57.07 ** 0.84 -58.35 ** 1.00 
3 years or more of RRT (ref.) ref. - - - 
Body surface area (Dubois formula) 278.23 ** 1.31 279.68 ** 1.57 
Underweight (BMI <18.5 kg/m
2
) 26.63 ** 1.44 26.29 ** 1.72 
Inability to ambulate (2728) 23.67 ** 1.73 23.83 ** 2.08 
Smoking -36.74 ** 1.54 -38.16 ** 1.85 
Alcohol Dependence between 1999-2004 67.32 ** 1.26 65.79 ** 1.51 
Drug Dependence between 1999-2004 58.73 ** 1.40 57.84 ** 1.67 
Cardiac Arrest within one year 100.11 ** 2.52 100.48 ** 3.03 
Cardiac dysrhythmia within one year 89.53 ** 0.63 89.85 ** 0.76 
Ischemic heart disease within one year 48.32 ** 0.63 48.55 ** 0.75 
Pericarditis within one year 148.62 ** 2.68 148.87 ** 3.21 
Cerebrovascular disease within one year 26.86 ** 0.66 27.13 ** 0.80 
Diabetes within one year 42.56 ** 0.61 43.26 ** 0.73 
Peripheral vascular disease within one year 73.81 ** 0.59 74.11 ** 0.71 
Chronic obstructive pulmonary disease within one year 73.44 ** 0.64 73.41 ** 0.77 
Acquired immunodeficiency disease within one year 138.89 ** 3.38 138.35 ** 4.05 
Human immnodeficiency virus within one year 97.74 ** 3.84 97.19 ** 4.60 
Bacterial Pneumonia six months ago 35.66 ** 4.50 36.01 ** 5.40 
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Hepatitis B within one year 42.58 ** 2.54 42.57 ** 3.04 
Other Hepatitis between 1999-2004 -37.89 ** 1.11 -38.02 ** 1.33 
Opportunistic Infection six months ago 114.75 ** 7.74 115.13 ** 9.28 
Pneumococcal pneumonia, emphysema, lung abcess within six months 36.40 ** 6.50 36.71 ** 7.80 
Septicemia within six months 111.53 ** 1.50 111.47 ** 1.80 
Gastro-Intestinal (GI) Tract Bleeding six months ago 155.54 ** 4.71 155.51 ** 5.65 
GI Ulcer - no hemorrhage within six months 56.33 ** 3.61 56.34 ** 4.33 
Esophogeal Varices within six months 339.89 ** 13.50 340.16 ** 16.17 
Acquired Hemolytic Anemias within one year 52.15 ** 2.42 52.65 ** 2.90 
Hereditary Hemolytic Anemias between 1999-2004 112.66 ** 2.05 112.98 ** 2.46 
Sickle-Cell Anemia between 1999-2004 251.44 ** 4.26 251.64 ** 5.11 
Leukemia within one year 130.66 ** 4.18 130.86 ** 5.01 
Lung, Upper Digestive Tract, and Other Severe Cancers within one 
year 
91.96 ** 2.56 91.97 ** 3.07 
Lymphoma within two years 91.23 ** 3.33 91.33 ** 4.00 
Metastatic Cancers within one year 186.98 ** 2.59 186.97 ** 3.11 
Multiple Myeloma within one year 299.74 ** 3.08 299.93 ** 3.69 
Breast, Prostate, Colorectal and Other Cancers within one year 63.76 ** 1.05 64.13 ** 1.26 
Hyperparathyroidism within one year 31.55 ** 0.92 31.68 ** 1.10 
Monoclonal Gammopathy within one year 23.97 ** 3.59 24.67 ** 4.31 
Myelofibrosis within one year 136.23 ** 3.97 136.78 ** 4.76 
Myelodysplastic Syndrome between 1999-2004 267.45 ** 2.55 267.73 ** 3.05 
       
Census region fixed effects yes 
Time trends  yes 
R
2
 7.47% 5.30% 
N (pat-mon-fac records) 7,188,698 
The exogenous variables included in all models are age, female, race, duration of RRT, body surface area, low BMI, 36 
functional and comorbid conditions,  hospital-based or freestanding facilities, facility size, chain status, exception, 
rural/urban location, and metropolitan status. 
** Significantly different from zero at 99 percent confidence. 
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Table 2-5. OLS and 2SLS regression results (cont’d) 
Variables 
Dependent variable: log (SB MAP/month) 
OLS (3) IV-2SLS (4) 
Coeff.  S.E. Mult. Coeff. S.E. Mult. 
       
  Independent variable of interest 
      
 
Number of skipped sessions -0.095 0.001 0.91 ** -7.60 0.37 0.0005 ** 
         
Demographic variables         
Ages <18 yrs -0.045 0.011 0.96 ** -0.035 0.023 0.97  
Ages 18-44 yrs 0.089 0.001 1.09 ** 0.087 0.002 1.09 ** 
Ages 45-59 yrs 0.023 0.001 1.02 ** 0.023 0.002 1.02 ** 
Ages 60-69 yrs (ref.) ref. - - - - - 
Ages 70-79 yrs -0.051 0.001 0.95 ** -0.051 0.002 0.95 ** 
Ages 80+ yrs -0.093 0.001 0.91 ** -0.094 0.002 0.91 ** 
Female 0.12 0.001 1.13 ** 0.12 0.002 1.13 ** 
Race: Native American -0.026 0.003 0.97 ** -0.025 0.006 0.98 ** 
Race: Asian 0.041 0.002 1.04 ** 0.040 0.004 1.04 ** 
Race: Black 0.13 0.001 1.14 ** 0.13 0.002 1.14 ** 
Race: White or Unknown/missing (ref.) ref. - - - - - 
Race: Other 0.034 0.003 1.03 ** 0.032 0.007 1.03 ** 
         
Patient characteristics and Comorbidities         
Started RRT during month -0.21 0.004 0.81 ** -0.20 0.009 0.82 ** 
1 previous month of RRT 0.41 0.003 1.51 ** 0.41 0.006 1.51 ** 
2 previous months of RRT 0.35 0.003 1.42 ** 0.35 0.006 1.42 ** 
3 previous months of RRT 0.18 0.002 1.19 ** 0.17 0.005 1.19 ** 
4 previous months of RRT 0.053 0.002 1.05 ** 0.051 0.005 1.05 ** 
5 previous months of RRT 0.014 0.002 1.01 ** 0.012 0.005 1.01 * 
6 previous months of RRT 0.002 0.002 1.00  -0.0007 0.005 1.00  
7 previous months of RRT -0.018 0.002 0.98 ** -0.02 0.005 0.98 ** 
8 previous months of RRT -0.057 0.002 0.95 ** -0.059 0.005 0.94 ** 
9 previous months of RRT -0.074 0.002 0.93 ** -0.077 0.005 0.93 ** 
10-12 previous months of RRT -0.087 0.001 0.92 ** -0.090 0.003 0.91 ** 
2nd year of RRT -0.075 0.001 0.93 ** -0.078 0.002 0.93 ** 
3rd year of RRT -0.042 0.001 0.96 ** -0.043 0.002 0.96 ** 
3 years or more of RRT (ref.) ref. - - - - - 
Body surface area (Dubois formula) 0.26 0.001 1.30 ** 0.27 0.0032 1.31 ** 
Underweight (BMI <18.5 kg/m
2
) 0.012 0.002 1.01 ** 0.012 0.0035 1.01 ** 
Inability to ambulate (2728) 0.016 0.002 1.02 ** 0.017 0.0043 1.02 ** 
Smoking -0.043 0.002 0.96 ** -0.045 0.0038 0.96 ** 
Alcohol Dependence between 1999-2004 0.070 0.001 1.07 ** 0.067 0.0031 1.07 ** 
Drug Dependence between 1999-2004 0.056 0.002 1.06 ** 0.055 0.0034 1.06 ** 
Cardiac Arrest within one year 0.074 0.003 1.08 ** 0.075 0.0062 1.08 ** 
Cardiac dysrhythmia within one year 0.079 0.001 1.08 ** 0.079 0.0016 1.08 ** 
Ischemic heart disease within one year 0.055 0.001 1.06 ** 0.055 0.0015 1.06 ** 
Pericarditis within one year 0.13 0.003 1.13 ** 0.13 0.0066 1.13 ** 
Cerebrovascular disease within one year 0.025 0.001 1.02 ** 0.025 0.0016 1.03 ** 
Diabetes within one year 0.060 0.001 1.06 ** 0.061 0.0015 1.06 ** 
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Peripheral vascular disease within one year 0.065 0.001 1.07 ** 0.065 0.0015 1.07 ** 
Chronic obstructive pulmonary disease within one 
year 
0.066 0.001 1.07 ** 0.066 0.0016 1.07 ** 
Acquired immunodeficiency disease within one 
year 
0.125 0.004 1.13 ** 0.12 0.0083 1.13 ** 
Human immnodeficiency virus within one year 0.080 0.004 1.08 ** 0.079 0.0094 1.08 ** 
Bacterial Pneumonia six months ago 0.021 0.005 1.02 ** 0.022 0.011 1.02  
Hepatitis B within one year 0.036 0.003 1.04 ** 0.037 0.006 1.04 ** 
Other Hepatitis between 1999-2004 -0.051 0.001 0.95 ** -0.051 0.003 0.95 ** 
Opportunistic Infection six months ago 0.086 0.009 1.09 ** 0.087 0.019 1.09 ** 
Pneumococcal pneumonia, emphysema, lung abcess 
within six months 
0.030 0.007 1.03 ** 0.030 0.016 1.03  
Septicemia within six months 0.085 0.002 1.09 ** 0.085 0.004 1.09 ** 
Gastro-Intestinal (GI) Tract Bleeding six months 
ago 
0.12 0.005 1.13 ** 0.120 0.012 1.13 ** 
GI Ulcer - no hemorrhage within six months 0.046 0.004 1.05 ** 0.046 0.009 1.05 ** 
Esophogeal Varices within six months 0.27 0.015 1.31 ** 0.27 0.033 1.31 ** 
Acquired Hemolytic Anemias within one year 0.006 0.003 1.01 * 0.008 0.006 1.01  
Hereditary Hemolytic Anemias between 1999-2004 0.089 0.002 1.09 ** 0.090 0.005 1.09 ** 
Sickle-Cell Anemia between 1999-2004 0.17 0.005 1.18 ** 0.170 0.010 1.18 ** 
Leukemia within one year 0.10 0.005 1.10 ** 0.099 0.010 1.10 ** 
Lung, Upper Digestive Tract, and Other Severe 
Cancers within one year 
0.070 0.003 1.07 ** 0.070 0.006 1.07 ** 
Lymphoma within two years 0.075 0.004 1.08 ** 0.075 0.008 1.08 ** 
Metastatic Cancers within one year 0.14 0.003 1.15 ** 0.14 0.006 1.15 ** 
Multiple Myeloma within one year 0.23 0.003 1.26 ** 0.23 0.008 1.26 ** 
Breast, Prostate, Colorectal and Other Cancers 
within one year 
0.067 0.001 1.07 ** 0.067 0.003 1.07 ** 
Hyperparathyroidism within one year 0.033 0.001 1.03 ** 0.033 0.002 1.03 ** 
Monoclonal Gammopathy within one year 0.025 0.004 1.03 ** 0.027 0.009 1.03 ** 
Myelofibrosis within one year 0.10 0.004 1.11 ** 0.10 0.010 1.11 ** 
Myelodysplastic Syndrome between 1999-2004 0.20 0.003 1.22 ** 0.20 0.006 1.22 ** 
       
  Census region fixed effects yes 
Time trends  yes 
R
2
 6.18% 1.37% 
N (pat-mon-fac records) 7,188,698 
The exogenous variables included in all models are age, female, race, duration of RRT, body surface area, low BMI, 36 
functional and comorbid conditions,  hospital-based or freestanding facilities, facility size, chain status, exception, rural/urban 
location, and metropolitan status. 
* Significantly different from zero at 95 percent confidence. 
       ** Significantly different from zero at 99 percent confidence. 
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Table 2-6. Results from three lagged effect models 
Variables 
Dependent Variable 
1-month lead SB 
MAP/month 
2-month lead SB 
MAP/month 
3-month lead SB 
MAP/month 
          
Independent variable of interest 
         
Number of skipped sessions 
18.01 ** 1.32 18.91 ** 1.36 19.41 ** 1.40 
          
Demographic variables 
         
Ages <18 yrs 165.08 ** 9.58 164.02 ** 10.00 163.28 ** 10.44 
Ages 18-44 yrs 106.86 ** 1.01 99.98 ** 1.04 94.95 ** 1.07 
Ages 45-59 yrs 41.22 ** 0.81 37.78 ** 0.83 35.22 ** 0.86 
Ages 60-69 yrs (ref.) ref. - - - - - 
Ages 70-79 yrs -58.03 ** 0.82 -56.42 ** 0.84 -55.43 ** 0.86 
Ages 80+ yrs -102.63 ** 1.00 -100.01 ** 1.03 -98.43 ** 1.07 
Female 99.00 ** 0.62 100.36 ** 0.64 100.27 ** 0.66 
Race: Native American -42.39 ** 2.33 -44.82 ** 2.39 -45.66 ** 2.45 
Race: Asian 21.21 ** 1.61 19.45 ** 1.65 19.29 ** 1.70 
Race: Black 94.75 ** 0.64 92.64 ** 0.66 91.87 ** 0.68 
Race: White or Unknown/missing (ref.) ref. - - - - - 
Race: Other 7.87 ** 2.72 6.68 * 2.79 6.81 * 2.87 
          
Patient characteristics and Comorbidities 
         
Started RRT during month 420.93 ** 3.69 262.57 ** 3.86 115.76 ** 4.03 
1 previous month of RRT 298.86 ** 2.36 135.90 ** 2.47 37.72 ** 2.56 
2 previous months of RRT 137.90 ** 2.34 34.61 ** 2.43 -4.37  2.52 
3 previous months of RRT 46.38 ** 2.09 5.11 * 2.16 -5.69 * 2.22 
4 previous months of RRT 1.55  2.13 -11.71 ** 2.19 -29.98 ** 2.26 
5 previous months of RRT -15.60 ** 2.12 -36.47 ** 2.18 -63.01 ** 2.25 
6 previous months of RRT -45.44 ** 2.17 -73.54 ** 2.24 -84.56 ** 2.31 
7 previous months of RRT -75.77 ** 2.16 -87.34 ** 2.22 -90.59 ** 2.29 
8 previous months of RRT -89.31 ** 2.21 -94.24 ** 2.28 -100.29 ** 2.35 
9 previous months of RRT -96.02 ** 2.23 -102.78 ** 2.30 -104.27 ** 2.37 
10-12 previous months of RRT -107.68 ** 1.35 -107.89 ** 1.38 -107.48 ** 1.42 
2nd year of RRT -88.42 ** 0.80 -86.20 ** 0.82 -83.34 ** 0.85 
3rd year of RRT -54.89 ** 0.85 -53.06 ** 0.87 -51.29 ** 0.90 
3 years or more of RRT (ref.) ref. - - - - - 
Body surface area (Dubois formula) 
279.84 ** 1.33 282.18 ** 1.37 279.67 ** 1.41 
Underweight (BMI <18.5 kg/m
2
) 14.09 ** 1.47 12.67 ** 1.53 10.43 ** 1.59 
Inability to ambulate (2728) 25.38 ** 1.78 27.97 ** 1.85 28.36 ** 1.92 
Smoking -34.63 ** 1.59 -32.99 ** 1.65 -32.18 ** 1.71 
Alcohol Dependence between 1999-2004 59.62 ** 1.29 59.66 ** 1.33 60.72 ** 1.37 
Drug Dependence between 1999-2004 42.72 ** 1.43 41.48 ** 1.48 41.83 ** 1.53 
Cardiac Arrest within one year 80.12 ** 2.60 61.66 ** 2.71 49.44 ** 2.83 
Cardiac dysrhythmia within one year 73.03 ** 0.64 64.44 ** 0.66 58.76 ** 0.68 
Ischemic heart disease within one year 39.52 ** 0.64 36.43 ** 0.65 34.75 ** 0.67 
Pericarditis within one year 123.63 ** 2.73 108.93 ** 2.81 98.30 ** 2.90 
Cerebrovascular disease within one year 17.89 ** 0.68 14.23 ** 0.70 12.87 ** 0.72 
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Diabetes within one year 35.82 ** 0.62 34.07 ** 0.64 34.33 ** 0.66 
Peripheral vascular disease within one year 56.54 ** 0.60 49.45 ** 0.62 46.00 ** 0.64 
Chronic obstructive pulmonary disease within 
one year 
59.65 ** 0.65 53.96 ** 0.67 50.83 ** 0.69 
Acquired immunodeficiency disease within one 
year 
132.80 ** 3.44 134.83 ** 3.53 134.29 ** 3.63 
Human immnodeficiency virus within one year 82.99 ** 3.90 76.67 ** 4.01 73.78 ** 4.11 
Bacterial Pneumonia six months ago 23.10 ** 4.62 22.02 ** 4.81 16.44 ** 5.02 
Hepatitis B within one year 31.30 ** 2.58 27.60 ** 2.66 25.51 ** 2.74 
Other Hepatitis between 1999-2004 -40.32 ** 1.13 -40.31 ** 1.16 -39.34 ** 1.19 
Opportunistic Infection six months ago 88.75 ** 7.92 79.55 ** 8.23 70.35 ** 8.53 
Pneumococcal pneumonia, emphysema, lung 
abcess within six months 
39.94 ** 6.64 35.83 ** 6.88 33.42 ** 7.12 
Septicemia within six months 81.93 ** 1.53 70.32 ** 1.58 64.58 ** 1.64 
Gastro-Intestinal (GI) Tract Bleeding six months 
ago 
127.70 ** 4.80 112.35 ** 4.98 110.92 ** 5.16 
GI Ulcer - no hemorrhage within six months 45.14 ** 3.68 46.31 ** 3.80 44.83 ** 3.93 
Esophogeal Varices within six months 307.98 ** 13.89 279.89 ** 14.53 276.87 ** 15.28 
Acquired Hemolytic Anemias within one year 30.10 ** 2.47 25.63 ** 2.55 17.82 ** 2.63 
Hereditary Hemolytic Anemias between 1999-
2004 
108.34 ** 2.10 106.75 ** 2.16 105.33 ** 2.24 
Sickle-Cell Anemia between 1999-2004 234.72 ** 4.35 235.61 ** 4.49 231.04 ** 4.63 
Leukemia within one year 119.68 ** 4.29 117.41 ** 4.47 115.47 ** 4.66 
Lung, Upper Digestive Tract, and Other Severe 
Cancers within one year 
78.47 ** 2.64 74.56 ** 2.76 68.82 ** 2.89 
Lymphoma within two years 83.32 ** 3.42 81.77 ** 3.55 80.01 ** 3.69 
Metastatic Cancers within one year 160.21 ** 2.67 151.68 ** 2.81 139.45 ** 2.94 
Multiple Myeloma within one year 277.59 ** 3.16 275.45 ** 3.30 268.80 ** 3.45 
Breast, Prostate, Colorectal and Other Cancers 
within one year 
58.38 ** 1.07 56.78 ** 1.11 55.41 ** 1.14 
Hyperparathyroidism within one year 22.40 ** 0.93 16.51 ** 0.96 12.10 ** 0.98 
Monoclonal Gammopathy within one year 23.38 ** 3.67 22.62 ** 3.81 24.55 ** 3.94 
Myelofibrosis within one year 118.67 ** 4.04 112.61 ** 4.16 107.55 ** 4.28 
Myelodysplastic Syndrome between 1999-2004 257.62 ** 2.61 253.52 ** 2.72 250.51 ** 2.82 
          
Census region fixed effects yes 
Time trends  yes 
R2 6.20% 5.52% 5.26% 
N (pat-mon-fac records) 6,772,535 6,381,413 6,013,770 
The exogenous variables included in all models are age, female, race, duration of RRT, body surface area, low BMI, 36 
functional and comorbid conditions,  hospital-based or freestanding facilities, facility size, chain status, exception, 
rural/urban location, and metropolitan status. 
 
* Significantly different from zero at 95 percent confidence. 
       
** Significantly different from zero at 99 percent confidence. 
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Table 2-7. Sensitivity analysis: OLS and 2SLS regression results after the exclusion of 
month of death and the month prior to death 
Variables 
Dependent variable: SB MAP/month 
OLS (1) IV-2SLS (2) 
Coeff.    S.E. Coeff.   S.E. 
       
Independent variable of interest 
      Number of skipped sessions -68.58 ** 1.3 -2254.71 ** 178.61 
       
Demographic variables       
Ages <18 yrs 175.33 ** 9.38 179.37 ** 11.13 
Ages 18-44 yrs 129.14 ** 1.01 127.34 ** 1.19 
Ages 45-59 yrs 49.45 ** 0.81 48.72 ** 0.96 
Ages 60-69 yrs (ref.) ref. - -  - 
Ages 70-79 yrs -63.89 ** 0.81 -63.77 ** 0.96 
Ages 80+ yrs -111.03 ** 1 -111.02 ** 1.18 
Female 101.93 ** 0.62 101.97 ** 0.73 
Race: Native American -37.14 ** 2.31 -37.30 ** 2.74 
Race: Asian 18.73 ** 1.59 18.73 ** 1.89 
Race: Black 98.46 ** 0.64 97.13 ** 0.76 
Race: White or Unknown/missing (ref.) ref. - -  - 
Race: Other 9.21 ** 2.71 8.68 ** 3.21 
       
Patient characteristics and Comorbidities       
Started RRT during month -128.63 ** 3.77 -126.50 ** 4.48 
1 previous month of RRT 411.43 ** 2.36 410.15 ** 2.80 
2 previous months of RRT 343.53 ** 2.33 342.13 ** 2.76 
3 previous months of RRT 179.89 ** 2.08 177.96 ** 2.47 
4 previous months of RRT 60.59 ** 2.12 58.63 ** 2.51 
5 previous months of RRT 8.51 ** 2.11 6.54 ** 2.50 
6 previous months of RRT -17.86 ** 2.16 -19.87 ** 2.56 
7 previous months of RRT -41.15 ** 2.14 -43.18 ** 2.54 
8 previous months of RRT -73.18 ** 2.2 -75.23 ** 2.61 
9 previous months of RRT -90.26 ** 2.22 -92.25 ** 2.63 
10-12 previous months of RRT -104.76 ** 1.34 -106.87 ** 1.59 
2nd year of RRT -90.73 ** 0.8 -92.58 ** 0.95 
3rd year of RRT -57.51 ** 0.85 -58.81 ** 1.00 
3 years or more of RRT (ref.) ref. - -  - 
Body surface area (Dubois formula) 278.78 ** 1.32 280.27 ** 1.57 
Underweight (BMI <18.5 kg/m
2
) 26.36 ** 1.47 26.00 ** 1.74 
Inability to ambulate (2728) 24.62 ** 1.77 24.76 ** 2.10 
Smoking -36.80 ** 1.56 -38.25 ** 1.86 
Alcohol Dependence between 1999-2004 67.22 ** 1.28 65.64 ** 1.52 
Drug Dependence between 1999-2004 59.03 ** 1.42 58.10 ** 1.68 
Cardiac Arrest within one year 103.56 ** 2.59 103.91 ** 3.08 
Cardiac dysrhythmia within one year 89.95 ** 0.64 90.26 ** 0.76 
Ischemic heart disease within one year 48.75 ** 0.63 48.98 ** 0.75 
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Pericarditis within one year 149.27 ** 2.71 149.52 ** 3.22 
Cerebrovascular disease within one year 26.93 ** 0.67 27.19 ** 0.80 
Diabetes within one year 42.51 ** 0.62 43.22 ** 0.73 
Peripheral vascular disease within one year 73.71 ** 0.6 74.00 ** 0.71 
Chronic obstructive pulmonary disease within one year 74.08 ** 0.65 74.04 ** 0.77 
Acquired immunodeficiency disease within one year 137.58 ** 3.41 137.03 ** 4.04 
Human immnodeficiency virus within one year 97.20 ** 3.88 96.64 ** 4.60 
Bacterial Pneumonia six months ago 35.29 ** 4.63 35.63 ** 5.49 
Hepatitis B within one year 43.22 ** 2.57 43.20 ** 3.04 
Other Hepatitis between 1999-2004 -38.50 ** 1.12 -38.65 ** 1.33 
Opportunistic Infection six months ago 115.96 ** 7.89 116.34 ** 9.36 
Pneumococcal pneumonia, emphysema, lung abcess within six 
months 
39.07 ** 6.65 39.40 ** 7.90 
Septicemia within six months 111.50 ** 1.53 111.44 ** 1.81 
Gastro-Intestinal (GI) Tract Bleeding six months ago 155.29 ** 4.81 155.24 ** 5.70 
GI Ulcer - no hemorrhage within six months 56.75 ** 3.67 56.73 ** 4.35 
Esophogeal Varices within six months 336.83 ** 13.8 337.02 ** 16.37 
Acquired Hemolytic Anemias within one year 51.73 ** 2.45 52.23 ** 2.91 
Hereditary Hemolytic Anemias between 1999-2004 112.23 ** 2.08 112.55 ** 2.47 
Sickle-Cell Anemia between 1999-2004 251.32 ** 4.32 251.52 ** 5.12 
Leukemia within one year 129.27 ** 4.28 129.45 ** 5.08 
Lung, Upper Digestive Tract, and Other Severe Cancers within 
one year 
92.18 ** 2.64 92.15 ** 3.14 
Lymphoma within two years 92.16 ** 3.4 92.23 ** 4.03 
Metastatic Cancers within one year 184.12 ** 2.68 184.05 ** 3.18 
Multiple Myeloma within one year 295.17 ** 3.16 295.33 ** 3.75 
Breast, Prostate, Colorectal and Other Cancers within one year 63.51 ** 1.07 63.88 ** 1.27 
Hyperparathyroidism within one year 31.47 ** 0.93 31.60 ** 1.10 
Monoclonal Gammopathy within one year 25.47 ** 3.66 26.19 ** 4.34 
Myelofibrosis within one year 136.04 ** 4.03 136.60 ** 4.78 
Myelodysplastic Syndrome between 1999-2004 265.17 ** 2.6 265.44 ** 3.08 
       
Census region fixed effects yes 
Time trends  yes 
R
2
 7.54% 5.45% 
N (pat-mon-fac records) 6,969,739 
The exogenous variables included in all models are age, female, race, duration of RRT, body surface area, low BMI, 36 
functional and comorbid conditions,  hospital-based or freestanding facilities, facility size, chain status, exception, rural/urban 
location, and metropolitan status. 
** Significantly different from zero at 99 percent confidence. 
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Table 2-7. Sensitivity analysis: OLS and 2SLS regression results after the exclusion of 
month of death and the month prior to death (cont’d) 
Variables 
Dependent variable: log (SB MAP/month) 
OLS (3) IV-2SLS (4) 
Coeff.  S.E. Mult. Coeff. S.E. Mult. 
       
  Independent variable of interest 
        Number of skipped sessions -0.096 0.001 0.91 ** -7.41 0.36 0.0006 ** 
     
 
 
  Demographic variables     
 
 
  Ages <18 yrs -0.041 0.011 0.96 ** -0.031 0.023 0.97
 Ages 18-44 yrs 0.089 0.0011 1.09 ** 0.087 0.002 1.09 ** 
Ages 45-59 yrs 0.024 0.0009 1.02 ** 0.023 0.002 1.02 ** 
Ages 60-69 yrs (ref.) ref. - - - - - 
Ages 70-79 yrs -0.051 0.0009 0.95 ** -0.051 0.002 0.95 ** 
Ages 80+ yrs -0.092 0.0011 0.91 ** -0.093 0.002 0.91 ** 
Female 0.124 0.0007 1.13 ** 0.12 0.001 1.13 ** 
Race: Native American -0.024 0.0026 0.98 ** -0.023 0.006 0.98 ** 
Race: Asian 0.041 0.0018 1.04 ** 0.040 0.004 1.04 ** 
Race: Black 0.132 0.0007 1.14 ** 0.13 0.002 1.14 ** 
Race: White or Unknown/missing (ref.) ref. - - - - - 
Race: Other 0.035 0.0031 1.04 ** 0.033 0.007 1.03 ** 
       
  Patient characteristics and Comorbidities       
  Started RRT during month -0.19 0.0043 0.82 ** -0.19 0.009 0.83 ** 
1 previous month of RRT 0.43 0.0027 1.54 ** 0.43 0.006 1.54 ** 
2 previous months of RRT 0.36 0.0026 1.43 ** 0.36 0.006 1.43 ** 
3 previous months of RRT 0.18 0.0024 1.20 ** 0.18 0.005 1.19 ** 
4 previous months of RRT 0.054 0.0024 1.06 ** 0.051 0.005 1.05 ** 
5 previous months of RRT 0.014 0.0024 1.01 ** 0.011 0.005 1.01 * 
6 previous months of RRT 0.002 0.0024 1.00  -0.0005 0.005 1.00  
7 previous months of RRT -0.018 0.0024 0.98 ** -0.021 0.005 0.98 ** 
8 previous months of RRT -0.057 0.0025 0.94 ** -0.059 0.005 0.94 ** 
9 previous months of RRT -0.075 0.0025 0.93 ** -0.077 0.005 0.93 ** 
10-12 previous months of RRT -0.087 0.0015 0.92 ** -0.090 0.003 0.91 ** 
2nd year of RRT -0.075 0.0009 0.93 ** -0.078 0.002 0.92 ** 
3rd year of RRT -0.042 0.0010 0.96 ** -0.044 0.002 0.96 ** 
3 years or more of RRT (ref.) ref. - - - - - 
Body surface area (Dubois formula) 0.26 0.0015 1.30 ** 0.27 0.003 1.31 ** 
Underweight (BMI <18.5 kg/m
2
) 0.013 0.0017 1.01 ** 0.013 0.004 1.01 ** 
Inability to ambulate (2728) 0.018 0.0020 1.02 ** 0.019 0.004 1.02 ** 
Smoking -0.043 0.0018 0.96 ** -0.045 0.004 0.96 ** 
Alcohol Dependence between 1999-2004 0.070 0.0014 1.07 ** 0.067 0.003 1.07 ** 
Drug Dependence between 1999-2004 0.057 0.0016 1.06 ** 0.056 0.003 1.06 ** 
Cardiac Arrest within one year 0.080 0.0029 1.08 ** 0.081 0.006 1.08 ** 
Cardiac dysrhythmia within one year 0.080 0.0007 1.08 ** 0.080 0.002 1.08 ** 
Ischemic heart disease within one year 0.055 0.0007 1.06 ** 0.056 0.002 1.06 ** 
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Pericarditis within one year 0.13 0.0031 1.13 ** 0.13 0.007 1.13 ** 
Cerebrovascular disease within one year 0.025 0.0008 1.03 ** 0.026 0.002 1.03 ** 
Diabetes within one year 0.060 0.0007 1.06 ** 0.061 0.001 1.06 ** 
Peripheral vascular disease within one year 0.065 0.0007 1.07 ** 0.065 0.001 1.07 ** 
Chronic obstructive pulmonary disease within one 
year 
0.067 0.0007 1.07 ** 0.067 0.002 1.07 ** 
Acquired immunodeficiency disease within one year 0.12 0.0038 1.13 ** 0.12 0.008 1.13 ** 
Human immnodeficiency virus within one year 0.080 0.0044 1.08 ** 0.079 0.009 1.08 ** 
Bacterial Pneumonia six months ago 0.022 0.0052 1.02 ** 0.023 0.011 1.02 * 
Hepatitis B within one year 0.037 0.0029 1.04 ** 0.037 0.006 1.04 ** 
Other Hepatitis between 1999-2004 -0.052 0.0013 0.95 ** -0.052 0.003 0.95 ** 
Opportunistic Infection six months ago 0.089 0.0089 1.09 ** 0.089 0.019 1.09 ** 
Pneumococcal pneumonia, emphysema, lung abcess 
within six months 
0.031 0.0075 1.03 ** 0.032 0.016 1.03 * 
Septicemia within six months 0.085 0.0017 1.09 ** 0.086 0.004 1.09 ** 
Gastro-Intestinal (GI) Tract Bleeding six months ago 0.12 0.0054 1.13 ** 0.12 0.012 1.13 ** 
GI Ulcer - no hemorrhage within six months 0.047 0.0041 1.05 ** 0.047 0.009 1.05 ** 
Esophogeal Varices within six months 0.27 0.0156 1.31 ** 0.27 0.033 1.31 ** 
Acquired Hemolytic Anemias within one year 0.006 0.0028 1.01 * 0.007 0.006 1.01  
Hereditary Hemolytic Anemias between 1999-2004 0.088 0.0023 1.09 ** 0.089 0.005 1.09 ** 
Sickle-Cell Anemia between 1999-2004 0.17 0.0049 1.18 ** 0.17 0.010 1.18 ** 
Leukemia within one year 0.10 0.0048 1.10 ** 0.10 0.010 1.10 ** 
Lung, Upper Digestive Tract, and Other Severe 
Cancers within one year 
0.072 0.0030 1.07 ** 0.072 0.006 1.07 ** 
Lymphoma within two years 0.077 0.0038 1.08 ** 0.077 0.008 1.08 ** 
Metastatic Cancers within one year 0.14 0.0030 1.15 ** 0.14 0.006 1.16 ** 
Multiple Myeloma within one year 0.23 0.0036 1.26 ** 0.23 0.008 1.26 ** 
Breast, Prostate, Colorectal and Other Cancers 
within one year 
0.067 0.0012 1.07 ** 0.067 0.003 1.07 ** 
Hyperparathyroidism within one year 0.033 0.0010 1.03 ** 0.033 0.002 1.03 ** 
Monoclonal Gammopathy within one year 0.026 0.0041 1.03 ** 0.027 0.009 1.03 ** 
Myelofibrosis within one year 0.10 0.0045 1.11 ** 0.10 0.010 1.11 ** 
Myelodysplastic Syndrome between 1999-2004 0.20 0.0029 1.22 ** 0.20 0.006 1.22 ** 
       
  Census region fixed effects yes 
Time trends  yes 
R
2
 6.29% 1.43% 
N (pat-mon-fac records) 6,969,739 
The exogenous variables included in all models are age, female, race, duration of RRT, body surface area, low BMI, 36 
functional and comorbid conditions,  hospital-based or freestanding facilities, facility size, chain status, exception, rural/urban 
location, and metropolitan status. 
* Significantly different from zero at 95 percent confidence. 
      ** Significantly different from zero at 99 percent confidence. 
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Table 2-8. Sensitivity analysis: Results from three lagged effect models after the 
exclusion of month of death and the month prior to death 
Variables 
Dependent Variable 
1-month lead SB 
MAP/month 
2-month lead SB 
MAP/month 
3-month lead SB 
MAP/month 
          
Independent variable of interest 
         Number of skipped sessions 19.80 ** 1.33 20.66 ** 1.37 20.97 ** 1.41 
          
Demographic variables          
Ages <18 yrs 166.53 ** 9.58 162.32 ** 9.99 162.84 ** 10.43 
Ages 18-44 yrs 106.79 ** 1.02 99.64 ** 1.05 94.51 ** 1.07 
Ages 45-59 yrs 40.93 ** 0.82 37.52 ** 0.84 34.95 ** 0.86 
Ages 60-69 yrs (ref.) ref.  - - - -   
Ages 70-79 yrs -57.46 ** 0.83 -55.63 ** 0.85 -54.78 ** 0.87 
Ages 80+ yrs -99.98 ** 1.02 -97.47 ** 1.05 -96.11 ** 1.09 
Female 99.72 ** 0.63 101.04 ** 0.65 101.05 ** 0.66 
Race: Native American -41.66 ** 2.35 -43.90 ** 2.41 -44.80 ** 2.47 
Race: Asian 20.11 ** 1.62 18.52 ** 1.66 18.32 ** 1.71 
Race: Black 94.57 ** 0.65 92.50 ** 0.67 91.67 ** 0.69 
Race: White or Unknown/missing (ref.) ref.  - - - -  - 
Race: Other 8.35 ** 2.74 6.79 * 2.82 6.71 * 2.90 
          
Patient characteristics and Comorbidities          
Started RRT during month 440.14 ** 3.78 272.40 ** 3.94 116.83 ** 4.10 
1 previous month of RRT 312.26 ** 2.41 139.83 ** 2.51 39.12 ** 2.61 
2 previous months of RRT 142.70 ** 2.39 36.11 ** 2.48 -4.74  2.56 
3 previous months of RRT 47.65 ** 2.12 5.58 * 2.19 -6.00 ** 2.25 
4 previous months of RRT 1.46  2.16 -12.16 ** 2.22 -30.78 ** 2.29 
5 previous months of RRT -16.56 ** 2.14 -37.62 ** 2.21 -63.25 ** 2.28 
6 previous months of RRT -47.14 ** 2.20 -73.89 ** 2.26 -85.82 ** 2.33 
7 previous months of RRT -76.30 ** 2.18 -88.47 ** 2.25 -92.46 ** 2.32 
8 previous months of RRT -90.73 ** 2.24 -96.67 ** 2.31 -100.63 ** 2.38 
9 previous months of RRT -98.63 ** 2.26 -103.21 ** 2.32 -107.45 ** 2.40 
10-12 previous months of RRT -109.86 ** 1.36 -110.52 ** 1.40 -109.95 ** 1.44 
2nd year of RRT -90.37 ** 0.81 -88.27 ** 0.83 -85.08 ** 0.86 
3rd year of RRT -55.99 ** 0.86 -54.01 ** 0.88 -52.24 ** 0.91 
3 years or more of RRT (ref.) ref.  - - - -  - 
Body surface area (Dubois formula) 279.67 ** 1.34 281.97 ** 1.38 279.47 ** 1.42 
Underweight (BMI <18.5 kg/m2) 17.17 ** 1.50 14.99 ** 1.56 12.57 ** 1.61 
Inability to ambulate (2728) 27.94 ** 1.81 30.06 ** 1.88 30.01 ** 1.96 
Smoking -34.53 ** 1.60 -32.64 ** 1.66 -32.21 ** 1.73 
Alcohol Dependence between 1999-2004 59.99 ** 1.30 59.92 ** 1.34 60.95 ** 1.39 
Drug Dependence between 1999-2004 44.30 ** 1.45 42.99 ** 1.50 43.06 ** 1.55 
Cardiac Arrest within one year 86.06 ** 2.67 66.38 ** 2.78 54.13 ** 2.89 
Cardiac dysrhythmia within one year 75.54 ** 0.65 66.66 ** 0.67 60.97 ** 0.69 
Ischemic heart disease within one year 40.71 ** 0.64 37.47 ** 0.66 35.85 ** 0.68 
Pericarditis within one year 125.24 ** 2.76 109.78 ** 2.85 98.33 ** 2.94 
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Cerebrovascular disease within one year 19.25 ** 0.69 15.66 ** 0.71 14.22 ** 0.73 
Diabetes within one year 36.98 ** 0.63 35.24 ** 0.64 35.46 ** 0.66 
Peripheral vascular disease within one year 57.86 ** 0.61 50.70 ** 0.63 47.08 ** 0.65 
Chronic obstructive pulmonary disease 
within one year 
61.73 ** 0.66 56.04 ** 0.68 52.84 ** 0.70 
Acquired immunodeficiency disease within 
one year 
132.55 ** 3.46 134.28 ** 3.55 134.24 ** 3.65 
Human immnodeficiency virus within one 
year 
83.22 ** 3.93 77.25 ** 4.03 73.49 ** 4.14 
Bacterial Pneumonia six months ago 26.04 ** 4.75 25.66 ** 4.94 16.97 ** 5.14 
Hepatitis B within one year 32.07 ** 2.61 27.51 ** 2.69 24.96 ** 2.77 
Other Hepatitis between 1999-2004 -40.81 ** 1.14 -40.67 ** 1.17 -39.93 ** 1.20 
Opportunistic Infection six months ago 91.81 ** 8.08 79.77 ** 8.38 71.18 ** 8.68 
Pneumococcal pneumonia, emphysema, lung 
abcess within six months 
40.07 ** 6.79 32.80 ** 7.02 33.89 ** 7.27 
Septicemia within six months 83.96 ** 1.56 71.76 ** 1.61 65.80 ** 1.67 
Gastro-Intestinal (GI) Tract Bleeding six 
months ago 
129.05 ** 4.91 112.87 ** 5.08 111.79 ** 5.26 
GI Ulcer - no hemorrhage within six months 48.10 ** 3.74 45.45 ** 3.86 44.54 ** 3.99 
Esophogeal Varices within six months 310.45 ** 14.28 288.14 ** 14.94 276.25 ** 15.63 
Acquired Hemolytic Anemias within one 
year 
29.87 ** 2.50 25.14 ** 2.58 17.67 ** 2.66 
Hereditary Hemolytic Anemias between 
1999-2004 
108.37 ** 2.12 107.14 ** 2.19 105.95 ** 2.26 
Sickle-Cell Anemia between 1999-2004 235.53 ** 4.40 236.23 ** 4.54 232.42 ** 4.68 
Leukemia within one year 120.38 ** 4.40 118.64 ** 4.57 115.64 ** 4.75 
Lung, Upper Digestive Tract, and Other 
Severe Cancers within one year 
83.03 ** 2.73 77.14 ** 2.85 70.91 ** 2.97 
Lymphoma within two years 86.61 ** 3.48 84.71 ** 3.62 82.24 ** 3.75 
Metastatic Cancers within one year 165.44 ** 2.77 154.57 ** 2.90 141.43 ** 3.04 
Multiple Myeloma within one year 278.26 ** 3.26 273.83 ** 3.39 266.36 ** 3.54 
Breast, Prostate, Colorectal and Other 
Cancers within one year 
58.92 ** 1.09 56.74 ** 1.12 55.36 ** 1.16 
Hyperparathyroidism within one year 22.18 ** 0.94 16.25 ** 0.97 11.68 ** 0.99 
Monoclonal Gammopathy within one year 24.56 ** 3.74 23.43 ** 3.87 24.53 ** 4.01 
Myelofibrosis within one year 119.17 ** 4.10 112.73 ** 4.21 107.35 ** 4.33 
Myelodysplastic Syndrome between 1999-
2004 
256.50 ** 2.66 253.26 ** 2.77 249.78 ** 2.88 
          
Census region fixed effects yes 
Time trends  yes 
R2 6.33% 5.61% 5.34% 
N (pat-mon-fac records) 6,586,921 6,210,882 5,855,789 
The exogenous variables included in all models are age, female, race, duration of RRT, body surface area, low BMI, 
36 functional and comorbid conditions,  hospital-based or freestanding facilities, facility size, chain status, exception, 
rural/urban location, and metropolitan status. 
  * Significantly different from zero at 95 percent confidence. 
       ** Significantly different from zero at 99 percent confidence. 
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Chapter III 
 
Chapter III. Examining the Association between Non-Adherence and Composite 
Rate Costs for Hemodialysis Facilities 
 
Abstract 
 
Background. The substantial body of studies exploring the relationship of non-adherence 
in hemodialysis (HD) sessions to the patients’ outcome and quality of life has rarely 
investigated the economic consequences within the end-stage renal disease (ESRD) 
community.  While a few existing studies have examined the relationship between non-
adherence with ESRD medical expenditure, none has investigated this relationship at the 
dialysis facility level.  
Objectives. This study investigates whether there is an association between non-
adherence, as measured by the average HD sessions missed per patient per month, and 
composite rate (CR) costs for dialysis facilities, using a nationally representative sample.  
Methods. The study population includes 11,600 facility-years from between the years 
2004 and 2006.  The sources of the CR cost data are the Medicare Independent Renal 
Dialysis Facility Cost Reports (Form CMS 265-94) and the Medicare Hospital Cost 
Reports (Form CMS 2552-96).  Patient characteristics, comorbidities, and factors 
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associated with an interrupted dialysis month, such as missed sessions, transfer between 
facility, hospitalization, and transplantation, were measured using CMS Form 2728 
and/or Medicare claims.  Since CR costs were right-skewed, we examined the association 
using both OLS and log-linear models and compared the coefficient estimates derived 
from each. In addition, this study investigates whether the inclusion of facility control 
variables significantly changes the effect.  
Results. Descriptive statistics show that the average CR cost per month was $2,089.50 
between 2004 and 2006.  The average dialysis sessions missed per patient per month at 
the facility level is 0.11.  Without facility control variables, the coefficient estimate of 
non-adherence was not statistically significant in the OLS model, with an R-square of 
1.59 percent.  The coefficient estimate from the log-linear model was 0.066 (p=0.0059; 
multiplier=1.07), with an R-square of 15.48 percent.  After the inclusion of facility 
control variables, the OLS coefficient estimate of non-adherence remained insignificant.  
The R-square increased to 3.37 percent.  In the log-linear model with facility control 
variables, the coefficient estimate of non-adherence was also insignificant, although the 
R-square increased dramatically to 39.44 percent. 
Conclusion. This study did not find an association between non-adherence and CR costs 
at the dialysis facility level, except for the log-linear model without facility control 
variables.  Since there are no meaningful cost savings for dialysis facilities when patients 
skipped routine HD treatments, combined with the revenue loss facing these facilities 
when patients do not show up for their appointments, there is a financial incentive for 
dialysis facilities to improve patient adherence.  In order to improve adherence, dialysis 
facilities could consider using various approaches, e.g., reminder phone calls, text 
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messages, and e-mails, to target patients who are more likely to skip sessions.  A policy 
intervention from the CMS may not be necessary at this time .  
Key Words. Non-adherence, health care costs, hemodialysis, dialysis facility, ESRD 
 
Introduction 
 
This study provides information on whether non-adherence in HD sessions is associated 
with short-run composite rate costs.  Specifically, in the OLS and log-linear regression 
models of CR costs on non-adherence, when controlling for patient case-mix factors 
and/or facility characteristics, no association was found between non-adherence and CR 
costs.   
 CR costs include the all-inclusive payments for a comprehensive bundle of 
institutional and home dialysis services, which may consist of nursing services supplies, 
equipment, drugs, and administrative efforts associated with dialysis treatments (Rettig et 
al., 1990).  In general, in-center HD sessions are administered three times per week for 
each HD patient, with three to four hours of dialysis per session.  There are usually three 
shifts of dialysis patients per day.  The ESRD industry does not overbook HD patients, 
unlike other industries such as the airline industry, which adopts an overbooking strategy 
to control for the damage on economic costs when a passenger does not show up.  
Therefore, when an HD patient misses his appointment randomly, the fixed cost 
component, e.g., nursing and administrative staff, of the CR costs would need to be 
absorbed by the dialysis facility.  Results from this study might be useful for both dialysis 
facilities and the CMS.  From the dialysis facilities’ perspective, they could implement 
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strategies to increase the adherence rate if the results show that non-adherence is 
associated with higher CR costs.  From the CMS’s perspective, it is important to know 
what the magnitude of non-adherence on CR costs is, in order to better monitor 
reimbursement and regulate budgetary issues.  
 Although an extensive body of literature exists to explore the effect of non-
adherence on a myriad of factors—such as its association with patient-specific 
characteristics and with patient outcomes—none has specifically assessed the impact of 
missed HD sessions on CR costs for dialysis facilities.  In terms of the assessment on data 
issues and methodologies used by previous non-adherence studies, there are two common 
limitations that constrain their reliability and validity.  Most studies use cross-sectional 
data to conduct analysis, failing to control for plausible temporal trends that may be 
associated with the dependent variable.  To address this concern, this study uses 
longitudinal panel data from 2004 to 2006.  Another issue is related to the sample size 
and sampling strategies.  Most of the literature on non-adherence of HD sessions used a 
relatively small number of study observations, which limits generalizability.  This study 
uses data on all in-center HD facilities in the United States without any missing values in 
covariates as the unit of analysis. 
 
Literature Review 
 
Within the ESRD literature, issues concerning patient non-adherence with HD 
prescriptions have been discussed extensively.  A large body of research regarding 
predictors and clinical outcomes of non-adherence has been published in the clinical 
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literature (Denhaerynck et al., 2005; Jarzembowski et al., 2004; Leggat et al., 1998; 
Leggat et al., 2005; Saran et al., 2003).  Most researchers define non-adherence in 
dialysis patients when there is an interdialytic weight gain >1.5 kg, a serum phosphorus 
level >6 mg/dL, and/or a predialysis serum potassium level >5.5 mEq/L, or when dialysis 
sessions are shortened or missed by the patient.  Many studies found a positive 
correlation between non-adherence in dialysis sessions and worsening health outcomes, 
and a negative association between non-adherence and quality of life (Denhaerynck et al., 
2005; Leggat et al., 1998; Saran et al., 2003).  Nevertheless, it is surprising to find that 
the economic consequences of non-adherence have rarely been investigated in the ESRD 
community.  Only a few studies have applied cost-effectiveness or cost-utility analyses to 
estimate the economic impact of non-adherence in renal transplant patients.  For example, 
Swanson and colleagues (1992) estimated that the non-adherence related additional 
hospital cost, after transplantation, amounts to $900 per non-adherent patient per year.  
Cleemput and colleagues (2004) conducted cost-utility analyses to assess non-adherence 
and its economic consequences in a renal transplant population and found that non-
adherent recipients’ lifetime treatment costs were actually lower, due to lower life 
expectancies.     
It is important to understand whether non-adherence has a significant impact on 
dialysis costs facing the current cost-conscious U.S. health care environment.  In 1973, 
the Medicare ESRD Program was established as a national health insurance program for 
eligible residents diagnosed with end-stage renal disease.  Over the past few decades, the 
total number of prevalent dialysis patients and the total expenditure of the ESRD program 
have continuously increased.  In 2007, there were 506,256 prevalent ESRD patients in the 
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U.S.  The medical expenditures associated with treating these patients have reached $20 
billion, accounting for 6.4% of the Medicare budget (U.S. Renal Data System [USRDS] 
2007).  The improved mortality rates of prevalent ESRD patients and the continuing 
growth of incident ESRD patients both contribute to the rising cost pressures encountered 
by the CMS.  
Non-adherence is commonly observed in dialysis patients (Curtin et al., 1999; 
Leggat et al., 1998).  Although dialysis is lifesaving, it only replaces 10 percent of normal 
renal function.  Patients may continue to encounter many medical problems such as salt 
and water retention, hyperparathyroidism, hypertension, and heart disease, among others 
(Loghman-Adham, 2003).  On average, dialysis patients need to take medication 6 to 10 
times per day (Loghman-Adham, 2003).  It takes a considerable amount of discipline and 
determination for patients to adhere to routine sessions and properly take the prescribed 
medications.  The non-adherence issue is particularly important for those living in the 
United States.  Bleyer and colleagues’ (1999) studies on international comparisons of 
patient adherence on hemodialysis found that roughly 2.3% of dialysis sessions were 
missed by patients in the United States, whereas missed dialysis treatments were virtually 
nonexistent in Japan and Sweden.  
There are wide variations in terms of what constitutes non-adherence.  How 
researchers define their non-adherence measures would affect the estimated prevalence 
and associated mortality risks (Kimmel et al., 1998; Kimmel et al., 1995; Leggat et al., 
1998; Saran et al., 2003).  Based on these definitions, the prevalence of non-adherence 
has been reported to vary from as little as 2% to as much as 100% (Leggat, 2005).  
Because different definitions were employed, it is difficult to make direct comparisons 
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across studies.  Results of predictors of non-adherence are mixed.  Most studies show that 
predictors in adult HD patients include age, race, sex, marital status, socioeconomic 
status, and educational level (Bame et al., 1993; Brownbridge et al., 1994; Gordon et al., 
2003; Hoover, 1989; Morduchowicz et al., 1993).  However, Leggat and colleagues 
(1998) did not find sex or education level statistically significant.  
Most studies examining the issues regarding missed and shortened HD sessions 
focused on patient characteristics and individual reasons leading to non-adherence 
(Gordon et al., 2003; Loghman-Adham, 2003).  In general, younger patients, incident 
patients, low-income patients, African-Americans, and males are more likely to be 
associated with non-adherent behaviors.  Reasons for non-adherence may include 
medical problems, life tasks, and difficulty in transportation.  Conclusions drawn from 
these studies often emphasized the development of interventions to target patient-specific 
characteristics in order to improve the adherence of HD sessions.  In terms of outcomes 
research of non-adherence on dialysis patients, recent studies by Leggat and colleagues 
(1998), Loghman-Adham (2003), and Saran and colleagues (2003) have shown that non-
adherence with HD treatment is associated with increased mortality risk.  Missed or 
shortened dialysis sessions can reduce dialysis adequacy, a potential factor for increased 
mortality.  A majority of dialysis patients suffer from anemia problems related to 
erythropoietin (EPO) deficiency and require renal anemia management.  It has been 
shown that untreated or under-treated anemia in the dialysis population is associated with 
increased morbidity and mortality (Tong et al., 2001).  
 Summarizing non-adherence studies within the ESRD transplantation literature, 
Denhaerynck and colleagues (2005) concluded that non-adherence in adult renal 
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transplant patients is associated with poor clinical outcomes.  However, non-adherence 
results in lower life-time costs because of shorter survival as well as lower quality 
adjusted life years.  Consistent determinants of non-adherence were age, social isolation, 
health beliefs, and health cognition.  Jarzembowski and colleagues (2004) examined 
pediatric patients who received renal transplantation and found that African-American 
recipients had a significantly higher rate of graft loss when compared to Caucasian and 
Hispanic recipients.  They drew the conclusion that non-adherence is a problem of great 
importance in the African-American pediatric transplant population.  In contrast to the 
excellent long-term survival rate in pediatric receipts of renal transplantation, Ettenger 
and colleagues (2005) found that the long-term transplant outcome in adolescents were 
disappointing because of non-adherence with immunosuppressive medications.  With 
early identification and appropriate interventions, significant improvement in adolescent 
graft survival is highly possible.  
 There are several studies that investigated the impact of non-adherence with 
medication regimens on health care costs (Coambs et al., 1995; Sullivan et al., 1990).  
Cleemput and colleagues (2002) provided a comprehensive literature review on the 
economics of non-adherence of therapeutic treatments and concluded that non-adherence 
is often associated with increased morbidity and mortality for chronic patients.  Studies 
from Iskedjian and colleagues (1998), Sullivan and colleagues (1990), and Coambs and 
colleagues (1995) have all suggested positive correlations between non-adherence in 
medication and hospitalization admissions.  Though it is very difficult to compare study 
results because of the lack of a gold standard in the assessment of methodology, non-
adherence literature seems to support the fact that it is more costly to treat non-adherent 
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patients than adherent ones.  Clearly, the underlying core concept of these studies is 
based on the idea that higher adherence is desirable.    
Non-adherence in medication utilization and refill behavior associated with cost 
pressure within Medicare, Medicaid, and the VA population has also received 
considerable attention.  Hirth and colleagues (2008) examined the relationship between 
out-of-pocket spending and cost-related medication underuse of hemodialysis patients 
across twelve countries.  They concluded that drug costs were associated with national 
drug financing policies as well as the non-adherence rate.  Using data on diabetic 
management, Piette and colleagues (2004) found that VA enrollees, who generally have 
more generous drug coverage, reported less cost-related medication underuse than 
patients with no health insurance, patients with Medicare or Medicaid coverage, and even 
patients with private health insurance.  Their study results also suggest that many diabetic 
patients use less than the required medication and have poorer health, due to cost-related 
non-adherence.  Mojtabai and colleagues (2003) tested the association of prescription 
drug coverage with adherence to chronic disease medications and the association of cost-
related poor adherence with health outcomes among Medicare beneficiaries at various 
income and out-of-pocket spending levels.  Results showed a positive correlation 
between the lack of drug coverage and cost-related poor adherence.  Cost-related poor 
adherence is related to adverse health outcomes, lower income level, and higher out-of-
pocket spending.  
 
Conceptual Framework 
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We consider a framework in which dialysis facilities are assumed to be profit-
maximizing, and will find means to improve patient adherence if the presence of non-
adherence reduces profitability.  There are two components of costs for CR services, the 
fixed costs and the variable costs.  Fixed costs include capital investments, operational 
overhead, and labor costs (e.g., nursing staff) associated with managing a dialysis facility.  
Variable costs are setup costs and supply costs (e.g., drugs).  
 Suppose there are two dialysis facilities, facility A and facility B, with an equal 
number of stations.  We assume that originally the stations in each facility are constantly 
full.  The fixed costs components are similar at these two facilities.  Suppose facility A 
experiences an exogenous shock in which the number of missed sessions increases over 
an extended period of time as compared with facility B.  Under this scenario, total setup 
and supply costs are expected to be lower in facility A due to fewer sessions provided, 
but average setup and supply costs will remain constant.  The number of patients 
receiving dialysis treatments at any given time is different at these two facilities, 
suggesting different staffing requirements.  Because missed sessions are assumed to be 
unpredictable, staffing arrangement cannot be easily adjusted in the short-run.  Hence, the 
fixed costs per treatment would increase.  Combining both fixed costs and variable costs 
effects, it is hypothesized that the net effect of non-adherence on CR costs per treatment 
should be positive.  
  This study attempts to examine the relationship and magnitude of the impact of 
non-adherence in HD sessions on CR costs.  Health economists often use linear models 
or logarithmic models to estimate health care expenditures, e.g., hospitalization costs.  
Logarithmic models are useful when dealing with heavy-tailed data, since a log-
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transformed dependent variable would better satisfy the assumption of normality under 
the requirement of linear models.  We first examine whether CR costs in this study 
feature a skewed distribution.  Then, since facility characteristics are often important 
predictors for CR costs, and can be used as either payment or control variables in a 
bundled case-mix adjusted payment system, we employ OLS and log-linear models, both 
with and without the inclusion of facility characteristics to assess the effects.  
 
Specific research and policy questions are: 
(1) What is the magnitude of impact regarding non-adherence on CR costs at the facility 
level using both linear and log-linear regression models? 
(2) How does controlling for facility characteristics affect the relationship between non-
adherence and CR costs? 
(3) What are the policy implications with respect to the effect of non-adherence on CR 
costs? 
 
Methods and Data 
 
Data 
 
The study sample included 11,600 dialysis facility-years between 2004 and 2006.  The 
CR costs for each dialysis patient from the patient-month-facility level dataset were 
summarized to the facility level.  Measures that can vary across month, e.g., missed 
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sessions and some comorbidities, were summarized at the annual facility-level as an 
average of their values across months.  
 The sources of the cost data are the Medicare Independent Renal Dialysis Facility 
Cost Reports (Form CMS 265-94) and the Medicare Hospital Cost Reports (Form CMS 
2552-96).  Patient characteristics, comorbidities and factors associated with a partial 
dialysis month such as missed sessions, transfer between facility, hospitalization and 
transplantation were measured using CMS Form 2728 and/or Medicare claims. 
 
Variables 
 
Dependent variables 
 
The dependent variable in this study was CR costs per patient per month.  Facility costs 
were based on Medicare allowable costs reported by facilities for dialysis and related 
services for which they are reimbursed through the composite rate.  A second dependent 
variable used in this study is the log transformation of CR costs.  
 The cost information for CR services is reported on the Medicare Cost Report 
from each dialysis facility.  Data on the actual costs of delivering CR services are not 
available at the patient level.  In this study, CR costs were measured as the average cost 
per patient per month.  Total CR costs reported on the Cost Report were divided by total 
treatments for each facility to obtain the average CR costs per treatment.  This measure 
was merged with the patient-month-facility dataset that has individual patient information 
(e.g., demographics and comorbidities) on dialysis treatments received in each month.  
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The average CR costs per month for each dialysis patient was derived by multiplying the 
average CR costs per treatment to the dialysis treatments each patient received during the 
month.  The final measure for the dependent variable was derived by summarizing the 
average CR costs per month variable from the patient-month-facility level back to the 
facility level.  
 
Independent variable of interest 
 
The non-adherence measure, the average HD sessions missed per patient per month, was 
derived using the following strategy.  Medicare claims from 2004 to 2006 were selected 
for analysis only if the number of dialysis sessions was between 0 and 20 for each claim.  
The average number of HD equivalent dialysis sessions was 12 sessions.  Several events 
that may explain low sessions in HD sessions, including starting month for dialysis with 
or without hospitalization, transplant with or without hospitalization, death with or 
without hospitalization, hospitalization only, switching dialysis modality, transfer 
between facilities, training sessions, and multiple events based on these aforementioned 
categories,  were identified using patient-month-facility level data set.  
 The measure of missed sessions was then defined as fewer than 12 HD equivalent 
sessions billed, with none of the above events identified on each record.  If the record was 
identified as a missed month, then the total number of missed sessions for that month was 
calculated using 12 minus dialysis sessions received for that month.  For example, if a 
dialysis patient was identified as a missed patient in December 2004, and the patient-
month-facility record shows that he received eight HD sessions in that month, then the 
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total number of HD sessions missed in December 2004 is four sessions.  The measure of 
the average HD sessions missed per patient per month was computed by summarizing the 
number of HD sessions missed from the patient-month-facility data set to the facility-
level data set. 
 Other studies have used different measures for non-adherence.  The most common 
four measures for non-adherence are missed HD sessions, shortened HD sessions by 10 
or more minutes, an interdialytic weight gain of more than 5.7 percent, or a serum 
phosphate of greater than 7.5 mg/Dl (Leggat et. al, 1998).  Since this data set did not 
include information beyond the number of HD sessions missed, an important caveat is the 
sensitivity of this measure as a proxy to capture the conventional non-adherence measure.  
Based on a study from Leggat and colleagues (1998), they showed that there was a high 
degree of correlation among various definitions of non-adherence.  For example, if a 
patient is classified as non-adherent using one definition, e.g., an interdialytic weight gain 
of more than 5.7 percent, then the odds of this patient being identified as a non-adherent 
patient using other definitions (e.g., missed sessions) are significantly higher.  The 
strongest correlation was found between missed HD sessions and shortened HD sessions.  
   
Patient characteristics 
 
Several patient characteristics including demographics (age, sex, race), time since start of 
renal replacement therapy (RRT), body surface area, low body mass index (BMI<18.5 
kg/m
2
), functional status, and clinical comorbidities that have significant impacts on 
explaining the variation of CR costs based on prior research (Hirth et al., 2003; Hirth et 
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al., 2007), were included in the regression models as control variables.  Data for the 
measures of patient characteristics were obtained from the ESRD Medical Evidence 
Report (CMS Form 2728) and/or Medicare claims.  Clinical comorbidities were obtained 
from both CMS Form 2728 and/or Medicare claims, since evidence shows that there were 
issues concerning underreporting of comorbidities using only CMS Form 2728.  
Additionally, this Medical Evidence Report does not capture changes in patients’ 
comorbidities after the initiation of RRT.  Comorbid conditions based purely on this form 
were not perfectly measured.  Thus, clinical comorbidity conditions were also based on 
diagnosis codes reported on various Medicare claims, including inpatient, outpatient, 
skilled nursing facility, home health, hospice, and physician claims covering a specified 
period of time.  
These claims-based comorbidity measures were limited to recent diagnoses (e.g., 
during the previous six months only) for acute conditions such as gastrointestinal 
bleeding.  Longer periods were used for chronic conditions.  Several ―look back‖ periods 
(e.g., diagnoses in last year vs. last two years) were tested to determine their ability to 
predict costs.  The most predictive look back period was chosen as the measure of the 
comorbidity to be entered into the regression models.  
 
Facility characteristics 
 
The relationship between non-adherence and CR costs may be significantly influenced by 
the inclusion or exclusion of facility characteristics.  Therefore, several facility 
characteristics including hospital-based vs. freestanding, facility size, membership in 
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major chains, whether a facility is qualified for an exception payment in CR costs, urban 
vs. rural location, metropolitan status, and census region were also used in the regression 
models. 
 
Statistical Modeling 
 
Two OLS regression models and two log-linear regression models were estimated to 
predict CR costs.  Model 1 (Equation 3-1) predicted CR costs as a function of HD 
sessions missed, patient characteristics, and census region and time fixed effects.  Model 
2 (Equation 3-2) changed the dependent variable to the log transformation of CR costs.  
Model 3 (Equation 3-3) added facility characteristics on top of the covariates used in 
Model 1.  The dependent variable for Model 4 (Equation 3-4) is log (CR costs), and the 
covariates included are HD sessions missed, patient characteristics, facility 
characteristics, and census region and time fixed effects.  For the regression analysis, 
each facility-year observation was weighted by the total number of dialysis sessions 
provided by the facility.  
 
Equation 3-1   ittiititit XNAtsCR   210cos  
Equation 3-2   ittiititit eXNAtsCR   210)coslog(  
Equation 3-3   ittiitititit FACXNAtsCR   3210cos  
Equation 3-4   ittiitititit FACXNAtsCR   3210)coslog(  
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 ittsCR cos  is the composite rate costs per patient per month for dialysis facility i 
in year t.  )coslog( ittsCR is the log transformation of CR costs for facility i in year t. 
itNA  is the non-adherence measure representing the average HD sessions missed per 
patient per month for dialysis facility i in year t.  itX  is a vector of patient characteristics 
for dialysis facility i in year t.  itFAC  is the vector of facility characteristics for dialysis 
facility i in year t.  The Census region ( i ) and year ( t ) dummy variables are also 
included to control for regional fixed effects and time trends.  Finally, Huber robust 
standard error are reported to adjust for the heteroscedasticity in error terms among 
dialysis facilities.  
 
Results 
 
Descriptive analysis 
 
Although the data show a certain degree of right-skewness in CR costs per month (Figure 
3-1), it is not as pronounced as that found in the separately billable Medicare Allowable 
Payments (SB MAP) per month.  After taking a log transformation in CR costs per 
month, we re-examined the shape of the distribution for log (CR costs).  The shape more 
closely resembles to a bell-shaped distribution (Figure 3-2).  
 Summary statistics for all variables used in this study are presented (Table 3-1).  
There are two dependent variables used in this study.  The average CR costs per patient 
per month from 2004-2006 is $2,089.50 (SD = $2,096.75).  The log (CR costs) is 7.61 
(SD = 0.20).  The average HD sessions missed per patient per month, the independent 
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variable of interest, is 0.11 (SD = 0.078).  In terms of demographics, the majority of HD 
patients in this study are between the ages of 45 and 79 (73.7 percent), males (53.3 
percent), and White (54.1 percent).  
 There are several other important patient characteristics that were used in the 
regression models.  The average body surface area (BSA) using a Dubois formula 
( 425.0725.02 )()(20247.0)( kgWeightmHeightmBSA  ) is 1.87 per 0.1 m2 (SD = 0.056).  
About 28 percent of the study population is underweight, which is defined by having a 
body mass index (BMI) less than 18.5.  About 49 percent of HD patients have received 
dialysis treatments for more than three years.  The most commonly observed 
comorbidities are diabetes (60 percent), peripheral vascular disease (45 percent), chronic 
obstructive pulmonary disease (28.3 percent), and cerebrovascular disease (26.1 percent).  
The least observed comorbidity is esophageal varices (0.04 percent). 
 For facility characteristics, 67 percent of the facility-year records indicated that 
more than 10,000 dialysis treatments were provided.  About 70 percent of the records 
showed that dialysis treatments were provided by the six largest chains (Fresenius, 
Gambro, Davita, Renal Care Group, Dialysis Centers Inc, and National Nephrology 
Associates).  Finally, 82 percent of these facility-year records are from urban location. 
 
Regression analysis 
 
Table 3-2 shows the set of estimated coefficients of the independent variables of interest 
on CR costs and log (CR costs), without the inclusion of facility characteristics.  The 
coefficient estimate of non-adherence in Model 1 shows that if an HD session is missed 
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by a patient in one month, the CR costs per patient per month would increase by $462.61.  
However, this finding is not statistically significant.  Statistically significant predictors on 
CR costs are the third year of renal replacement therapy, body surface area, and percent 
of HD patients with hepatitis B within one year. 
 For the log-linear model (Model 2), we found a statistically significant positive 
effect of non-adherence on log (CR costs).  The coefficient estimate is 0.066, and after 
the retransformation to the unlogged scale, the multiplier derived from this estimate is 
1.07.  The interpretation for this multiplier is that if an HD session is missed by a patient 
in a month, the CR costs per patient per month would increase by 7 percentage points, 
which on a dollar scale is $146.27.  Other statistically significant variables are older age, 
percentage of African American HD patients, start month and duration (3 years) of renal 
replacement therapy, body surface area, and 15 functional statuses and comorbid 
measures.  The explanatory power, R-squared, is higher in the log-linear model (15.48 
percent) than in the OLS model (1.59 percent).  
 Table 3-3 shows the regression results for the OLS and log-linear models, with 
the inclusion of facility characteristics.  The coefficient estimate of non-adherence on CR 
costs is $284.66, which remains statistically insignificant.  With the inclusion of facility 
characteristics, none of the patient characteristics has a statistically significant effect on 
measuring CR costs (Model 3).  Unlike the findings from Model 2, the effect of non-
adherence on log (CR costs) from Model 4 is not statistically significant after controlling 
for facility characteristics.  Other statistically significant explanatory variables include 
age, sex, body surface area, low BMI, and 10 functional status and comorbid measures.  
The R-squared statistic increased slightly from 1.59 percent (in Model 1) to 3.37 percent 
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(in Model 3).  The R-squared statistic increased considerably from 15.48 percent (in 
Model 2) to 39.44 percent (in Model 4), after the inclusion of facility characteristics.  
 
Sensitivity analysis 
 
We conducted a two-stage-least-square (2SLS) estimation on the association between CR 
costs and non-adherence, using distance and its square term as two instrumental 
variables.  However, since the Hausman test rejected the existence of endogeneity at the 
facility level, the 2SLS results are not reported.  
 It is highly likely to observe more voluntary withdrawal cases for dialysis patients 
who are close to the end of life.  Based on our identification strategy for non-adherence, 
we were not able to distinguish whether individual missed treatments were due to 
permanent withdrawal or temporary withdrawal.  To address this concern of possible 
misclassification, we conducted a sensitivity analysis in which we dropped observations 
on the month of death and the month prior to death, to ensure the results are not biased.  
 After excluding the observations of "month of death" and "month prior to death," 
the sample size was reduced from 11,600 to 11,598 facility years (Table 3-4).  For the 
OLS model without facility characteristics, the coefficient estimate on non-adherence 
dropped from $462.61 to $204.57, and remained statistically insignificant.  The 
magnitude of coefficient estimates on other covariates dropped consistently, as compared 
with the original model.  The coefficient estimate on non-adherence for the log-linear 
model is -0.0243 (multiplier=0.96), and is no longer statistically significant. 
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 CR costs typically fluctuate more among dialysis patients who are close to the end 
of their lives.  Results of this sensitivity analysis suggest that if we excluded these months 
with higher fluctuation in CR costs, the impact, in terms of magnitude, of non-adherence 
on CR costs is even smaller, and statistically insignificant for both linear and log-linear 
models.  
 For the OLS and log-linear models with the inclusion of facility characteristics, 
the results of this sensitivity analysis are somewhat different.  For the OLS model, the 
coefficient estimate on non-adherence dropped to $46 (SD=$230) from $284.66 
(SD=$608), and is again statistically insignificant.  Most of the coefficient estimates on 
patient characteristics are smaller in scale, and are, not surprisingly, statistically 
insignificant.  On the contrary, many of the coefficient estimates on facility 
characteristics increase after excluding records, suggesting that dialysis patients 
consumed higher CR services before they reached the end of life.  
 As a third sensitivity analysis, we excluded those months with any kind of ―event‖ 
(e.g., hospitalization, withdrawal, death) being identified and re-fit all four models.  The 
rationale to exclude these months is based on the fact that they have a zero probability of 
being identified as missing, according to the way we defined the non-adherence measure.  
Although in reality, a patient could plausibly have an ―event‖ and also skipped an HD 
session in a particular month.  In order to carefully examine the true effect of missing 
sessions on CR costs, it is important to see how sensitive the coefficient estimates are 
when excluding these ―event‖ months.  Table 3-5 shows the results.  11,584 facility years 
were used in this analysis.  For both OLS models, with and without facility 
characteristics, the coefficient estimates on non-adherence are not statistically significant, 
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consistent with previous findings.  For the log-linear models, the coefficient estimates on 
non-adherence increase for both models.    
  
Discussion 
 
This study makes several contributions to the ESRD non-adherence literature.  First, 
although abundant studies had explored the effect of non-adherence on health outcomes 
and quality of life, none specifically looked at the impact of non-adherence of HD 
sessions in CR costs for dialysis providers.  With the use of CMS Evidence Form (Form 
2728) and claims files for all Medicare HD patients, we can estimate the impact of non-
adherence on CR costs more accurately.  
 This study provides information on whether non-adherence in HD sessions is 
associated with cost-saving (or cost-increasing) for the providers, using CR costs as the 
health care costs measure.  The findings from Model 1, Model 3, and Model 4 
consistently show that there is no association between non-adherence and CR costs. 
 According to the log-linear model without controlling for facility characteristics 
(Model 2), non-adherence is associated with a seven percent increase (or $146.27) in CR 
costs.  One possible explanation for the seven percent increase in CR costs in Model 2 is 
that the non-adherence measure picks up on the impact of those facility characteristics, 
e.g., hospital-based facilities, small and medium facility size, and regional chain status.  
All of these have a positive statistically significant impact on CR costs.  When adding 
facility characteristics into the log-linear model (Model 4), the effect of non-adherence on 
CR costs fades away, suggesting that there are correlations between the average HD 
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sessions missed per patient per month and some or all of these facility characteristics.  
 Second, to take into account for the skewedness in CR costs, we examined both 
the linear and logarithmic forms of the case-mix models.  Despite the exclusion and 
inclusion of facility characteristics, the explanatory power of the logarithmic models 
(Model 2 and Model 4) was higher than that of the linear models (Model 1 and Model 3).  
In addition, standard deviations derived from the logarithmic models consistently present 
a tighter distribution than those derived from OLS models.  The findings suggest that the 
logarithmic form of CR costs model might be better than the linear form in satisfying the 
normality assumption of a statistical model.  Logged estimates for health care costs are 
often more precise and robust than the direct analysis of unlogged dependent variables.  
However, researchers are not interested in log scale results due to the difficulty in 
interpreting the coefficient estimates in log dollars.  When retransforming the logged 
estimates to the raw scale, Manning and colleagues (2001) suggested that researchers 
should consider a smearing adjustment (Duan, 1983) to correct for any form of 
heteroscedasticity in error terms to yield consistent predictions.  We have not dealt with 
this concern in this study, and would like to revisit more about this retransformation issue 
in future research.   
 With the presence of non-adherence, total revenues for dialysis facilities are 
expected to drop due to fewer sessions provided.  The study results show that there are no 
meaningful cost savings for dialysis facilities when patients skipped routine HD 
treatments.  Consequently, there is a financial incentive for dialysis facilities to improve 
patient adherence in order to maximize profit.  Dialysis facilities could consider using 
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various approaches, e.g., reminder phone calls, text messages, and e-mails, to target 
patients who are more likely to skip sessions to improve adherence.    
 From the perspective of the CMS, policy intervention to improve patient 
adherence seems unnecessary because the financial incentive associated with higher 
adherence is sufficient for dialysis facilities to monitor and improve adherence.  From the 
societal perspective, assuming that dialysis facilities will internalize the costs associated 
with improving adherence without having incentive programs from the CMS, e.g. a pay-
for-performance program, society as a whole would benefit from an increasing adherence 
in dialysis sessions, given that higher adherence is associated with better quality of life 
and better health outcomes from previous literature. 
 There are several limitations pertaining to this study.  One limitation is related to 
the quality of Medicare cost report data. Researchers have raised concerns about the 
incompleteness of cost report data (Bednar, 1992; Magnus et al., 2000; Medicare 
Payment Advisory Commission, 2004).  Being the only available data source of dialysis 
costs, cost reports have been used extensively.  To the extent that the CMS has recently 
refined the minimum file requirements and increased the controls to monitor providers’ 
behavior in ―Potential Rejection Error,‖ e.g., zero or negative values for the number of 
dialysis treatments, this concern is lessened.  It is important to note that non-adherence, 
as defined in this study, is measured conservatively.  For instance, if a patient is identified 
to have an event (e.g., hospitalization) in a month, then he will not be defined as a 
―missed‖ patient for that month based on our identification strategy.  In reality, he might 
be both ―hospitalized‖ and ―non-adherent‖ for that month.  For months with 31 days, 
patients may receive 13 treatments instead of 12 treatments.  Suppose a record shows that 
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a patient received 11 treatments in a 31-day month, without any other event being 
identified.  Using our identification strategy, this patient would be reported as missing 
one treatment, although in reality he missed two treatments.  To the extent that this non-
adherence measure was underestimated, the prevalence of non-adherence should be 
greater than 0.11 sessions per patient per month, and the coefficient estimates on non-
adherence as well as other covariates could also be affected. 
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Figure 3-1. Distribution of CR costs per patient per month 
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Figure 3-2. Distribution of log (CR costs per patient per month) 
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Table 3-1. Summary statistics of all variables, 2004-2006 
Variables Mean  S.D. 
Dependent variables   
     CR costs per month 2089.50 2096.75 
     log (CR costs per month) 7.61 0.20 
Variable of interest   
     Average HD sessions missed per patient per month 0.11 0.078 
Demographic variables   
     Ages <18 yrs 0.001 0.015 
     Ages 18-44 yrs 0.129 0.061 
     Ages 45-59 yrs 0.259 0.085 
     Ages 60-69 yrs 0.235 0.061 
     Ages 70-79 yrs 0.243 0.078 
     Ages 80+ yrs 0.133 0.077 
     Female 0.467 0.076 
     Race: Native American 0.016 0.077 
     Race: Asian 0.035 0.091 
     Race: Black 0.397 0.313 
     Race: White 0.541 0.302 
     Race: Other 0.011 0.023 
     Race: Unknown/missing 0.0002 0.0016 
Patient characteristics and comorbidities   
     Body surface area (Dubois formula) 1.867 0.056 
     Underweight (BMI <18.5 kg/m
2
) 27.76 1.32 
     Started RRT during month 0.0058 0.0043 
     1 previous month of RRT 0.0148 0.0084 
     2 previous months of RRT 0.0149 0.0079 
     3 previous months of RRT 0.0186 0.0082 
     4 previous months of RRT 0.0178 0.0075 
     5 previous months of RRT 0.0179 0.0073 
     6 previous months of RRT 0.0170 0.0069 
     7 previous months of RRT 0.0172 0.0068 
     8 previous months of RRT 0.0163 0.0064 
     9 previous months of RRT 0.0160 0.0062 
     10-12 previous months of RRT 0.0474 0.0172 
     2nd year of RRT 0.164 0.049 
     3rd year of RRT 0.138 0.041 
     3 years or more of RRT 0.49 0.11 
     Inability to ambulate (2728) 0.026 0.030 
     Inability to transfer (2728) 0.008 0.015 
     Smoking 0.034 0.042 
     Alcohol Dependence between 1999-2004 0.053 0.037 
     Drug Dependence between 1999-2004 0.042 0.030 
     Cardiac Arrest within one year 0.012 0.013 
     Cardiac dysrhythmia within one year 0.34 0.11 
     Ischemic heart disease within one year 0.51 0.12 
     Pericarditis within one year 0.011 0.013 
     Cerebrovascular disease within one year 0.261 0.078 
     Diabetes within one year 0.60 0.11 
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     Peripheral vascular disease within one year 0.45 0.11 
     Chronic obstructive pulmonary disease within one year 0.283 0.093 
     Acquired immunodeficiency disease within one year 0.015 0.024 
     Human immnodeficiency virus within one year 0.012 0.023 
     Bacterial Pneumonia six months ago 0.0047 0.0046 
     Hepatitis B within one year 0.012 0.043 
     Other Hepatitis between 1999-2004 0.072 0.068 
     Opportunistic Infection six months ago 0.0012 0.0021 
     Pneumococcal pneumonia, emphysema, lung abcess within six months 0.0022 0.0031 
     Septicemia within six months 0.035 0.030 
     Gastro-Intestinal (GI) Tract Bleeding six months ago 0.0035 0.0032 
     GI Ulcer - no hemorrhage within six months 0.0060 0.0054 
     Esophogeal Varices within six months 0.0004 0.0011 
     Acquired Hemolytic Anemias within one year 0.013 0.078 
     Hereditary Hemolytic Anemias between 1999-2004 0.018 0.023 
     Sickle-Cell Anemia between 1999-2004 0.004 0.011 
      Leukemia within one year 0.0043 0.0093 
      Lung, Upper Digestive Tract, and Other Severe Cancers within one year 0.012 0.013 
      Lymphoma within two years 0.007 0.011 
     Metastatic Cancers within one year 0.013 0.015 
     Multiple Myeloma within one year 0.008 0.012 
     Breast, Prostate, Colorectal and Other Cancers within one year 0.080 0.040 
     Hyperparathyroidism within one year 0.10 0.17 
     Monoclonal Gammopathy within one year 0.0061 0.0099 
     Myelofibrosis within one year 0.005 0.012 
     Myelodysplastic Syndrome between 1999-2004 0.012 0.017 
Facility characteristics   
     Hospital-based facility 0.07 0.25 
     Facility size: < 5,000 treatments 0.08 0.27 
     Facility size: 5,000 - 9,999 treatments 0.26 0.44 
     Facility size: 10,000+ treatments 0.67 0.47 
     Large dialysis organization (chain1-chain6) 0.70 0.46 
     Regional chain 0.10 0.30 
     Independent 0.17 0.37 
     Unknown 0.03 0.17 
     CR exception (HD claims or CMS list) 0.07 0.26 
     Rural location 0.18 0.38 
     Metropolitan area 0.83 0.37 
     Micropolitan area  0.12 0.32 
     Not in micro or metro area  0.05 0.21 
N(facility-years) 11,600   
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Table 3-2. OLS and Log-linear regression results (without facility characteristics) 
Dependent variable 
CR 
costs/month 
log (CR 
costs/month) 
  OLS (1) Log-linear (2) 
Variables  Coeff. Coeff. Mult. 
Average HD sessions skipped per patient per month 462.61 0.066* 1.07 
 
(599.23) (0.032) - 
Percent of HD patients with ages <18 years old 2829.03* 1.18** 3.25 
 (1136.88) (0.13) - 
Percent of HD patients with ages between 18 and 44 years old -349.02 0.059 1.06 
 (422.71) (0.046) - 
Percent of HD patients with ages between 70 and 79 years old 79.19 0.11** 1.12 
 
(281.55) (0.037) - 
Percent of HD patients with ages greater than 80 years old 93.78 0.18** 1.20 
 
(704.52) (0.043) - 
Percent of female HD patients  210.49 0.09** 1.09 
 
(324.34) (0.03) - 
Percent of African American HD patients -209.30** -0.06** 0.94 
 
(53.67) (0.01) - 
Started renal replacement therapy during month 13094 4.70** 109.95 
 
(10386) (0.78) - 
Third year of renal replacement therapy -554.25* -0.13** 0.88 
 
(246.35) (0.044) - 
Body surface area (Dubois formula) 1619.8** 0.48** 1.61 
 
(603.75) (0.051) - 
Percent of HD patient with BMI < 18.5 kg/m
2
 1076.1 0.002 1.00 
 
(992.29) (0.077) - 
Percent of HD patients with inability to ambulate (2728) 1855.41 0.19* 1.21 
 
(1801.32) (0.092) - 
Percent of HD patients with smoking habit 83.82 0.13* 1.14 
 
(300.97) (0.055) - 
Percent of HD patients with drug dependence 34.28 0.24** 1.28 
 (394.32) (0.063) - 
Percent of HD patients with ischemic heart disease within one year -423.67 -0.068* 0.93 
 (387.47) (0.027) - 
Percent of HD patients with cerebrovascular disease within one year -382.29 -0.095* 0.91 
 (378.67) (0.033) - 
Percent of HD patients with peripheral vascular disease within one 
year 
631.29 0.070** 1.07 
 (387.34) (0.027) - 
Percent of HD patients with acquired immunodeficiency disease within 
one year 
512.68 0.43** 1.54 
 (475.79) (0.12) - 
Percent of HD patients with bacterial pneumonia within six months 28615 1.45* 4.26 
 (18898) (0.65) - 
Percent of HD patients with hepatitis B within one year 703.1** 0.28** 1.32 
 
(214.03) (0.069) - 
Percent of HD patients with septicemia within six months -749.59 -0.072 0.93 
 
(517.00) (0.088) - 
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Percent of HD patients with gastro-intestinal ulcer within six months -1417.94 -0.42 0.66 
 
(3298.59) (0.40) - 
Percent of HD patients with opportunistic infection within six months 18833 1.85* 6.36 
 (12187) (0.86) - 
Percent of HD patients with acquired hemolytic anemias within one 
year 
312.74** 0.17** 1.18 
 (65.91) (0.024) - 
Percent of HD patients with sickle-cell anemia 986.94 0.60** 1.82 
 (656.89) (0.14) - 
Percent of HD patients with hyperparathyroidism within one year 116.44 0.076** 1.08 
 (65.55) (0.015) - 
Percent of HD patients with myelofibrosis within one year 2533.57 0.57** 1.77 
 (1494.83) (0.15) - 
Percent of HD patients with myelodysplastic syndrome -2157.50 -0.30** 0.74 
 (1181.60) (0.11) - 
Facility control variables no no 
Census region fixed effects yes yes 
Time trends  yes yes 
R
2
 1.59% 15.48% 
Observations 11,600 11,600 
Note: Huber Robust standard errors are in parentheses.  
   Fixed effects of census region and time trend are included in all specifications. 
   The exogenous variables included in all models are age, female, race, duration of RRT, body surface area, low BMI, 
37 functional and comorbid conditions,  hospital-based or freestanding facilities, facility size, chain status, exception, 
rural/urban location, and metropolitan area or not. 
* Significantly different from zero at 95 percent confidence. 
   ** Significantly different from zero at 99 percent confidence. 
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Table 3-3. OLS and Log-linear regression results (with facility characteristics) 
Dependent variable 
CR 
costs/month 
log (CR 
costs/month) 
  OLS (3) Log-linear (4) 
Variables  Coeff. Coeff. Mult. 
Average HD sessions skipped per patient per month 284.66 0.016 1.02 
 
(608.00) (0.027) - 
Percent of HD patients with ages <18 years old 937.83 0.50** 1.65 
 
(1147.39) (.11) - 
Percent of HD patients with ages between 18 and 44 years old -216.96 0.13** 1.14 
 
(443.44) (0.038) - 
Percent of HD patients with ages between 70 and 79 years old -42.63 0.075* 1.08 
 
(292.19) (0.031) - 
Percent of HD patients with ages greater than 80 years old -164.91 0.10** 1.11 
 
(712.92) (0.035) - 
Percent of female HD patients  179.75 0.067** 1.07 
 
(315.62) (0.023) - 
Percent of African American HD patients -39.49 0.0021 1.00 
 
(41.19) (0.0084) - 
Started renal replacement therapy during month 1008.16 0.33 1.39 
 
(10098) (0.65) - 
Third year of renal replacement therapy -392.48 -0.054 0.95 
 
(252.55) (0.036) - 
Body surface area (Dubois formula) 987.4 0.22** 1.25 
 
(565.20) (0.042) - 
Percent of HD patient with BMI < 18.5 kg/m
2
 687.62 -0.13* 0.88 
 
(935.79) (0.065) - 
Percent of HD patients with inability to ambulate (2728) 1061.19 -0.062 0.94 
 
(1713.61) (0.077) - 
Percent of HD patients with smoking habit -228.44 -0.009 0.99 
 
(266.53) (0.047) - 
Percent of HD patients with drug dependence -219.29 0.18* 1.19 
 
(438.98) (0.055) - 
Percent of HD patients with ischemic heart disease within one year -374.97 -0.048* 0.95 
 
(384.28) (0.022) - 
Percent of HD patients with cerebrovascular disease within one year -178.66 -0.009 0.99 
 
(374.35) (0.028) - 
Percent of HD patients with peripheral vascular disease within one year 594.85 0.077** 1.08 
 
(351.91) (0.022) - 
Percent of HD patients with acquired immunodeficiency disease within 
one year 
168.08 0.32** 1.38 
 
(463.81) (0.09) - 
Percent of HD patients with bacterial pneumonia within six months 27040 0.83 2.29 
 
(18808) (0.6) - 
Percent of HD patients with hepatitis B within one year 286.02 0.12* 1.13 
 
(193.68) (0.049) - 
Percent of HD patients with septicemia within six months -1157.56 -0.18* 0.83 
 
(601.45) (0.075) - 
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Percent of HD patients with gastro-intestinal ulcer within six months -4358.79 -1.50** 0.22 
 
(3258.64) (0.37) - 
Percent of HD patients with opportunistic infection within six months 17095 0.99 2.69 
 
(12411) (0.74) - 
Percent of HD patients with acquired hemolytic anemias within one 
year 
149.87 0.13** 1.14 
 
(100.48) (0.022) - 
Percent of HD patients with sickle-cell anemia 732.69 0.58** 1.79 
 
(736.02) (0.15) - 
Percent of HD patients with hyperparathyroidism within one year -40.46 0.028* 1.03 
 
(76.87) (0.012) - 
Percent of HD patients with myelofibrosis within one year 1387.37 0.11 1.12 
 
(1525.65) (0.12) - 
Percent of HD patients with myelodysplastic syndrome -1374.11 -0.012 0.99 
 
(1114.02) (0.093) - 
Hospital-based facility 818.43** 0.34** 1.40 
 
(72.99) (0.015) - 
Facility size: < 5,000 treatments 807.59** 0.23** 1.26 
 
(195.64) (0.008) - 
Facility size: 5,000 - 9,999 treatments 224.92** 0.10** 1.11 
 
(9.70) (0.003) - 
Large dialysis organization (chain1-chain6) -56.30 0.021** 1.02 
 
(91.90) (0.006) - 
Regional chain 59.43 0.030** 1.03 
 
(139.81) (0.009) - 
Unknown 45.22 0.041* 1.04 
 
(61.50) (0.021) - 
CR exception (HD claims or CMS list) 48.61* 0.029** 1.03 
 
(21.03) (0.007) - 
Rural location -128.21* -0.034 0.97 
 
(63.75) (0.02) - 
Metropolitan area -53.79 -0.041* 0.96 
 
(59.84) (0.021) - 
Not in micro or metro area  -50.36 0.006 1.01 
 
(44.82) (0.007) - 
Facility control variables yes  yes 
Census region fixed effects yes  yes 
Time trends  yes  yes 
R
2
 3.37% 39.44% 
Observations 11,600 11,600 
Note: Huber Robust standard errors are in parentheses.  
   Fixed effects of census region and time trend are included in all specifications. 
   
The exogenous variables included in all models are age, female, race, duration of RRT, body surface area, low BMI, 
37 functional and comorbid conditions,  hospital-based or freestanding facilities, facility size, chain status, exception, 
rural/urban location, and metropolitan area or not. 
* Significantly different from zero at 95 percent confidence. 
   ** Significantly different from zero at 99 percent confidence. 
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Table 3-4. First sensitivity analysis: OLS and Log-linear regression results after the 
exclusion of month of death and the month prior to death (without facility characteristics) 
Dependent variable 
CR 
costs/month 
log (CR 
costs/month) 
  OLS (1) Log-linear (2) 
Variables  Coeff. Coeff. Mult. 
Percent of HD sessions skipped in the month 204.57 -0.024 0.98 
 
(439.42) (0.033) - 
Percent of HD patients with ages <18 years old 1899.37 0.85** 2.35 
 
(1219.05) (0.10) - 
Percent of HD patients with ages between 18 and 44 years old -93.18 0.14* 1.15 
 
(515.88) (0.058) - 
Percent of HD patients with ages between 70 and 79 years old -16.31 0.075 1.08 
 
(281.71) (0.041) - 
Percent of HD patients with ages greater than 80 years old -6.35 0.12* 1.13 
 
(639.29) (0.046) - 
Percent of female HD patients  70.89 0.035 1.04 
 
(334.64) (0.032) - 
Percent of African American HD patients -229.27** -0.055 0.95 
 
(70.70) (0.012) - 
Started renal replacement therapy during month 9496.7 2.8* 16.44 
 
(7186.72) (1.30) - 
Third year of renal replacement therapy -395.88 -0.045 0.96 
 
(357.17) (0.056) - 
Body surface area (Dubois formula) 1508.86* 0.37** 1.45 
 
(612.73) (0.056) - 
Percent of HD patient with BMI < 18.5 kg/m
2
 1290.31 -0.013 0.99 
 
(1269.20) (0.10) - 
Percent of HD patients with inability to ambulate (2728) 1984.69 0.1 1.11 
 
(2217.92) (0.10) - 
Percent of HD patients with smoking habit 21.3 0.14* 1.15 
 
(351.78) (0.062) - 
Percent of HD patients with drug dependence 151.09 0.26** 1.29 
 
(371.39) (0.076) - 
Percent of HD patients with ischemic heart disease within one year -432.45 -0.057 0.94 
 
(437.11) (0.032) - 
Percent of HD patients with cerebrovascular disease within one year -289.54 -0.085* 0.92 
 
(462.98) (0.043) - 
Percent of HD patients with peripheral vascular disease within one year 800.47 0.1** 1.11 
 
(470.76) (0.03) - 
Percent of HD patients with acquired immunodeficiency disease within 
one year 
282.12 0.3* 1.35 
 
(529.61) (0.14) - 
Percent of HD patients with bacterial pneumonia within six months 24458 0.7 2.01 
 
(16450) (0.90) - 
Percent of HD patients with hepatitis B within one year 507.25* 0.19** 1.21 
 
(248.07) (0.069) - 
Percent of HD patients with septicemia within six months -882.30 -0.035 0.97 
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(715.83) (0.09) - 
Percent of HD patients with gastro-intestinal ulcer within six months 1101.2 0.33 1.39 
 
(3540.42) (0.48) - 
Percent of HD patients with opportunistic infection within six months 15110 0.02 1.02 
 
(13230) (0.83) - 
Percent of HD patients with acquired hemolytic anemias within one year 198.45* 0.13** 1.13 
 
(84.47) (0.025) - 
Percent of HD patients with sickle-cell anemia 1291.29 0.67** 1.95 
 
(867.05) (0.22) - 
Percent of HD patients with hyperparathyroidism within one year 83.06 0.069** 1.07 
 
(72.36) (0.014) - 
Percent of HD patients with myelofibrosis within one year 2562.04 0.33 1.39 
 
(2167.21) (0.19) - 
Percent of HD patients with myelodysplastic syndrome -2595.33 -0.04 0.96 
 
(2074.09) (0.15) - 
Facility control variables no no 
Census region fixed effects yes yes 
Time trends  yes yes 
R
2
 1.49% 13.23% 
Observations 11,598 11,598 
Note: Huber Robust standard errors are in parentheses.  
   Fixed effects of census region and time trend are included in all specifications. 
   
The exogenous variables included in all models are age, female, race, duration of RRT, body surface area, low BMI, 
37 functional and comorbid conditions,  hospital-based or freestanding facilities, facility size, chain status, exception, 
rural/urban location, and metropolitan area or not. 
* Significantly different from zero at 95 percent confidence. 
   ** Significantly different from zero at 99 percent confidence. 
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Table 3-4. First sensitivity analysis: OLS and Log-linear regression results after the 
exclusion of month of death and the month prior to death (with facility characteristics) 
Dependent variable 
CR 
costs/month 
log (CR 
costs/month) 
  OLS (3) Log-linear (4) 
Variables  Coeff. Coeff. Mult. 
Percent of HD sessions skipped in the month 46 -0.066* 0.94 
 
(437.76) (0.027) - 
Percent of HD patients with ages <18 years old 347.38 0.33** 1.39 
 
(1243.63) (0.093) - 
Percent of HD patients with ages between 18 and 44 years old -164.46 0.15** 1.16 
 
(557.73) (0.048) - 
Percent of HD patients with ages between 70 and 79 years old -157.84 0.04 1.04 
 
(293.37) (0.034) - 
Percent of HD patients with ages greater than 80 years old -320.88 0.036 1.04 
 
(649.55) (0.04) - 
Percent of female HD patients  58.84 0.019 1.02 
 
(317.22) (0.026) - 
Percent of African American HD patients -27.98 0.02* 1.02 
 
(60.94) (0.01) - 
Started renal replacement therapy during month 615.42 -0.23 0.79 
 
(6351.84) (0.83) - 
Third year of renal replacement therapy -240.60 0.017 1.02 
 
(355.80) (0.047) - 
Body surface area (Dubois formula) 943.31 0.15** 1.16 
 
(571.60) (0.047) - 
Percent of HD patient with BMI < 18.5 kg/m
2
 910.56 -0.15 0.86 
 
(1250.22) (0.085) - 
Percent of HD patients with inability to ambulate (2728) 1226.4 -0.14 0.87 
 
(2146.09) (0.088) - 
Percent of HD patients with smoking habit -296.15 -0.023 0.98 
 
(283.71) (0.052) - 
Percent of HD patients with drug dependence -151.77 0.18** 1.20 
 
(426.50) (0.063) - 
Percent of HD patients with ischemic heart disease within one year -341.53 -0.019 0.98 
 
(434.80) (0.027) - 
Percent of HD patients with cerebrovascular disease within one year -250.29 -0.056 0.95 
 
(453.05) (0.039) - 
Percent of HD patients with peripheral vascular disease within one year 690.98 0.084** 1.09 
 
(427.07) (0.026) - 
Percent of HD patients with acquired immunodeficiency disease within 
one year 
31.94 0.24* 1.27 
 
(494.42) (0.11) - 
Percent of HD patients with bacterial pneumonia within six months 22577 0.01 1.01 
 
(16423) (0.88) - 
Percent of HD patients with hepatitis B within one year 154.74 0.08 1.08 
 
(249.90) (0.055) - 
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Percent of HD patients with septicemia within six months -1456.94 -0.18* 0.83 
 
(843.13) (0.078) - 
Percent of HD patients with gastro-intestinal ulcer within six months -1248.83 -0.54 0.58 
 
(3462.15) (0.45) - 
Percent of HD patients with opportunistic infection within six months 14859 -0.21 0.81 
 
(13621) (0.77) - 
Percent of HD patients with acquired hemolytic anemias within one 
year 
-5.09 0.094** 1.10 
 
(146.77) (0.023) - 
Percent of HD patients with sickle-cell anemia 795.31 0.53** 1.70 
 
(850.53) (0.19) - 
Percent of HD patients with hyperparathyroidism within one year -80.22 0.025* 1.03 
 
(90.92) (0.012) - 
Percent of HD patients with myelofibrosis within one year 1627.7 -0.02 0.98 
 
(2195.48) (0.16) - 
Percent of HD patients with myelodysplastic syndrome -2201.60 0.09 1.09 
 
(2029.89) (0.12) - 
Hospital-based facility 764.8** 0.32** 1.37 
 
(101.55) (0.014) - 
Facility size: < 5,000 treatments 816.46** 0.27** 1.30 
 
(115.54) (0.007) - 
Facility size: 5,000 - 9,999 treatments 239.18** 0.11** 1.11 
 
(10.12) (0.004) - 
Large dialysis organization (chain1-chain6) -86.64 0.032** 1.03 
 
(137.55) (0.007) - 
Regional chain 73.91 0.038** 1.04 
 
(200.63) (0.009) - 
Unknown 229.69* 0.097** 1.10 
 
(94.90) (0.021) - 
CR exception (HD claims or CMS list) 59.35** 0.031** 1.03 
 
(22.25) (0.008) - 
Rural location -162.66** -0.041** 0.96 
 
(62.60) (0.014) - 
Metropolitan area -38.19 -0.045** 0.96 
 
(63.88) (0.015) - 
Not in micro or metro area  -56 -0.002 1.00 
 
(40.23) (0.008) - 
Facility control variables yes  yes 
Census region fixed effects yes  yes 
Time trends  yes  yes 
R
2
 3.16% 37.76% 
Observations 11,598 11,598 
Note: Huber Robust standard errors are in parentheses.  
   Fixed effects of census region and time trend are included in all specifications. 
   
The exogenous variables included in all models are age, female, race, duration of RRT, body surface area, low BMI, 
37 functional and comorbid conditions,  hospital-based or freestanding facilities, facility size, chain status, exception, 
rural/urban location, and metropolitan area or not. 
* Significantly different from zero at 95 percent confidence. 
   ** Significantly different from zero at 99 percent confidence. 
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Table 3-5. Second sensitivity analysis: OLS and Log-linear regression results after the 
exclusion of months of any type of events (without facility characteristics) 
Dependent variable 
CR 
costs/month 
log (CR 
costs/month) 
  OLS (1) Log-linear (2) 
Variables  Coeff. Coeff. Mult. 
Percent of HD sessions skipped in the month -53.84 0.10** 1.11 
 
(108.23) (0.021) - 
Percent of HD patients with ages <18 years old 170.92* 0.87** 2.38 
 
(75.18) (0.092) - 
Percent of HD patients with ages between 18 and 44 years old -1.91 0.15** 1.17 
 
(38.93) (0.059) - 
Percent of HD patients with ages between 70 and 79 years old -2.73 0.08 1.08 
 
(22.89) (0.041) - 
Percent of HD patients with ages greater than 80 years old 7.95 0.13** 1.14 
 
(45.54) (0.046) - 
Percent of female HD patients  1.96 0.02 1.02 
 
(20.66) (0.032) - 
Percent of African American HD patients -13.58* -0.031* 0.97 
 
(5.33) (0.014) - 
Started renal replacement therapy during month 320.28 1.54** 4.66 
 
(178.23) (0.54) - 
Third year of renal replacement therapy -23.40 -0.043 0.96 
 
(23.08) (0.054) - 
Body surface area (Dubois formula) 105.16* 0.32** 1.38 
 
(49.08) (0.056) - 
Percent of HD patient with BMI < 18.5 kg/m
2
 81.06 0.003 1.00 
 
(71.33) (0.097) - 
Percent of HD patients with inability to ambulate (2728) 170.01 0.1 1.11 
 
(190.66) (0.10) - 
Percent of HD patients with smoking habit -4.09 0.089 1.09 
 
(23.78) (0.062) - 
Percent of HD patients with drug dependence 37.97 0.33** 1.40 
 
(33.62) (0.086) - 
Percent of HD patients with ischemic heart disease within one year -34.56 -0.044 0.96 
 
(37.30) (0.033) - 
Percent of HD patients with cerebrovascular disease within one year -2.79 -0.046 0.96 
 
(42.30) (0.054) - 
Percent of HD patients with peripheral vascular disease within one year 70.51 0.11** 1.12 
 
(41.54) (0.03) - 
Percent of HD patients with acquired immunodeficiency disease within 
one year 
59.69 0.35 1.42 
 
(54.78) (0.18) - 
Percent of HD patients with bacterial pneumonia within six months 1076.24 0.42 1.52 
 
(749.72) (0.60) - 
Percent of HD patients with hepatitis B within one year 48.58* 0.19* 1.21 
 
(21.52) (0.075) - 
Percent of HD patients with septicemia within six months -41.10 0.085 1.09 
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(59.01) (0.091) - 
Percent of HD patients with gastro-intestinal ulcer within six months 69.03 0..25 1.28 
 
(136.03) (0.45) - 
Percent of HD patients with opportunistic infection within six months 342.7 3.84 46.53 
 
(178.32) (2.85) - 
Percent of HD patients with acquired hemolytic anemias within one 
year 
20.47** 0.14** 1.15 
 
(6.90) (0.027) - 
Percent of HD patients with sickle-cell anemia 91.17 0.63** 1.88 
 
(78.16) (0.24) - 
Percent of HD patients with hyperparathyroidism within one year 7.75 0.071** 1.07 
 
(5.92) (0.014) - 
Percent of HD patients with myelofibrosis within one year 131.77 0.36* 1.43 
 
(126.42) (0.17) - 
Percent of HD patients with myelodysplastic syndrome -51.85 0.21 1.23 
 
(98.49) (0.16) - 
Facility control variables no no 
Census region fixed effects yes yes 
Time trends  yes yes 
R
2
 1.46% 15.26% 
Observations 11,584 11,584 
Note: Huber Robust standard errors are in parentheses.  
   Fixed effects of census region and time trend are included in all specifications. 
   
The exogenous variables included in all models are age, female, race, duration of RRT, body surface area, low BMI, 
37 functional and comorbid conditions,  hospital-based or freestanding facilities, facility size, chain status, exception, 
rural/urban location, and metropolitan area or not. 
* Significantly different from zero at 95 percent confidence. 
   ** Significantly different from zero at 99 percent confidence. 
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Table 3-5. Second sensitivity analysis: OLS and Log-linear regression results after the 
exclusion of months of any type of events (with facility characteristics)  
Dependent variable 
CR 
costs/month 
log (CR 
costs/month) 
  OLS (3) Log-linear (4) 
Variables  Coeff. Coeff. Mult. 
Percent of HD sessions skipped in the month 24.2 0.065** 1.07 
 
(101.85) (0.016) - 
Percent of HD patients with ages <18 years old 35.16 0.31** 1.37 
 
(78.60) (0.083) - 
Percent of HD patients with ages between 18 and 44 years old -9.36 0.16** 1.17 
 
(41.63) (0.048) - 
Percent of HD patients with ages between 70 and 79 years old -16.28 0.037 1.04 
 
(23.92) (0.034) - 
Percent of HD patients with ages greater than 80 years old -18.88 0.046 1.05 
 
(45.73) (0.037) - 
Percent of female HD patients  0.7 0.002 1.00 
 
(19.34) (0.025) - 
Percent of African American HD patients 3.63 0.048** 1.05 
 
(4.55) (0.012) - 
Started renal replacement therapy during month 146.05 0.74* 2.10 
 
(146.65) (0.37) - 
Third year of renal replacement therapy -11.35 0.016 1.02 
 
(22.45) (0.043) - 
Body surface area (Dubois formula) 62.17 0.12** 1.12 
 
(45.40) (0.045) - 
Percent of HD patient with BMI < 18.5 kg/m
2
 49.39 -0.13 0.88 
 
(68.01) (0.081) - 
Percent of HD patients with inability to ambulate (2728) 112.56 -0.12 0.89 
 
(184.92) (0.092) - 
Percent of HD patients with smoking habit -26.70 -0.058 0.94 
 
(18.62) (0.051) - 
Percent of HD patients with drug dependence 4.95 0.23** 1.26 
 
(35.21) (0.064) - 
Percent of HD patients with ischemic heart disease within one year -25.65 -0.0004 1.00 
 
(36.88) (0.028) - 
Percent of HD patients with cerebrovascular disease within one year -4.41 -0.039 0.96 
 
(41.11) (0.054) - 
Percent of HD patients with peripheral vascular disease within one year 60.79 0.087** 1.09 
 
(38.04) (0.025) - 
Percent of HD patients with acquired immunodeficiency disease within 
one year 
31.15 0.26 1.30 
 
(46.91) (0.14) - 
Percent of HD patients with bacterial pneumonia within six months 958.03 -0.12 0.89 
 
(744.12) (0.48) - 
Percent of HD patients with hepatitis B within one year 15.54 0.058 1.06 
 
(20.83) (0.063) - 
Percent of HD patients with septicemia within six months -96.86 -0.092 0.91 
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(70.09) (0.075) - 
Percent of HD patients with gastro-intestinal ulcer within six months -111.63 -0.54 0.58 
 
(128.14) (0.41) - 
Percent of HD patients with opportunistic infection within six months 291.86 0.55** 1.73 
 
(184.89) (0.087) - 
Percent of HD patients with acquired hemolytic anemias within one 
year 
3.21 0.11** 1.12 
 
(11.71) (0.024) - 
Percent of HD patients with sickle-cell anemia 73.66 0.58** 1.79 
 
(72.39) (0.21) - 
Percent of HD patients with hyperparathyroidism within one year -6.20 0.026* 1.03 
 
(7.54) (0.012) - 
Percent of HD patients with myelofibrosis within one year 61.98 0.03 1.03 
 
(126.55) (0.13) - 
Percent of HD patients with myelodysplastic syndrome -62.85 0.147 1.16 
 
(91.48) (0.096) - 
Hospital-based facility 66.71** 0.33** 1.39 
 
(7.69) (0.014) - 
Facility size: < 5,000 treatments 72.02** 0.29** 1.33 
 
(10.25) (0.007) - 
Facility size: 5,000 - 9,999 treatments 20.80** 0.11** 1.12 
 
(0.86) (0.004) - 
Large dialysis organization (chain1-chain6) -6.14 0.034** 1.03 
 
(10.80) (0.007) - 
Regional chain 6.43 0.033** 1.03 
 
(16.13) (0.009) - 
Unknown 20.65** 0.098** 1.10 
 
(7.05) (0.022) - 
CR exception (HD claims or CMS list) 5.44** 0.031** 1.03 
 
(1.88) (0.007) - 
Rural location -14.89* -0.04** 0.96 
 
(5.90) (0.014) - 
Metropolitan area -2.16 -0.035* 0.97 
 
(4.51) (0.015) - 
Not in micro or metro area  -4.93 -0.004 1.00 
 
(3.17) (0.008) - 
Facility control variables yes  yes 
Census region fixed effects yes  yes 
Time trends  yes  yes 
R
2
 3.37% 41.07% 
Observations 11,584 11,584 
Note: Huber Robust standard errors are in parentheses.  
   Fixed effects of census region and time trend are included in all specifications. 
   
The exogenous variables included in all models are age, female, race, duration of RRT, body surface area, low BMI, 
37 functional and comorbid conditions,  hospital-based or freestanding facilities, facility size, chain status, exception, 
rural/urban location, and metropolitan area or not. 
* Significantly different from zero at 95 percent confidence. 
   ** Significantly different from zero at 99 percent confidence. 
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Chapter IV 
 
Chapter IV. Is Non-adherence in Hemodialysis a Contributing Factor to Kidney 
Transplantation Failure? 
  
Abstract 
 
Using broad population data and a robust statistical approach, I did not 
consistently find a link between non-adherence in hemodialysis (HD) sessions, which 
was measured pre-transplant, and kidney transplantation failure.  Although in a 
sensitivity analysis in which months with any kind of events were excluded (e.g., 
hospitalization and withdrawal), I did observe an association between a binary non-
adherence measure and kidney transplantation failure.  Data were analyzed using twelve 
Cox proportional hazards models, controlling for patient case-mix adjusters.  These 
include patient demographics such as age and race, duration of renal replacement therapy 
(RRT), body surface area, BMI<18.5 kg/m
2
, functional statuses, and clinical 
comorbidities.  Results are consistent across these statistical models, indicating that there 
is no statistically significant relationship between non-adherence in hemodialysis sessions 
and kidney transplantation failure. 
Though this association has been explored in the end-stage renal disease (ESRD) 
transplantation literature, population-based information has not yet been formed due to 
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limited data sources from previous studies.  This observational study uses 18,393 kidney 
transplant recipients from 2004 to 2006.  Data sources are from the CMS Medical 
Evidence Form (CMS Form 2728) and Medicare claims.  A different perspective is given 
using average skipped HD sessions as the measure for non-adherence, instead of using 
the intake of immunosuppressive drugs.  
Previous studies consistently found an association between non-adherence in 
medication regime and kidney transplantation failure.  They emphasized the importance 
of design schemes in improving patients’ adherence to medication.  Findings from this 
study suggest that implementing an intervention to improve non-adherence in 
hemodialysis sessions in order to decrease the likelihood of kidney transplantation failure 
may not be cost-effective, since no causality between non-adherence in HD sessions and 
kidney transplantation failure was established.  
 
Key words. Non-adherence, hemodialysis, kidney transplantation, kidney transplantation 
failure, Cox proportional hazards model 
 
Introduction 
 
Because it takes discipline and determination for dialysis patients to adhere to three 
routine dialysis sessions per week, and six to ten medications per day (Loghman-Adham, 
2003), non-adherence in hemodialysis sessions is an important research topic in the end-
stage renal disease (ESRD) literature.  Previous research has demonstrated that kidney 
transplantation is a better form of treatment for ESRD patients because, compared to 
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dialysis patients, kidney transplant recipients live longer, enjoy better quality of life, and 
use fewer health care resources (Wolfe et al., 1999; Laupacis et al., 1996; Winkelmayer 
et al, 2002; Gill et al., 2009).  However, kidney transplant recipients need to adhere to the 
lifelong intake of immunosuppressive medication to prevent a progression towards 
kidney transplantation failure (Michelon et. al, 1999). 
Though the average cost of a kidney transplant ranges widely between $25,000 
and $150,000, the costs of dialysis treatments are consistently higher over time.  Costs 
fluctuate depending on whether the kidney transplant recipient has a deceased or living 
donor transplant.  The severity of rejection and the number of medications or procedures 
needed after the transplantation also affect hospital costs.  The costs for prescriptions for 
a recipient after being discharged ranges from between $700 to $2,000 per month (Emory 
health care website, 2009).  From both a quality of life and health care costs perspective, 
a kidney transplantation failure is undesirable. 
 
Literature Review 
 
Non-adherence is an important research area in kidney transplantation literature because 
non-adherence is frequently observed among kidney transplant recipients.  Adherence to 
medical regimens after a kidney transplantation is required to maintain good functional 
status of the transplanted kidney (Griffin et al., 2001). There is a wide variation in non-
adherence rates as researchers use different measurements for time post-transplant and 
various definitions for non-adherence (Greenstein et al, 1999).  The incidence of non-
adherence after renal transplantation could be as high as 75 percent (Troppmann et al., 
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1995).  The range of kidney graft loss due to non-adherence is reported to be from 0.6 
percent to 1.3 percent (Najarian 1975; Ettenger et al., 1991).   
Several studies investigated the predictors for non-adherence post-transplant.  
Greenstein and colleagues (1999) identified that education, employment, and occupation 
are significant predictors of adherence.  Kiley and colleagues (1993) found that there is 
an association between lower adherence rate and unemployment status.  Sehweizer and 
colleagues concluded that patients with lower socioeconomic status have lower 
adherence.  Other studies consistently found that younger patients have a higher 
incidence of non-adherence (Rovelli 1985; Lai 1992; Garcia 1997).  Siegal and 
colleagues found that a longer interval after the transplant significantly increased the 
likelihood of non-adherence, plausibly because patients are less aware of their medication 
regimens.  Previous studies have identified factors that might be associated with a higher 
risk of non-adherence.  These predictors include age, sex, socioeconomic status, 
education level, complexity of treatment, duration or type of immunosuppressive 
regimens, patients’ belief in treatment efficacy, and type of kidney donor (Rovelli et al., 
1985; Lai et al., 1992; Schweizer et al., 1990; Didlake et al., 1998; Frazier et al., 1994; 
Garcia et al., 1999). 
Many studies investigated the impact of non-adherence in medication regimen on 
kidney graft loss.  Garcia and colleagues (1997) found a non-adherence incidence with 
graft loss of 3.4 percent.  Michelon and colleagues (1999) found that the incidence of 
non-adherence leading to graft loss was different in relation to post-transplant time.  The 
results from Morrissey and colleagues (2005) show that non-adherence is a risk factor for 
acute rejection, and acute rejection is a risk factor for allograft failure.  Examining the 
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impact of non-adherence on outcome for pediatric kidney transplant recipients, 
Jarzembowski and colleagues (2004) found that there is a significant association between 
non-adherence and worse long-term graft survival in African American children.  
 
Conceptual Framework 
 
Several studies have investigated whether non-adherence is a major cause of kidney graft 
failure (Morrissey et al., 2005; Garcia et al., 1997; Michelon et al., 1999).  These 
researchers consistently found that non-adherence, as defined by the irregular intake of 
immunosuppressive medication, is associated with late acute rejection. There are three 
limitations on the findings from these studies.  First, these studies were limited by 
focusing on only one medical institution.  This study uses Medicare data that include 
Medicare HD patients who received kidney transplantations across the nation. 
Second, most of these studies used simple statistical methods which do not 
control for other exogenous variables. Previous research focused on descriptive statistics, 
univariate regression, simple correlations, Student’s t test, chi-square test, and the 
Kaplan-Meier estimation. This study uses Cox proportional hazards models to predict 
kidney transplantation failure, which takes into account the interval until the first kidney 
transplantation and transplantation failure and controls for a full list of patient case-mix 
characteristics.  
Third, the non-adherence of previous studies is measured by the quantity intake of 
the immunosuppressive regimen.  This study used the average number of hemodialysis 
sessions skipped in a month.  This new non-adherence measure is important in that 
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treatment types (hemodialysis, peritoneal, or kidney transplantation) for ESRD are 
sequential.  Most kidney transplant recipients were on dialysis for a certain period of time 
until they could receive kidney transplantation.  If there is an association between non-
adherence in hemodialysis sessions and kidney transplantation failure, then this finding 
could possibly affect the kidney allocation score (KAS) system (Wolfe et al., 1999), or be 
used to target patients for counseling about adherence prior to transplant and for more 
aggressive monitoring or support after transplant.  Dialysis patients with a higher 
adherence rate will have an allocation advantage for organs.  I assume that dialysis 
patients are rational in their decision-making process on whether to adhere to dialysis 
protocols.  If they are aware of this information that lower adherence will lead to a lower 
likelihood of receiving kidney transplantation, then we should be able to observe a 
spontaneous decrease in the non-adherence rate without any policy intervention.  This 
would help dialysis outcomes but not necessarily post-transplant outcomes.  
 For the conceptual model, I would like to test whether non-adherence is a broad 
concept or a specific concept.  I define ―broad non-adherence‖ as non-adherence as a 
consistent behavior that carries across different types of medical treatment.  For example, 
if a patient is non-adherent in receiving dialysis treatments pre-transplant, he likely will 
be non-adherent in taking immunosuppressant drugs, in keeping his medical 
appointments, and in following medical guidelines post transplantation.  ―Specific non-
adherence‖ refers to a patient who is non-adherent in receiving dialysis treatments pre-
transplant, yet would adhere to other medical treatments, such as taking 
immunosuppressant drugs, keeping medical appointments, and following medical 
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guidelines, post-transplant.  Non-adherence in one aspect of life is independent of 
adherence to other medical treatments.  
Under the ―broad non-adherence‖ scenario, the benefit-cost structure of a 
patient’s decision in being adherent is static pre- and post- transplant.  The patient faces 
the question – How should I allocate my time to maximize utility?  The utility is a 
measure of the satisfaction derived from the allocation of time used to receive dialysis 
treatments or used to do other activities.  The patient must choose whether to adhere to 
routine dialysis treatments.  The benefits of being adherent include longer life 
expectancy, positive feelings of control, and a sense of responsibility for others (family, 
friends).  The costs of being adherent are: time costs (travel time for dialysis patients 
from home to dialysis facility), the physical and mental discomfort of treatment (injected 
syringes into their body for 3~4 hours per session), effort (three sessions per week), and 
the opportunity costs of not doing activities that interest them (socializing with friends 
and family, working).  If a patient perceives the benefits of being adherent do not justify 
the costs, then he may skip routine sessions.  Since non-adherence is a broad concept, 
these patients would also be non-adherent in taking immunosuppressant drugs post-
transplantation, and thus have a higher risk of experiencing kidney transplantation failure.  
I would expect to see non-adherence in hemodialysis sessions having a positive effect on 
kidney transplantation failure. 
Under the ―specific non-adherence‖ scenario, I assume that a kidney 
transplantation is perceived by a patient as a critical event in life.  His benefit-cost 
structure in deciding whether to be non-adherent shifts pre- and post-transplant.  The 
benefit-cost structure is dynamic over time.  A patient who is non-adherent in 
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hemodialysis sessions pre-transplant reconsiders his benefit-cost structure in being non-
adherent post-transplant.  He transforms to believe that long-term health benefits 
outweigh short-term leisure, and becomes more adherent to taking immunosuppressant 
drugs.  I would expect to see a lower (or no) impact of non-adherence in hemodialysis on 
kidney transplantation failure.  
 
Methods and Data 
 
Methods 
 
For the first part of this analysis, I use three Cox proportional hazards models to examine 
the effect of non-adherence in hemodialysis on the risk of having a kidney transplantation 
failure, after adjusting for none, some, and a full list of patient characteristics and 
comorbidities.  For the second part of the study, I use a binary measure for non-adherence 
to estimate this association to check for non-linear effects.   
 
3.1 Cox proportional hazards model 
 
The Cox proportional hazards model is a statistical model used in survival analysis to 
demonstrate the multiplicative effect of several designated covariates, showing that this 
effect does not change over time.   
Equation 4-1  
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In Equation 4-1,  is the resultant hazard, is the baseline hazard,  is a 
vector of parameter estimates,  is duration, and  is the vector of covariates.  Model 1 
estimated the hazard ratio of non-adherence on kidney transplantation failure without any 
patient case-mix adjusters.  Model 2 added age, sex, race, time since start of renal 
replacement therapy, body surface area, and an underweight measure (BMI<18.5 kg/m
2
).  
Model 3 further adjusted for 37 functional status and comorbid measures.  Models 4 
through 6 resembled models 1 through 3, except that I used a binary variable to define 
skipped sessions as the second non-adherence measure to test for non-linear effects. 
  
Data 
 
I used Standard Analytical Files (SAF) from the CMS to identify patient information with 
respect to kidney transplantation and kidney transplantation failure.  Medicare claims for 
hemodialysis patients for whom Medicare was the primary payer between January 1, 
2004, and December 31, 2006, were used and merged with SAF to derive the final study 
sample of 18,393 kidney transplantation recipients.  Patient demographics, time since 
start of renal replacement therapy, functional status, and comorbidities were obtained 
from the CMS Medical Evidence Form (CMS Form 2728) and/or Medicare claims.   
 
Variable 
 
Dependent variable 
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The dependent variable is a binary variable coded ―1‖ if a kidney transplantation 
recipient is identified to have a kidney transplantation failure and coded ―0‖ if the 
transplantation is successful during this study period.  Death is also coded as a failure 
event.  A kidney transplantation recipient could have multiple kidney transplantations and 
thus multiple kidney transplantation failures.  In this study, I only observe the kidney 
transplantation recipients until their first kidney transplantation failure occurred.  I did 
not deal with multiple kidney transplantation failures in order to simplify my models and 
to make the interpretation cleaner.  
 
Independent variable of interest 
 
The independent variable of interest, non-adherence, is measured as the average number 
of HD sessions skipped in a month.  The follow up days, a measure needed for the Cox 
proportional hazards model, was calculated as the difference in days between the date of 
first kidney transplantation and the date of first kidney transplantation failure.  For those 
censored kidney transplant recipients, the measure for follow up days was calculated as 
days between their first transplantation dates and their censored dates.  Since the average 
skipped HD sessions in a month are mostly zeros, and then >0, I use a binary measure for 
non-adherence, coded ―1‖ if average skipped HD sessions is greater than 0, and ―0‖ if 
average skipped HD sessions is 0,  to estimate this association to check for non-linear 
effects.   
 
Patient characteristics 
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Age in six categories (<18, 18-44, 45-59, 60-69, 70-79, and >80), sex, race, body surface 
area (Dubois formula: ), a low BMI 
indicator (BMI<18.5 kg/m
2
), duration of renal replacement therapy, and 37 functional 
statuses and comorbidities were included to control for exogenous factors that may also 
have an influence on kidney transplantation failure. 
 Data for the measures of patient characteristics were obtained from the ESRD 
Medical Evidence Report (CMS Form 2728) and/or Medicare claims.  Clinical 
comorbidities were obtained from both CMS Form 2728 and/or Medicare claims, since 
evidence shows that there were issues concerning underreporting of comorbidities using 
only CMS Form 2728.  Additionally, this Medical Evidence Report does not capture 
changes in patients’ comorbidities after the initiation of RRT.  Comorbid conditions 
based purely on this form were not perfectly measured.  Thus, clinical comorbidity 
conditions were based on diagnosis codes reported on Medicare inpatient, outpatient, 
skilled nursing facility, home health, hospice, and physician claims covering a specified 
period of time.  
These claims-based comorbidity measures were limited to recent diagnoses (i.e., 
during the previous six months only) for acute conditions such as gastrointestinal 
bleeding.  Longer periods were used for chronic conditions.  Several ―look back‖ periods 
(i.e., diagnoses in last year vs. last two years) were tested to determine their ability to 
predict costs.  The most predictive look back period was chosen as the measure of the 
comorbidity to be entered into the regression models.   
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Results 
 
Descriptive analysis 
 
For these 18,393 kidney transplant recipients, 17 percent experienced a kidney 
transplantation failure, with an average duration from kidney transplantation to kidney 
transplantation failure of 262 days (Table 4-1).  The average number of HD sessions 
skipped in a month is 0.036 (SD=0.12).  23 percent of the transplant recipients had a 
record of skipping HD sessions.  For the 397,770 HD patients who did not have kidney 
transplantation, the average HD sessions skipped in a month is 0.061 (SD=0.16).  29 
percent of these HD patients had a record of skipped HD sessions.  Compared to HD 
patients without kidney transplantation, kidney transplant recipients are younger, more 
likely to be male, and slightly more likely to be Asians.  They have larger body surface 
area and are less likely to be underweight.  These kidney transplant recipients have a 
higher ratio of being on dialysis treatments for three years or more. They have lower 
mean percentages on 28 out of the 37 functional statuses and comorbidities compared to 
non-recipients. The differences in average HD sessions skipped, demographic variables, 
patient characteristics, and comorbidities between kidney transplant recipients and non-
recipients are mostly statistically significant at the p < 0.0001 level.  
 
Regression analysis 
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Table 4-2 through Table 4-7 list the results for the six Cox proportional hazards models 
which adjusted for a different set of covariates.  Model 1 (Table 4-2), the unadjusted 
model, shows that if a kidney transplant recipient had, on average, one skipped HD 
sessions in a month pre-transplant, there would be an 18 percentage increase in kidney 
transplantation failure.  However, this estimate is not statistically significant.  Model 2 
(Table 4-3) adjusts for patient demographics, duration of renal replacement therapy, body 
surface area, and low BMI.  The hazard ratio dropped from 1.18 to 1.05, which is 
statistically insignificant.  Model 3 (Table 4-4) adjusts for 37 additional functional status 
and comorbidities.  The regression results show that the hazard ratio increased slightly 
from 1.05 to 1.08, and remained statistically insignificant.  Interestingly, the hazard ratios 
on non-adherence fluctuate somewhat and are statistically insignificant, despite the fact 
that each model uses a different set of covariates.  This suggests that the finding of no 
association between non-adherence and kidney transplantation failure is a strong and 
consistent result.  This finding supports the ―specific non-adherence‖ conceptual model.  
 To check for whether there is a non-linear effect, models 4 through 6 resembled 
models 1 through 3, the only difference being the non-adherence measure.  I used a 
binary variable to replace the linear variable, and re-examined the relationship between 
non-adherence and kidney transplantation failure.  Model 4 shows that if a kidney 
transplant recipient had a history of skipping HD sessions pre-transplant, then the hazards 
of experiencing transplantation failure would be increased by 11 percent, and this 
association is statistically significant.  Model 5 shows that, after partial adjustment for 
patient characteristics, the hazard ratio dropped from 1.11 to 1.07, and became 
statistically insignificant.  This finding suggests that there are some correlations between 
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non-adherence and patient characteristics, such that the impact of non-adherence on 
kidney transplantation failure diminished.  Finally, model 6 adjusts for a full list of 
patient characteristics, and the results are similar to model 5 in that they are statistically 
insignificant and with a hazard ratio of 1.06.   
 
Sensitivity analysis 
 
We excluded those months with any kind of ―event‖ (e.g., hospitalization, withdrawal, 
and transfer between facilities) being identified and re-fit all six models.  The rationale to 
exclude these months is based on the fact that they have a zero probability of being 
identified as missing, according to the way I defined the non-adherence measure.  
Although in reality, a patient could plausibly have an ―event‖ and also skipped an HD 
session in a particular month.  In order to carefully examine the true effect of missing 
sessions on kidney transplantation failure, it is important to see how sensitive the hazard 
ratios are when excluding these ―event‖ months.   
Models 7-9 show the results using a linear non-adherence measure (Tables 8-10), 
and  Models 10-12 show the results using a binary non-adherence measure (Tables 11-
13).  Compared with the results presented in models 1-3, the hazard ratios on non-
adherence in models 7-9 are slightly higher and remain statistically insignificant.  
Remarkably, the hazard ratios on the binary non-adherence measure are statistically 
significant at the 95 percent confidence interval across models 10-12.  Model 10 shows 
that if a kidney transplant recipient had a history of skipping HD sessions pre-transplant, 
then the hazards of experiencing transplantation failure would be increased by 13 percent.  
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Models 11-12 show that, after partial and full adjustment for patient characteristics, the 
hazard ratios dropped from 1.13 to 1.10.  This finding suggests that compared with 
transplant patients who never skipped any HD treatments,  transplant patients with a 
history of missing HD treatments would have a 10 percent increase in hazards of 
experiencing kidney transplantation failure.   
 
Discussion 
 
One of the primary concerns for transplantation centers is to have a successful recipient 
of an organ transplant lose the graft due to non-adherence (Garcia et al., 1997).  
Transplant is the best treatment for ESRD patients.  Due to the short supply of 
transplantable organs, the allocation of organs to ESRD patients on the waitlist who will 
yield the best transplantation results is an important research and policy issue.  In a 
previous study (Schweizer et al., 1990), 91% of the loss of allograft function or death in 
kidney transplant recipients was due to non-adherence.  Informed decisions should be 
made to minimize losing organs secondary to non-adherence.  
 The findings of this study seem to support the fact that adherent patients are more 
favored in being selected to receive kidney transplantations.  It would be in the patient’s 
interest to be adherent in receiving routine HD treatments in order to increase the 
likelihood of receiving kidney transplantation. 
 In contrast to previous studies using medication regimens as the non-adherence 
measure, this study found that there is no association between non-adherence in HD 
sessions and kidney transplantation failure.  From a policy perspective, this finding is 
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encouraging in two aspects.  Increasing medical costs arising from a failed organ are not 
associated with pre-transplant non-adherence.  When evaluating the KAS system, non-
adherence in HD sessions may not need to be included in calculating the allocation score, 
and should not affect a patient’s status on the waitlist.  Since there is no association 
between non-adherence in HD sessions pre-transplant, and non-adherence in taking 
immunosuppressant drugs post-transplant, it may not be cost-effective to allocate medical 
resources to provide pre-transplant counseling interventions on these targeted non-
adherent HD patients.  From a dialysis patient’s perspective, it would be advantageous to 
adhere to HD treatments to potentially increase the likelihood of receiving a kidney 
transplantation, though adherence would not decrease the likelihood of kidney 
transplantation failure.  It is noteworthy to address that in a sensitivity analysis in which 
months with any kind of events were excluded, I did observe an association between a 
binary non-adherence measure and kidney transplantation failure.  Thus, whether the 
CMS should allocate medical resources to improve the adherence rate of these HD 
patients with a history of skipping sessions in order to lower the possibility of kidney 
transplantation failure requires more refined research.  
There are a few limitations of this study.  First, the empirical analysis presented 
only looks at transplantation data from 2004-2006.  Findings may not be applicable to 
other time periods.  Next, the analysis also did not take into account the impact of non-
adherence in HD sessions on multiple transplantation and multiple transplantation 
failures.  Further, the costs on kidney transplantation vary largely based on whether a 
kidney is received by a living or deceased donor.  Since I do not have this information 
from my available data set, I am not able to address this concern.  Lastly, non-adherence, 
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as defined in this study, is measured conservatively.  For instance, if a patient is identified 
to have an event (e.g., hospitalization) in a month, then he will not be defined as a 
―skipped‖ patient for that month based on my identification strategy.  In reality, he might 
be both ―hospitalized‖ and ―non-adherent‖ for that month.  For months with 31 days, 
patients may receive 13 treatments instead of 12 treatments.  Suppose a record shows that 
a patient received 11 treatments in a 31-day month, without any other event being 
identified.  Using my identification strategy, this patient would be reported as skipping 
one treatment, although in reality he skipped two treatments.  To the extent that this non-
adherence measure was underestimated, the prevalence of average HD sessions skipped 
in a month should be greater than 0.036, and the coefficient estimates on non-adherence 
as well as other covariates could also be affected.  Future research could be conducted to 
further explore this interesting research topic. 
  
129 
 
Table 4-1 Summary statistics of all variables, 2004-2006 
  
Kidney transplant 
recipients 
HD Patients 
without 
transplantation   
Variables Mean  S.D. Mean  S.D. 
Two 
sample      
t-test 
Dependent variables 
     Kidney transplantation failure: binary variable 0.17 0.38 - - - 
      
Independent variable of interest 
     Average HD sessions skipped in a month 0.036 0.12 0.061 0.16 p <.0001 
Average skipped sessions in a month > 0 (Binary 
variable) 
0.23 0.42 0.29 0.45 p <.0001 
Follow up days from kidney transplantation to 
transplantation failure 
261.85 926.39 - - - 
      
Demographic variables      
Ages <18 yrs 0.012 0.11 0.001 0.03 p <.0001 
Ages 18-44 yrs 0.35 0.47 0.11 0.31 p <.0001 
Ages 45-59 yrs 0.38 0.47 0.23 0.41 p <.0001 
Ages 60-69 yrs 0.21 0.40 0.23 0.41 p <.0001 
Ages 70-79 yrs 0.056 0.22 0.27 0.43 p <.0001 
Ages 80+ yrs 0.002 0.04 0.16 0.36 p <.0001 
Female 0.37 0.48 0.47 0.50 p <.0001 
Race: Native American 0.014 0.12 0.014 0.12 p=0.868 
Race: Asian 0.051 0.22 0.032 0.18 p <.0001 
Race: Black 0.34 0.47 0.35 0.48 p <.0001 
Race: White 0.58 0.49 0.59 0.49 p=0003 
Race: Other 0.019 0.13 0.010 0.10 p <.0001 
Race: Unknown/missing 0.0005 0.02 0.0003 0.02 p=0.186 
      
Patient characteristics and Comorbidities      
Body surface area (Dubois formula) 1.89 0.25 1.86 0.24 p <.0001 
Underweight (BMI <18.5 kg/m2) 0.039 0.18 0.05 0.18 p <.0001 
Started RRT during month 0.006 0.05 0.037 0.14 p <.0001 
1 previous month of RRT 0.010 0.06 0.062 0.17 p <.0001 
2 previous months of RRT 0.008 0.05 0.042 0.11 p <.0001 
3 previous months of RRT 0.018 0.07 0.043 0.11 p <.0001 
4 previous months of RRT 0.016 0.05 0.034 0.08 p <.0001 
5 previous months of RRT 0.016 0.05 0.029 0.07 p <.0001 
6 previous months of RRT 0.015 0.05 0.025 0.06 p <.0001 
7 previous months of RRT 0.014 0.05 0.024 0.06 p <.0001 
8 previous months of RRT 0.013 0.04 0.021 0.05 p <.0001 
9 previous months of RRT 0.013 0.04 0.019 0.05 p <.0001 
10-12 previous months of RRT 0.040 0.11 0.051 0.10 p <.0001 
2nd year of RRT 0.13 0.25 0.14 0.23 p <.0001 
3rd year of RRT 0.15 0.28 0.11 0.21 p <.0001 
3 years or more of RRT 0.55 0.46 0.36 0.45 p <.0001 
Inability to ambulate (2728) 0.005 0.07 0.041 0.20 p <.0001 
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Inability to transfer (2728) 0.001 0.03 0.016 0.13 p <.0001 
Smoking 0.019 0.12 0.035 0.17 p <.0001 
Alcohol Dependence between 1999-2004 0.033 0.17 0.055 0.22 p <.0001 
Drug Dependence between 1999-2004 0.025 0.15 0.041 0.19 p <.0001 
Cardiac Arrest within one year 0.005 0.06 0.017 0.11 p <.0001 
Cardiac dysrhythmia within one year 0.20 0.34 0.39 0.42 p <.0001 
Ischemic heart disease within one year 0.35 0.42 0.55 0.44 p <.0001 
Pericarditis within one year 0.013 0.09 0.012 0.09 p=0.268 
Cerebrovascular disease within one year 0.14 0.29 0.30 0.39 p <.0001 
Diabetes within one year 0.42 0.46 0.62 0.45 p <.0001 
Peripheral vascular disease within one year 0.30 0.39 0.48 0.42 p <.0001 
Chronic obstructive pulmonary disease within 
one year 
0.15 0.31 0.33 0.41 p <.0001 
Acquired immunodeficiency disease within one 
year 
0.006 0.07 0.015 0.12 p <.0001 
Human immnodeficiency virus within one year 0.004 0.06 0.011 0.10 p <.0001 
Bacterial Pneumonia six months ago 0.002 0.02 0.006 0.04 p <.0001 
Hepatitis B within one year 0.015 0.10 0.012 0.09 p=0.002 
Other Hepatitis between 1999-2004 0.076 0.26 0.063 0.24 p <.0001 
Opportunistic Infection six months ago 0.002 0.02 0.002 0.02 p=0.584 
Pneumococcal pneumonia, emphysema, lung 
abcess within six months 
0.002 0.02 0.003 0.025 p <.0001 
Septicemia within six months 0.024 0.08 0.037 0.103 p <.0001 
Gastro-Intestinal (GI) Tract Bleeding six months 
ago 
0.002 0.02 0.004 0.032 p <.0001 
GI Ulcer - no hemorrhage within six months 0.004 0.03 0.007 0.042 p <.0001 
Esophogeal Varices within six months 0.001 0.02 0.0006 0.013 p=0.852 
Acquired Hemolytic Anemias within one year 0.018 0.12 0.015 0.109 p=0.0002 
Hereditary Hemolytic Anemias between 1999-
2004 
0.015 0.12 0.018 0.129 p <.0001 
Sickle-Cell Anemia between 1999-2004 0.004 0.06 0.004 0.063 p=0.539 
Leukemia within one year 0.003 0.05 0.007 0.07 p <.0001 
Lung, Upper Digestive Tract, and Other Severe 
Cancers within one year 
0.004 0.05 0.018 0.12 p <.0001 
Lymphoma within two years 0.005 0.07 0.009 0.09 p <.0001 
Metastatic Cancers within one year 0.004 0.05 0.021 0.13 p <.0001 
Multiple Myeloma within one year 0.002 0.04 0.015 0.12 p <.0001 
Breast, Prostate, Colorectal and Other Cancers 
within one year 
0.043 0.18 0.094 0.27 p <.0001 
Hyperparathyroidism within one year 0.12 0.29 0.094 0.25 p <.0001 
Monoclonal Gammopathy within one year 0.003 0.05 0.009 0.09 p <.0001 
Myelofibrosis within one year 0.005 0.06 0.005 0.06 p=0.461 
Myelodysplastic Syndrome between 1999-2004 0.005 0.07 0.016 0.12 p <.0001 
      
N  18,393   397,770     
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Table 4-2 Results from the Cox proportional hazards models, 2004-2006 
  Model 1 - Unadjusted 
Variable H.R. 95% CI Pr > Chi 
Independent variable of interest     
    Average skipped HD sessions in a month 1.18 0.88 1.56 0.2676 
     
Observations 18,393 
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Table 4-3 Results from the Cox proportional hazards models, 2004-2006 (cont’d) 
  
Model 2 - Adjusted for patient 
demographics, time since start 
of RRT, body surface area, and 
low BMI 
Variables H.R. 95% CI Pr > Chi 
Independent variable of interest     
     Average skipped HD sessions in a month 1.05 0.78 1.41 0.748 
Demographic variables     
    Ages <18 yrs 1.00 0.72 1.40 0.995 
    Ages 18-44 yrs 0.83 0.75 0.93 0.001 
    Ages 45-59 yrs 0.79 0.71 0.88 <.0001 
    Ages 60-69 yrs ref. - - - 
    Ages 70-79 yrs 1.19 0.97 1.47 0.097 
    Ages 80+ yrs 3.11 1.21 7.97 0.018 
    Female 1.01 0.93 1.09 0.863 
    Race: Native American 1.10 0.79 1.54 0.576 
    Race: Asian 1.32 1.10 1.58 0.003 
    Race: Black 1.50 1.38 1.62 <.0001 
    Race: White ref. - - - 
    Race: Other 1.38 1.02 1.86 0.038 
    Race: Unknown/missing 7.82 1.11 55.32 0.039 
Patient characteristics and Comorbidities     
    Started RRT during month 2.70 0.76 9.59 0.123 
    1 previous month of RRT 2.34 0.44 12.43 0.319 
    2 previous months of RRT 2.85 0.66 12.26 0.160 
    3 previous months of RRT 1.87 0.65 5.38 0.247 
    4 previous months of RRT 3.46 0.57 21.03 0.178 
    5 previous months of RRT 2.75 0.43 17.58 0.284 
    6 previous months of RRT 6.62 1.03 42.67 0.047 
    7 previous months of RRT 1.44 0.40 5.22 0.581 
    8 previous months of RRT 3.39 0.83 13.82 0.089 
    9 previous months of RRT 2.30 0.57 9.28 0.241 
    10-12 previous months of RRT 2.31 1.39 3.85 0.001 
    2nd year of RRT 2.80 2.28 3.43 <.0001 
    3rd year of RRT 3.20 2.71 3.78 <.0001 
    3 years or more of RRT ref. - - - 
    Body surface area (Dubois formula) 1.33 1.10 1.60 0.003 
    Underweight (BMI <18.5 kg/m2) 0.96 0.79 1.16 0.678 
     
Observations 18,393 
 
133 
 
Table 4-4 Results from the Cox proportional hazards models, 2004-2006 (cont’d) 
  
Model 3 - Model 2 +37 
functional status and 
comorbidities 
Variables H.R. 95% CI Pr > Chi 
Independent variable of interest     
     Average skipped HD sessions in a month 1.08 0.80 1.46 0.6185 
Demographic variables     
    Ages <18 yrs 1.14 0.81 1.61 0.4632 
    Ages 18-44 yrs 0.90 0.80 1.01 0.0738 
    Ages 45-59 yrs 0.82 0.73 0.92 0.0007 
    Ages 60-69 yrs ref. - - - 
    Ages 70-79 yrs 1.17 0.95 1.45 0.1503 
    Ages 80+ yrs 2.95 1.15 7.54 0.0239 
    Female 0.99 0.91 1.08 0.8564 
    Race: Native American 1.03 0.73 1.44 0.8874 
    Race: Asian 1.35 1.13 1.62 0.001 
    Race: Black 1.52 1.41 1.65 <.0001 
    Race: White ref. - - - 
    Race: Other 1.39 1.03 1.88 0.0328 
    Race: Unknown/missing 7.69 1.08 54.51 0.0413 
Patient characteristics and Comorbidities     
    Started RRT during month 2.72 0.80 9.22 0.1093 
    1 previous month of RRT 1.31 0.22 7.69 0.768 
    2 previous months of RRT 3.70 0.90 15.30 0.0703 
    3 previous months of RRT 2.15 0.76 6.05 0.1476 
    4 previous months of RRT 2.97 0.46 19.13 0.253 
    5 previous months of RRT 2.87 0.43 19.32 0.2791 
    6 previous months of RRT 6.41 0.96 42.86 0.0554 
    7 previous months of RRT 1.64 0.44 6.06 0.4608 
    8 previous months of RRT 2.96 0.74 11.90 0.1267 
    9 previous months of RRT 2.14 0.55 8.23 0.2701 
    10-12 previous months of RRT 2.24 1.35 3.73 0.0019 
    2nd year of RRT 2.65 2.16 3.26 <.0001 
    3rd year of RRT 3.10 2.62 3.68 <.0001 
    3 years or more of RRT ref. - - - 
    Body surface area (Dubois formula) 1.31 1.08 1.58 0.0051 
    Underweight (BMI <18.5 kg/m2) 0.95 0.78 1.16 0.617 
    Inability to ambulate (2728) 0.74 0.41 1.31 0.2966 
    Inability to transfer (2728) 3.73 1.38 10.08 0.0094 
    Smoking 1.41 1.03 1.94 0.0328 
    Alcohol Dependence between 1999-2004 1.14 0.94 1.39 0.1781 
    Drug Dependence between 1999-2004 1.04 0.85 1.26 0.7214 
    Cardiac Arrest within one year 1.41 0.85 2.34 0.1798 
    Cardiac dysrhythmia within one year 1.09 0.98 1.21 0.115 
    Ischemic heart disease within one year 0.96 0.88 1.06 0.4629 
    Pericarditis within one year 0.97 0.68 1.37 0.8542 
    Cerebrovascular disease within one year 1.03 0.91 1.17 0.6159 
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    Diabetes within one year 1.24 1.14 1.35 <.0001 
    Peripheral vascular disease within one year 1.14 1.03 1.25 0.0079 
    Chronic obstructive pulmonary disease within one year 1.02 0.91 1.15 0.684 
    Acquired immunodeficiency disease within one year 1.52 0.89 2.57 0.1234 
    Human immnodeficiency virus within one year 1.34 0.74 2.43 0.329 
    Bacterial Pneumonia six months ago 0.68 0.13 3.54 0.645 
    Hepatitis B within one year 0.90 0.65 1.24 0.5052 
    Other Hepatitis between 1999-2004 0.93 0.82 1.05 0.2311 
    Opportunistic Infection six months ago 2.31 0.64 8.33 0.1996 
    Pneumococcal pneumonia, emphysema, lung abcess within six 
months 
0.39 0.06 2.67 0.334 
    Septicemia within six months 0.96 0.64 1.45 0.8536 
    Gastro-Intestinal (GI) Tract Bleeding six months ago 1.26 0.39 4.10 0.6997 
    GI Ulcer - no hemorrhage within six months 0.97 0.28 3.36 0.9656 
    Esophogeal Varices within six months 3.49 0.47 25.63 0.2199 
    Acquired Hemolytic Anemias within one year 1.14 0.88 1.47 0.3159 
    Hereditary Hemolytic Anemias between 1999-2004 0.94 0.73 1.22 0.6466 
    Sickle-Cell Anemia between 1999-2004 1.25 0.78 2.02 0.3496 
    Leukemia within one year 0.78 0.37 1.67 0.5275 
    Lung, Upper Digestive Tract, and Other Severe Cancers within one 
year 
1.11 0.66 1.88 0.6861 
    Lymphoma within two years 0.71 0.47 1.07 0.0995 
    Metastatic Cancers within one year 2.38 1.15 4.93 0.0201 
    Multiple Myeloma within one year 3.06 1.24 7.53 0.0148 
    Breast, Prostate, Colorectal and Other Cancers within one year 0.89 0.73 1.07 0.2147 
    Hyperparathyroidism within one year 1.01 0.90 1.13 0.9108 
    Monoclonal Gammopathy within one year 0.94 0.47 1.90 0.8683 
    Myelofibrosis within one year 1.39 0.76 2.52 0.2825 
    Myelodysplastic Syndrome between 1999-2004 0.90 0.61 1.32 0.5747 
     
Observations 18,393 
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Table 4-5 Results from the Cox proportional hazards models, sensitivity analysis (binary 
skipped sessions variable), 2004-2006 
  Model 4 - Unadjusted 
Variable H.R. 95% CI Pr > Chi 
Independent variable of interest     
    Binary variable: Average skipped HD sessions in a month > 0 1.11 1.02 1.20 0.0156 
     
Observations 18,393 
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Table 4-6 Results from the Cox proportional hazards models, sensitivity analysis (binary 
skipped sessions variable), 2004-2006 (cont’d)  
  
Model 5 - Adjusted for patient 
demographics, time since start 
of RRT, body surface area, and 
low BMI 
Variables H.R. 95% CI Pr > Chi 
Independent variable of interest     
    Binary variable: Average skipped HD sessions in a month > 0 1.07 0.98 1.16 0.1134 
Demographic variables     
    Ages <18 yrs 1.00 0.72 1.40 0.9871 
    Ages 18-44 yrs 0.83 0.75 0.93 0.0008 
    Ages 45-59 yrs 0.79 0.71 0.88 <.0001 
    Ages 60-69 yrs ref. - - - 
    Ages 70-79 yrs 1.19 0.97 1.47 0.0974 
    Ages 80+ yrs 3.11 1.22 7.98 0.0179 
    Female 1.01 0.93 1.09 0.8612 
    Race: Native American 1.10 0.79 1.54 0.5741 
    Race: Asian 1.32 1.10 1.58 0.0026 
    Race: Black 1.49 1.38 1.61 <.0001 
    Race: White ref. - - - 
    Race: Other 1.37 1.02 1.85 0.0382 
    Race: Unknown/missing 7.90 1.12 55.91 0.0384 
Patient characteristics and Comorbidities     
    Started RRT during month 2.74 0.77 9.72 0.1179 
    1 previous month of RRT 2.37 0.45 12.57 0.3124 
    2 previous months of RRT 2.89 0.67 12.43 0.1532 
    3 previous months of RRT 1.89 0.66 5.45 0.2371 
    4 previous months of RRT 3.38 0.55 20.70 0.1885 
    5 previous months of RRT 2.75 0.43 17.63 0.2871 
    6 previous months of RRT 6.67 1.03 43.10 0.0462 
    7 previous months of RRT 1.47 0.41 5.34 0.5561 
    8 previous months of RRT 3.32 0.81 13.54 0.0948 
    9 previous months of RRT 2.29 0.56 9.29 0.2479 
    10-12 previous months of RRT 2.29 1.37 3.83 0.0015 
    2nd year of RRT 2.79 2.27 3.41 <.0001 
    3rd year of RRT 3.22 2.72 3.80 <.0001 
    3 years or more of RRT ref. - - - 
    Body surface area (Dubois formula) 1.33 1.11 1.61 0.0025 
    Underweight (BMI <18.5 kg/m2) 0.96 0.79 1.16 0.6805 
     
Observations 18,393 
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Table 4-7 Results from the Cox proportional hazards models, sensitivity analysis (binary 
skipped sessions variable), 2004-2006 (cont’d) 
  
Model 6 - Model 5 +37 
functional status and 
comorbidities 
Variables H.R. 95% CI Pr > Chi 
Independent variable of interest     
    Binary variable: Average skipped HD sessions in a month > 0 1.06 0.98 1.16 0.1649 
Demographic variables     
    Ages <18 yrs 1.14 0.81 1.61 0.4645 
    Ages 18-44 yrs 0.90 0.80 1.01 0.0743 
    Ages 45-59 yrs 0.82 0.73 0.92 0.0007 
    Ages 60-69 yrs ref. - - - 
    Ages 70-79 yrs 1.17 0.95 1.45 0.1512 
    Ages 80+ yrs 2.95 1.16 7.55 0.0237 
    Female 0.99 0.91 1.08 0.8587 
    Race: Native American 1.03 0.73 1.44 0.8877 
    Race: Asian 1.36 1.13 1.62 0.001 
    Race: Black 1.52 1.40 1.65 <.0001 
    Race: White ref. - - - 
    Race: Other 1.39 1.03 1.88 0.0329 
    Race: Unknown/missing 7.74 1.09 54.89 0.0406 
Patient characteristics and Comorbidities     
    Started RRT during month 2.75 0.81 9.32 0.1051 
    1 previous month of RRT 1.33 0.23 7.82 0.753 
    2 previous months of RRT 3.74 0.91 15.44 0.0679 
    3 previous months of RRT 2.17 0.77 6.12 0.1414 
    4 previous months of RRT 2.92 0.45 18.92 0.2617 
    5 previous months of RRT 2.87 0.42 19.44 0.2796 
    6 previous months of RRT 6.44 0.96 43.25 0.0552 
    7 previous months of RRT 1.66 0.45 6.15 0.4483 
    8 previous months of RRT 2.91 0.73 11.71 0.1318 
    9 previous months of RRT 2.13 0.55 8.25 0.2739 
    10-12 previous months of RRT 2.23 1.34 3.72 0.0021 
    2nd year of RRT 2.64 2.15 3.25 <.0001 
    3rd year of RRT 3.12 2.63 3.70 <.0001 
    3 years or more of RRT ref. - - - 
    Body surface area (Dubois formula) 1.31 1.09 1.58 0.0045 
    Underweight (BMI <18.5 kg/m2) 0.95 0.78 1.16 0.6201 
    Inability to ambulate (2728) 0.75 0.42 1.33 0.3167 
    Inability to transfer (2728) 3.73 1.38 10.08 0.0094 
    Smoking 1.41 1.03 1.94 0.0342 
    Alcohol Dependence between 1999-2004 1.14 0.94 1.39 0.1823 
    Drug Dependence between 1999-2004 1.03 0.85 1.26 0.7402 
    Cardiac Arrest within one year 1.42 0.85 2.35 0.1778 
    Cardiac dysrhythmia within one year 1.08 0.98 1.20 0.1298 
    Ischemic heart disease within one year 0.97 0.88 1.06 0.4768 
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    Pericarditis within one year 0.96 0.68 1.36 0.8288 
    Cerebrovascular disease within one year 1.04 0.91 1.18 0.6002 
    Diabetes within one year 1.24 1.14 1.35 <.0001 
    Peripheral vascular disease within one year 1.13 1.03 1.25 0.0091 
    Chronic obstructive pulmonary disease within one year 1.02 0.91 1.15 0.7047 
    Acquired immunodeficiency disease within one year 1.49 0.88 2.54 0.1369 
    Human immnodeficiency virus within one year 1.35 0.75 2.44 0.3219 
    Bacterial Pneumonia six months ago 0.68 0.13 3.54 0.6429 
    Hepatitis B within one year 0.89 0.64 1.24 0.4974 
    Other Hepatitis between 1999-2004 0.93 0.82 1.05 0.2354 
    Opportunistic Infection six months ago 2.34 0.65 8.42 0.1921 
    Pneumococcal pneumonia, emphysema, lung abcess within six months 0.38 0.06 2.66 0.3315 
    Septicemia within six months 0.96 0.64 1.45 0.844 
    Gastro-Intestinal (GI) Tract Bleeding six months ago 1.30 0.40 4.22 0.6676 
    GI Ulcer - no hemorrhage within six months 0.99 0.29 3.42 0.9882 
    Esophogeal Varices within six months 3.47 0.47 25.54 0.222 
    Acquired Hemolytic Anemias within one year 1.14 0.88 1.47 0.3177 
    Hereditary Hemolytic Anemias between 1999-2004 0.94 0.73 1.22 0.6604 
    Sickle-Cell Anemia between 1999-2004 1.26 0.78 2.02 0.3481 
    Leukemia within one year 0.80 0.37 1.69 0.5511 
    Lung, Upper Digestive Tract, and Other Severe Cancers within one 
year 
1.12 0.66 1.88 0.6776 
    Lymphoma within two years 0.71 0.47 1.07 0.1 
    Metastatic Cancers within one year 2.35 1.13 4.89 0.0217 
    Multiple Myeloma within one year 3.04 1.23 7.51 0.0158 
    Breast, Prostate, Colorectal and Other Cancers within one year 0.88 0.73 1.07 0.1962 
    Hyperparathyroidism within one year 1.01 0.90 1.13 0.8479 
    Monoclonal Gammopathy within one year 0.93 0.46 1.87 0.8439 
    Myelofibrosis within one year 1.40 0.77 2.54 0.2724 
    Myelodysplastic Syndrome between 1999-2004 0.89 0.61 1.32 0.5666 
     
Observations 18,393 
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Table 4-8 Results from the Cox proportional hazards models, sensitivity analysis (the 
exclusion of any kind of event), 2004-2006  
  Model 7 - Unadjusted 
Variable H.R. 95% CI Pr > Chi 
Independent variable of interest 
        Average skipped HD sessions in a month 1.20 0.93 1.54 0.1619 
     Observations 18,393 
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Table 4-9 Results from the Cox proportional hazards models, sensitivity analysis (the 
exclusion of any kind of event), 2004-2006 (cont’d) 
  
Model 8 - Adjusted for patient 
demographics, time since start 
of RRT, body surface area, and 
low BMI 
Variables H.R. 95% CI 
Pr > Ch
i 
Independent variable of interest 
        Average skipped HD sessions in a month 1.07 0.83 1.39 0.5983 
Demographic variables     
    Ages <18 yrs 1.09 0.79 1.50 0.5948 
    Ages 18-44 yrs 0.85 0.76 0.95 0.0025 
    Ages 45-59 yrs 0.81 0.73 0.91 0.0002 
    Ages 60-69 yrs ref. - - - 
    Ages 70-79 yrs 1.18 0.96 1.44 0.1111 
    Ages 80+ yrs 2.57 0.89 7.39 0.0806 
    Female 1.01 0.93 1.09 0.844 
    Race: Native American 1.11 0.79 1.56 0.5571 
    Race: Asian 1.35 1.12 1.61 0.0012 
    Race: Black 1.49 1.38 1.61 <.0001 
    Race: White ref. - - - 
    Race: Other 1.43 1.07 1.93 0.0172 
    Race: Unknown/missing 12.8
8 
1.82 91.35 0.0106 
Patient characteristics and Comorbidities     
    Started RRT during month 4.09 1.32 12.64 0.0145 
    1 previous month of RRT 3.75 0.94 14.90 0.0604 
    2 previous months of RRT 3.94 1.29 12.00 0.0158 
    3 previous months of RRT 2.86 1.39 5.88 0.0045 
    4 previous months of RRT 2.75 0.58 13.09 0.2047 
    5 previous months of RRT 4.86 1.08 21.83 0.0393 
    6 previous months of RRT 4.12 0.82 20.80 0.0863 
    7 previous months of RRT 2.17 0.86 5.50 0.1022 
    8 previous months of RRT 3.03 1.04 8.87 0.0426 
    9 previous months of RRT 2.52 0.85 7.45 0.0955 
    10-12 previous months of RRT 2.91 1.84 4.61 <.0001 
    2nd year of RRT 3.08 2.55 3.73 <.0001 
    3rd year of RRT 3.55 3.03 4.15 <.0001 
    3 years or more of RRT ref. - - - 
    Body surface area (Dubois formula) 1.43 1.19 1.72 0.0001 
    Underweight (BMI <18.5 kg/m2) 0.98 0.81 1.18 0.8098 
     Observations 18,393 
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Table 4-10 Results from the Cox proportional hazards models, sensitivity analysis (the 
exclusion of any kind of event), 2004-2006 (cont’d) 
  
Model 9 - Model 8 +37 
functional statuses and 
comorbidities 
Variables H.R. 95% CI Pr > Chi 
Independent variable of interest 
        Average skipped HD sessions in a month 1.08 0.83 1.41 0.560 
Demographic variables     
    Ages <18 yrs 1.20 0.86 1.67 0.276 
    Ages 18-44 yrs 0.90 0.80 1.01 0.073 
    Ages 45-59 yrs 0.83 0.74 0.93 0.002 
    Ages 60-69 yrs ref. - - - 
    Ages 70-79 yrs 1.15 0.94 1.41 0.186 
    Ages 80+ yrs 2.40 0.84 6.91 0.104 
    Female 1.00 0.92 1.08 0.950 
    Race: Native American 1.02 0.73 1.44 0.900 
    Race: Asian 1.36 1.14 1.63 0.001 
    Race: Black 1.51 1.40 1.64 <.0001 
    Race: White ref. - - - 
    Race: Other 1.43 1.06 1.93 0.018 
    Race: Unknown/missing 12.77 1.80 90.75 0.011 
Patient characteristics and Comorbidities     
    Started RRT during month 3.71 1.20 11.50 0.023 
    1 previous month of RRT 3.94 0.99 15.70 0.052 
    2 previous months of RRT 3.59 1.09 11.81 0.035 
    3 previous months of RRT 3.13 1.53 6.43 0.002 
    4 previous months of RRT 2.48 0.51 12.11 0.262 
    5 previous months of RRT 5.20 1.17 23.18 0.031 
    6 previous months of RRT 4.13 0.84 20.32 0.081 
    7 previous months of RRT 2.32 0.91 5.92 0.079 
    8 previous months of RRT 2.59 0.90 7.49 0.079 
    9 previous months of RRT 2.41 0.83 7.01 0.108 
    10-12 previous months of RRT 2.77 1.74 4.40 <.0001 
    2nd year of RRT 2.97 2.45 3.60 <.0001 
    3rd year of RRT 3.44 2.93 4.04 <.0001 
    3 years or more of RRT ref. - - - 
    Body surface area (Dubois formula) 1.40 1.17 1.68 0.000 
    Underweight (BMI <18.5 kg/m2) 0.99 0.82 1.20 0.903 
    Inability to ambulate (2728) 0.76 0.43 1.35 0.353 
    Inability to transfer (2728) 2.62 0.91 7.54 0.074 
    Smoking 1.43 1.04 1.96 0.029 
    Alcohol Dependence between 1999-2004 1.14 0.94 1.38 0.192 
    Drug Dependence between 1999-2004 1.02 0.84 1.23 0.885 
    Cardiac Arrest within one year 1.17 0.71 1.92 0.541 
    Cardiac dysrhythmia within one year 1.05 0.95 1.17 0.308 
    Ischemic heart disease within one year 0.97 0.88 1.06 0.503 
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    Pericarditis within one year 0.89 0.64 1.23 0.477 
    Cerebrovascular disease within one year 1.03 0.91 1.16 0.680 
    Diabetes within one year 1.22 1.13 1.33 <.0001 
    Peripheral vascular disease within one year 1.13 1.03 1.23 0.011 
    Chronic obstructive pulmonary disease within one year 1.01 0.91 1.13 0.816 
    Acquired immunodeficiency disease within one year 1.57 0.95 2.60 0.080 
    Human immnodeficiency virus within one year 1.33 0.75 2.36 0.337 
    Bacterial Pneumonia six months ago 1.22 0.36 4.20 0.748 
    Hepatitis B within one year 0.89 0.65 1.23 0.489 
    Other Hepatitis between 1999-2004 0.93 0.82 1.04 0.204 
    Opportunistic Infection six months ago 0.99 0.28 3.58 0.992 
    Pneumococcal pneumonia, emphysema, lung abcess within six 
months 
0.59 0.09 3.99 0.590 
    Septicemia within six months 0.90 0.62 1.29 0.559 
    Gastro-Intestinal (GI) Tract Bleeding six months ago 1.80 0.68 4.74 0.235 
    GI Ulcer - no hemorrhage within six months 0.92 0.33 2.56 0.867 
    Esophogeal Varices within six months 2.59 0.52 13.02 0.247 
    Acquired Hemolytic Anemias within one year 1.08 0.84 1.39 0.555 
    Hereditary Hemolytic Anemias between 1999-2004 0.91 0.71 1.16 0.431 
    Sickle-Cell Anemia between 1999-2004 1.14 0.69 1.87 0.612 
    Leukemia within one year 0.80 0.37 1.73 0.572 
    Lung, Upper Digestive Tract, and Other Severe Cancers within one 
year 
0.96 0.55 1.67 0.887 
    Lymphoma within two years 0.71 0.47 1.06 0.090 
    Metastatic Cancers within one year 2.39 1.00 5.71 0.049 
    Multiple Myeloma within one year 2.14 0.76 5.99 0.148 
    Breast, Prostate, Colorectal and Other Cancers within one year 0.80 0.67 0.97 0.022 
    Hyperparathyroidism within one year 1.01 0.90 1.12 0.907 
    Monoclonal Gammopathy within one year 1.18 0.60 2.34 0.636 
    Myelofibrosis within one year 1.22 0.73 2.04 0.445 
    Myelodysplastic Syndrome between 1999-2004 0.86 0.58 1.26 0.441 
     Observations 18,393 
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Table 4-11 Results from the Cox proportional hazards models, sensitivity analysis (binary 
skipped sessions variable and the exclusion of any kind of event), 2004-2006  
  Model 10 - Unadjusted 
Variable H.R. 95% CI Pr > Chi 
Independent variable of interest 
        Binary variable: Average skipped HD sessions in a month > 0 1.13 1.04 1.23 0.003 
     Observations 18,393 
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Table 4-12 Results from the Cox proportional hazards models, sensitivity analysis (binary 
skipped sessions variable and the exclusion of any kind of event), 2004-2006 (cont’d) 
  
Model 11 - Adjusted for patient 
demographics, time since start of 
RRT, body surface area, and low 
BMI 
Variables H.R. 95% CI Pr > Chi 
Independent variable of interest 
         Binary variable: Average skipped HD sessions in a month > 0 1.10 1.01 1.20 0.0228 
Demographic variables     
    Ages <18 yrs 1.09 0.79 1.50 0.5972 
    Ages 18-44 yrs 0.85 0.76 0.94 0.0024 
    Ages 45-59 yrs 0.81 0.73 0.91 0.0002 
    Ages 60-69 yrs ref. - - - 
    Ages 70-79 yrs 1.18 0.97 1.45 0.1016 
    Ages 80+ yrs 2.57 0.89 7.40 0.0803 
    Female 1.01 0.93 1.09 0.8604 
    Race: Native American 1.11 0.79 1.55 0.5601 
    Race: Asian 1.35 1.13 1.61 0.0012 
    Race: Black 1.48 1.38 1.60 <.0001 
    Race: White ref. - - - 
    Race: Other 1.43 1.07 1.93 0.0176 
    Race: Unknown/missing 13.05 1.84 92.58 0.0102 
Patient characteristics and Comorbidities     
    Started RRT during month 4.17 1.35 12.87 0.0132 
    1 previous month of RRT 3.76 0.94 15.01 0.0603 
    2 previous months of RRT 4.02 1.32 12.24 0.0143 
    3 previous months of RRT 2.89 1.40 5.95 0.0041 
    4 previous months of RRT 2.69 0.56 12.91 0.2159 
    5 previous months of RRT 4.94 1.10 22.25 0.0376 
    6 previous months of RRT 3.97 0.78 20.13 0.0959 
    7 previous months of RRT 2.23 0.88 5.64 0.0911 
    8 previous months of RRT 3.06 1.05 8.97 0.0412 
    9 previous months of RRT 2.47 0.83 7.37 0.1063 
    10-12 previous months of RRT 2.91 1.83 4.61 <.0001 
    2nd year of RRT 3.06 2.53 3.70 <.0001 
    3rd year of RRT 3.57 3.05 4.18 <.0001 
    3 years or more of RRT ref. - - - 
    Body surface area (Dubois formula) 1.44 1.20 1.73 <.0001 
    Underweight (BMI <18.5 kg/m2) 0.98 0.81 1.18 0.8123 
     Observations 18,393 
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Table 4-13 Results from the Cox proportional hazards models, sensitivity analysis (binary 
skipped sessions variable and the exclusion of any kind of event), 2004-2006 (cont’d) 
  
Model 12 - Model 11 +37 
functional statuses and 
comorbidities 
Variables H.R. 95% CI Pr > Chi 
Independent variable of interest 
         Binary variable: Average skipped HD sessions in a month > 0 1.10 1.01 1.19 0.0338 
Demographic variables     
    Ages <18 yrs 1.20 0.86 1.67 0.2824 
    Ages 18-44 yrs 0.90 0.80 1.01 0.0719 
    Ages 45-59 yrs 0.83 0.74 0.93 0.0017 
    Ages 60-69 yrs ref. - - - 
    Ages 70-79 yrs 1.15 0.94 1.41 0.1737 
    Ages 80+ yrs 2.41 0.84 6.93 0.1028 
    Female 1.00 0.92 1.08 0.9366 
    Race: Native American 1.02 0.73 1.44 0.9038 
    Race: Asian 1.36 1.14 1.63 0.0008 
    Race: Black 1.51 1.39 1.63 <.0001 
    Race: White ref. - - - 
    Race: Other 1.44 1.07 1.93 0.0176 
    Race: Unknown/missing 12.91 1.82 91.73 0.0106 
Patient characteristics and Comorbidities     
    Started RRT during month 3.78 1.22 11.71 0.0212 
    1 previous month of RRT 3.92 0.98 15.66 0.0534 
    2 previous months of RRT 3.69 1.12 12.09 0.0313 
    3 previous months of RRT 3.16 1.54 6.49 0.0017 
    4 previous months of RRT 2.44 0.50 12.00 0.2715 
    5 previous months of RRT 5.27 1.18 23.57 0.0296 
    6 previous months of RRT 4.00 0.81 19.80 0.0893 
    7 previous months of RRT 2.37 0.93 6.04 0.0716 
    8 previous months of RRT 2.62 0.91 7.57 0.0756 
    9 previous months of RRT 2.36 0.80 6.96 0.118 
    10-12 previous months of RRT 2.77 1.74 4.40 <.0001 
    2nd year of RRT 2.95 2.44 3.58 <.0001 
    3rd year of RRT 3.46 2.94 4.06 <.0001 
    3 years or more of RRT ref. - - - 
    Body surface area (Dubois formula) 1.41 1.17 1.69 0.0002 
    Underweight (BMI <18.5 kg/m2) 0.99 0.82 1.20 0.903 
    Inability to ambulate (2728) 0.78 0.44 1.37 0.3835 
    Inability to transfer (2728) 2.62 0.91 7.55 0.0735 
    Smoking 1.42 1.03 1.95 0.0319 
    Alcohol Dependence between 1999-2004 1.14 0.94 1.38 0.1968 
    Drug Dependence between 1999-2004 1.01 0.83 1.23 0.9226 
    Cardiac Arrest within one year 1.17 0.71 1.93 0.5282 
    Cardiac dysrhythmia within one year 1.05 0.95 1.16 0.3396 
    Ischemic heart disease within one year 0.97 0.88 1.07 0.5331 
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    Pericarditis within one year 0.88 0.63 1.22 0.4453 
    Cerebrovascular disease within one year 1.03 0.91 1.16 0.6435 
    Diabetes within one year 1.23 1.13 1.33 <.0001 
    Peripheral vascular disease within one year 1.12 1.03 1.23 0.0128 
    Chronic obstructive pulmonary disease within one year 1.01 0.91 1.13 0.8382 
    Acquired immunodeficiency disease within one year 1.53 0.92 2.54 0.0981 
    Human immnodeficiency virus within one year 1.34 0.75 2.38 0.3253 
    Bacterial Pneumonia six months ago 1.21 0.35 4.17 0.7613 
    Hepatitis B within one year 0.89 0.65 1.23 0.4853 
    Other Hepatitis between 1999-2004 0.93 0.83 1.04 0.2173 
    Opportunistic Infection six months ago 1.01 0.28 3.64 0.9895 
    Pneumococcal pneumonia, emphysema, lung abcess within six 
months 
0.61 0.09 4.13 0.6116 
    Septicemia within six months 0.89 0.62 1.28 0.5233 
    Gastro-Intestinal (GI) Tract Bleeding six months ago 1.86 0.70 4.90 0.2107 
    GI Ulcer - no hemorrhage within six months 0.93 0.33 2.60 0.8889 
    Esophogeal Varices within six months 2.60 0.52 13.06 0.2458 
    Acquired Hemolytic Anemias within one year 1.08 0.84 1.38 0.5633 
    Hereditary Hemolytic Anemias between 1999-2004 0.91 0.71 1.16 0.4565 
    Sickle-Cell Anemia between 1999-2004 1.14 0.69 1.87 0.6081 
    Leukemia within one year 0.82 0.38 1.77 0.6062 
    Lung, Upper Digestive Tract, and Other Severe Cancers within one  
year 
0.96 0.56 1.67 0.8887 
    Lymphoma within two years 0.71 0.47 1.06 0.0911 
    Metastatic Cancers within one year 2.41 1.01 5.76 0.0477 
    Multiple Myeloma within one year 2.11 0.75 5.95 0.1591 
    Breast, Prostate, Colorectal and Other Cancers within one year 0.80 0.66 0.96 0.0189 
    Hyperparathyroidism within one year 1.01 0.91 1.13 0.8247 
    Monoclonal Gammopathy within one year 1.15 0.58 2.29 0.6811 
    Myelofibrosis within one year 1.23 0.74 2.05 0.4297 
    Myelodysplastic Syndrome between 1999-2004 0.85 0.58 1.25 0.419 
     Observations 18,393 
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Chapter V 
 
Chapter V. Conclusion 
 
Summary of Findings 
 
This dissertation provides important information for policy makers, researchers, dialysis 
providers, and dialysis patients with respect to how non-adherence would have an effect 
on health care costs and kidney transplantation failure.  Since the CMS implemented a 
full bundling system on January 1, 2011, the findings from Chapter II are especially 
salient in understanding how this new bundling system will change implications of 
skipped treatments for dialysis providers and the CMS.  Based on study results which 
show that skipping sessions is associated with lower SB utilization, with some evidence 
of slightly more SB utilization in the following months to make up for the missed 
treatments, it is expected that dialysis providers would find means to reduce non-
adherence in order to maximize profit.  Facilities can design appointment follow-up 
programs to target those patients who commonly skip HD treatments.  From the CMS 
perspective, since the bundled payment is made per patient per treatment, there is enough 
financial incentive for facilities to improve patient adherence because they will not 
receive reimbursement from a missed session.  The CMS probably needs not design 
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policy intervention in improving patient adherence at this point.  Results from this study 
also show that compared with 2SLS and log-linear estimations, the OLS estimation is a 
more reliable approach in examining the association of non-adherence on SB MAP.  
Distance is not a strong and valid instrument in the 2SLS estimation, and future work 
could be conducted to find a better instrument in order to tackle the endogeneity concern.  
  Chapter III provides information on whether non-adherence in HD sessions is 
associated with cost-savings for the providers, using CR costs as the health care costs 
measure.  Results show that there are no meaningful cost-savings for dialysis facilities 
when patients skipped routine HD treatments.  With the presence of non-adherence, total 
revenues for dialysis facilities are expected to drop due to fewer sessions provided.  
Consequently, there is a financial incentive for dialysis facilities to improve patient 
adherence.  Since there is no meaning effect of non-adherence on CR costs, policy 
interventions from the CMS to improve the adherence rate in hemodialysis is dubious.  In 
addition, findings from this study show that log-linear models perform better than OLS 
models.  The concern of retransformation issues when using a log-linear model to 
estimate health care costs and the need to use a smearing estimator (Duan, 1983) to adjust 
for heteroscedasticity in error terms need to be studied further.  Adding facility 
characteristics to the models increases the explanatory power.   
 One of the primary concerns for transplantation centers is to have a successful 
recipient of an organ transplant lose the graft due to non-adherence (Garcia et al., 1997).  
Transplant is the best treatment for ESRD patients.  Due to the short supply of 
transplantable organs, the allocation of organs to ESRD patients on the waitlist who will 
yield the best transplantation results is an important research and policy issue.  The 
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findings of Chapter IV seem to support the fact that adherent patients are more favored in 
being selected to receive kidney transplantations.  From a dialysis patient’s perspective, it 
would be advantageous to adhere to HD treatments to potentially increase the likelihood 
of receiving a kidney transplantation. 
 In contrast to previous studies using medication regimens as the non-adherence 
measure, this study found that there is no association between non-adherence in HD 
sessions and kidney transplantation failure.  From a policy perspective, this finding is 
encouraging in two aspects.  Increasing medical costs arising from a failed organ are not 
associated with pre-transplant non-adherence.  When evaluating the KAS system, non-
adherence in HD sessions may not need to be included in calculating the allocation score, 
and should not affect a patient’s status on the waitlist.  Since there is no association 
between non-adherence in HD sessions pre-transplant, and non-adherence in taking 
immunosuppressant drugs post-transplant, it may not be cost-effective to allocate medical 
resources to provide pre-transplant counseling interventions on these targeted non-
adherent HD patients 
  
Study Limitations 
 
There are a number of limitations pertinent to this dissertation.  (1) Non-adherence, as 
defined in this study, is measured conservatively.  To the extent that this non-adherence 
measure was underestimated, the true prevalence of non-adherence should be greater than 
presented, and the coefficient estimates on non-adherence as well as other covariates 
could also be affected.  Future research that applies a broader non-adherence measure 
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incorporating shortened HD sessions by 10 or more minutes, an interdialytic weight gain 
of more than 5.7 percent or dry weight, and a serum phosphate of greater than 7.5 mg/Dl 
would be extremely interesting.  (2) The empirical analyses presented in three chapters 
only look at data from 2004-2006, so findings may not be applicable to other time 
periods.  Future research using different time periods to examine the association would be 
helpful.  (3) For Chapters II and III, since I only observe the pattern of health care costs 
for hemodialysis patients, these findings could not be generalized to patients using other 
modalities.  Future studies can be conducted on peritoneal dialysis patients or home 
hemodialysis patients.  (4) Causal inference between non-adherence and CR costs could 
not be drawn from Chapter III.  (5) Another limitation from Chapter III is related to the 
quality of Medicare cost report data.  Researchers have raised concerns about the 
incompleteness of the cost report data (Bednar, 1992; Magnus et al., 2000; Medicare 
Payment Advisory Commission, 2004).  Though imperfect, there are several strengths 
with respect to the cost report data.  These data are the only available source of ESRD 
cost data, and are used widely by researchers and the CMS to modify ESRD payment 
policy.  There is a high correlation between the number of dialysis treatments presented 
on the cost report and the dialysis treatments reported on Medicare claims data.  The 
CMS has continuously refined the minimum file requirements and reminded providers in 
terms of ―Potential Rejection Errors‖  to correct for implausible values on the number of 
treatments and dates.  (6) For Chapter III, I did not consider the impact of non-adherence 
in HD sessions on multiple transplantation and multiple transplantation failures.  Future 
research can be conducted to address this concern. 
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